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Summary
Protein Kinases constitute a promising pharmaceutical target since they are involved in a large
number of tumorigenic functions such as immune evasion, proliferation, anti-apoptosis, metas-
tasis and angiogenesis. Although a small number of single-nucleotide kinase aberrations are
causally associated with human diseases, most of the many protein kinase mutations published
in the literature are tolerated and therefore, they are neutral in terms of protein and cell activity.
The mechanisms by which mutations elicit aberrant phenotypes have been studied and
characterized in some relevant cases for which cause-effect relationships are now well under-
stood. Nevertheless, the biochemical characterization of mutations cannot keep up with the
pace of current high-throughput mutation discovery technologies, since the detailed study of
each single mutation requires an enormous amount of effort, time and resources.
Thus, there is a clear need to broaden our understanding of mutations in the protein
kinase superfamily and, in particular, the mechanisms by which these alter protein function
and cause disease. This will help to develop cost-efficient protocols to identify, annotate,
characterize and prioritize mutations, such that communal efforts can focus on those most
likely to play a direct role in human disease.
The aims of this thesis are to extend our understanding of the mechanisms by which
pathogenic mutations disrupt the structure and function of protein kinases, and to design
a reliable pipeline to identify mutations likely to be causally implicated in human disease.
Focusing our efforts on protein kinases makes possible the use of methods and ideas regarding
their specific evolution and organization in protein families. This exclusive information can
yield better results than those achieved by general-purpose methods.
Such challenging biological problems will be tackled in this doctoral thesis from the
perspective of Computational Biology, a discipline that provides a powerful framework for
the integrated analysis of complex information from multiple sources. Current advances
in biostatistics and automatic machine learning technologies enable generalized rules to be
established based on prior observation, which can then be used to assess the probability of
newly discovered mutation being harmful.
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DISSERTATION

Chapter 1
Introduction
1.1 Genomic diversity in the cell
1.1.1 Defining genomic diversity in the cell
The first draft of the human genome was made publicly available at the beginning of this
century [1]. Although it undoubtedly represents a remarkable milestone in scientific research,
the existence of a human genome common to all individuals is an unrealistic simplification.
Every individual, except identical twins, has its own genome that is only approximately 99.9%
identical to that of the rest of the human population. Although this 0.1% might look like
an insignificant difference at first glance, it represents more than 3 billion base pairs. This
variable fraction in the genome accounts for the different phenotypes in the population and it
explains most of the varying susceptibility to diseases [2].
The majority of these differences are single base variations. Indeed, single nucleotide
variations are the most common form of genetic diversity in humans, comprising approximately
90% of sequence polymorphisms [3, 4] at a frequency of about 1 mutation per 200-1000
nucleotides [4–7]. These variations include transitions, transversions, and single base insertions
and deletions (indels). Transitions are base changes from purine to purine or from pyrimidine to
pyrimidine, whereas transversions change a purine to a pyrimidine and vice versa. Other forms
of genetic variation not considered here include microsatellites, longer simple sequence repeats,
copy number variants, transposable element insertions, large deletions, chromosome inver-
sions, chromosome translocations and aneuploidy, among others. Even though the analysis of
their consequences would also produce interesting results, this is beyond the scope of this thesis.
It is crucial to differentiate three closely related terms that are quite often misused in
the literature to refer to single nucleotide divergences: mutation, variation and polymorphism.
Mutation describes an allele that deviates from the wild type (the majority type), especially
if the aberrant allele alters the organisms phenotype or leads to disease. The other two,
variation and polymorphism, are closely related terms with a common origin. Both variations
and polymorphisms originally arose as mutations in that the conversion of one nucleotide into
another is a purely mutational event. By the time a sequence variant is observed in a given
population, this original episode has long passed and the observed divergence is no longer a
mutation but rather, a rare sequence variant or a polymorphism depending on the observed
frequency. Accordingly, the widely accepted value to differentiate between these two states is
a minor allele frequency of at least 1% in the studied population [3, 4]. It is quite common to
refer to single nucleotide polymorphisms as SNPs.
3
4 CHAPTER 1. INTRODUCTION
However, several paradoxes arise. First, polymorphisms in one population might be
rare variations in another. Second, in the genomic era, most SNPs are first detected in a small
sample (<10 individuals) and hence, this population frequency criterion cannot be applied
robustly. Therefore, the definition of SNP is subtle and most mutations should initially be
described as candidate SNPs [8].
1.1.2 Sorting out genomic diversity
There are plenty of ways to classify genomic diversity, each relying on different criterion, scope
and aims (for a detailed review, refer to [8]). Firstly, we can categorize mutations according
to the chemical nature of the bases involved. Previously, we defined transitions as changes
that do not alter this chemical nature since they involve changes from purine to purine or of
pyrimidine to pyrimidine (A to G, C to T, G to A and T to C). By contrast, transversions
involve changes from a purine to a pyrimidine and vice versa (A to C, A to T, G to C, G
to T, C to A, C to G, T to A and T to G). Interestingly, although there are twice as many
possible transversions than transitions, both occur at similar frequencies, which to some extent
might be explained by the genetic code. Indeed, transitions are less likely to affect amino
acid sequences than transversions and thus, they are thought to have a higher probability of
retention in coding regions [8].
Based on their genomic location, polymorphisms can be classified as coding and non-
coding. Non-coding mutations are located in the introns of a gene locus, intragenic regions,
transcription factors binding domains and any other genomic region that does not yield a
protein product. Coding mutations occur in DNA regions that lead to a protein product, that
is, in the exons of the coding sequence.
Additionally, coding polymorphisms can be further sub-classified depending on whether
they alter the resulting protein product or not. Non-synonymous variations alter the amino
acid sequence of the protein through either amino acid substitution (missense polymorphisms)
or the insertion of truncation mutations (nonsense polymorphisms). By contrast, synonymous
variations (also described as silent) are those that do not alter the amino acid sequence of the
protein even if the sequence is altered at the genomic level due to the degeneracy of the genetic
code.
We can also classify mutations according to their origin as germline or somatic [9] (Fig-
ure 1.1). If the mutation is inherited and, consequently, it is present in every cell of the
individual, we define it as germline. Conversely, if the mutation is acquired after conception,
for instance through the effects of carcinogens, UV light or problems during DNA replication,
we call it somatic. These mutations are not passed on to the offspring and they are not
present in all the cells of the individual. Consequently, if the mutated cell continues to
divide, it generates a patch of tissue expressing a genotype that differs from that of the
rest of the body. Cancer is a good example of such events and we will discuss the implica-
tion of somatic mutations in current models of cancer onset and progression later in this chapter.
1.1.3 Genotyping studies to detect genes harboring disease-associated
mutations
Novel point mutations that affect gene function have historically been identified by small-scale
sequencing of individual (or a few) genes. Technical advances in the last decade have favored
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Figure 1.1: Differences between somatic and germline mutations. Germline mutations (blue star)
are transmitted to the offspring and they are present in all the cells of the offspring (profile of filled
squares). If a mutation becomes fixed in the population, it becomes a polymorphism. Conversely,
somatic mutations (red star) are not present in all the cells of the individual and they are not inherited.
the development of high-throughput methods to detecting candidate disease-associated genes.
High-throughput resequencing screening can detect polymorphisms as well as small ‘indels’ [10],
and the introduction of ‘next generation sequencing’ (NGS) technologies [11] has not only
produced massive amounts of data, but it has also permitted the quantitative identification of
individual gene variants and the detection of abnormal transcripts [12].
Current methods to identify mutated candidate genes follow two closely related yet dif-
ferent approaches, as reviewed recently [13]. On one hand, a number of methods are based
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on sequencing a relatively small subset of genes (for instance, Greenman [14] analyzed
the genes encoding the human kinome), which are then genotyped in a large number of
samples. Although this approach may identify candidate genes harboring mutations at low
frequencies, the major drawback is that it requires a priori gene selection (also referred to
as prioritization). On the other hand, there are methods that analyze the coding sequences
of whole genomes in a smaller number of samples, such as colon and breast tumors [15, 16],
pancreas adenocarcinomas [17] or glioblastomas [18]. This approach identifies the genes most
frequently mutated in the context of disease.
The most important high-throughput cancer genomic projects from the last decade have
been summarized in Table 1.1 (extracted from our 2009 revision, Baudot et al., 2009 [13])
and as can be seen, protein kinases and cancer samples are very amenable targets for the
approaches discussed here (the relationship between cancer and protein kinases will be studied
more thoroughly below). Indeed, cancer is an interesting example of a complex disease with a
profound genomic component.
Author Year Genes Tumors Screening size
Bardelli 2003 Tyrosine kinase Colon 138 genes, 35 samples, a subset
in 147 additional samples
Wang 2004 Tyrosine phos-
phatase
Colon 87 genes, 18 samples, a subset in
157 additional samples
Stephens 2005 Kinase Breast 518 genes, 25 samples, a subset
in 56 additional samples
Davies 2005 Kinase Lung 518 genes, 33 samples, a subset
in 56 additional samples
Sjblom 2006 All Breast / colon 13023 genes, 22 samples, a subset
in 48 additional samples
Greenman 2007 Kinase Several 518 genes in 210 human cancers
Wood 2007 All Breast / colon 18191 genes, 22 samples, a subset
in 48 additional samples
Loriaux 2008 Tyrosine kinase Acute myeloid
leukemia
85 genes, 188 samples
Tomasson 2008 Tyrosine kinase Acute myeloid
leukemia
26 genes, 94 samples, a subset in
94 additional samples
Brown 2008 Tyrosine kinase Chronic lympho-
cytic leukemia
70 genes, 95 samples
Jones 2008 All Pancreas 20661 genes, 24 samples
Parsons 2008 All Glioblastoma 20661 genes, 22 samples, a subset
in 83 additional samples
CGARN* 2008 Custom Glioblastoma 601 genes, 91 samples
Ding 2008 Custom Lung 623 genes, 188 samples
Table 1.1: Catalogue of the main recent high-throughput cancer genomic studies and initiatives.
Adapted from Baudot et al. (2009) [13]. CGARN: Cancer Genome Atlas Research Network.
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1.1.4 The ‘driver gene, passenger gene’ metaphor
During a keynote lecture in 1964, Sir Christopher Andrewes coined the terms drivers and
passengers to refer metaphorically to the role of certain viruses in either causing cancer or
merely being passengers in infected cells [19]. Nowadays, the terms have slightly different
meanings, but the underlying metaphor is still valid. The term driver is often used for somatic
mutations that are positively selected and contribute to tumor development or progression,
whereas the term passenger is used for cancer-neutral mutations that are retained during the
evolution of cancerous cells but do not affect tumor progression [9]. This classification can be
extended to the genes that harbor these mutations as well.
To identify the noxious mutations involved in cancer it would clearly be logical to iso-
late these driver genes. An interesting predictive strategy would be to use the overall frequency
of mutations in a gene to detect the positive selection that could explain its behavior as a driver
of oncogenesis. The assumption here is that positive selection is exerted on non-synonymous
mutations. The degeneration of the genetic code yields a 2:1 ratio of non-synonymous
mutations to synonymous ones and thus, higher ratios indicate positive selection due to a
competitive advantage. In reality, more complex models borrowed from the field of molecular
biology apply, these taking into account the types of mutation (transition or transversion), the
sequence context (for example a C to A transversion in a CpG island) and the conservation of
the amino acids associated with the mutation [14, 20–22]. Another group of similar methods
account for the differences between the observed frequencies of non-synonymous mutations
and the estimated expected frequencies. These approaches are based on the rationale that the
presence of genes mutated in a number of tumors would suggest that positive selection has
occurred during tumorigenesis, which could be taken as an indicator of the selective advantage
conferred by that gene during the process of tumorigenesis. The frequency expected for the
background mutations is commonly derived from the synonymous mutation rates, which are
assumed to be independent of selection. To the best of our knowledge, the first publication
applying this kind of statistics to predict driver genes was published in 2006 [15]. In this study,
the probability of a gene containing a given number of mutations was computed according to
gene size. However, this approach did not consider that the background mutation and repair
rates vary between tissues, chromosomes, regions and genes. A later study [16] complemented
this analysis by including chromosome-specific background mutation rates, correcting the ratio
of non-synonymous:synonymous mutations and investigating the potential effects on protein
function.
The obvious limitation of these approaches to predict driver genes, apart from the need
of a large number of samples to provide statistical significance, is that they do not provide
information about the specific alleles (point mutations) but only the genes harboring them.
This is an important problem, since from the vast amount of mutations that are detected by
current high-throughput approaches, only a handful are directly implicated in disease, while
the others are neutral [13, 14]. The consequences of individual mutations in disease will be
discussed in the following sections.
1.1.5 Mutations and disease
Disease is a harmful kind of altered phenotype. Since the early days of genomics, association
studies have demonstrated the relationship between an aberrant allele and its pathogenic
manifestation, with experimental validation of the biochemical effects of a given alteration
considered as proof of a mechanistic involvement. Indeed, later in this chapter, we will
introduce some examples of key mutations within the human kinome causally involved in
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certain types of cancer and in drug resistance.
The 1000 Genomes project [4] (www.1000genomes.org) aims to characterize the human
variome from a broader perspective than the Human Genome project [1]. Thus, it is devoted
to the genome-wide high-throughput sequencing of a broad set of individuals from different
populations. In fact, the project includes three sub-projects: low-coverage whole-genome
sequencing of 179 individuals from four populations; high-coverage sequencing of two mother-
father-child trios; and exon-targeted sequencing of 697 individuals from seven populations.
Despite being at a very early stage, the results that have been obtained are striking: 15 million
single nucleotide polymorphisms, in addition to 1 million short insertions and 20,000 structural
variants, have been characterized. Most of them are neutral and are not causally associated
with any aberrant phenotype. Nevertheless, on average, each person has been found to have
around 250 to 300 variations that disrupt protein function and 50 to 100 variants previously
implicated in inherited disorders [4].
1.1.6 Somatic mutations in cancer: cancer evolution models
Cancer is a complex disease of which certain aspects are still not fully understood [13, 23–26].
Over the last couple of decades, a number of models have attempted to shed light on diverse
aspects of the disease, such as the different contribution of mutations to tumor development
and progression [9, 13,27].
Historically, the prevailing model has been the clonal evolution theory (Figure 1.2, blue
pathway), where cancer cells accumulate specific genetic changes that lead to clonal expansion.
These changes are selected through a competitive Darwinian process, where the mutations
conferring a selective advantage become fixed, thereby permitting phylogenetic tracing of
the history of the evolving cancer cell populations. Thus, it is generally accepted that
malignant tumors arise from benign precursors, whereby genomically stable tumors precede
their genomically unstable counterparts, and that metastasis is the final step in tumor evolution.
Unfortunately, not all results fit this simplified model. For instance, some breast cancer
metastases do not resemble the primary tumor [28], while a small proportion of normal mouse
mammary epithelial cells injected intravenously can survive at distant sites and eventually
produce tumors [29]. These observations have generated a new model, the parallel evolution
(Figure 1.2, red pathway), where cells that generate metastases are segregated relatively early
from the primary tumor and evolve independently [30, 31]. Gene-expression profiles that
predict metastases in certain primary breast tumors support this model [32].
The differences between these two models affects the interpretation and clinical imple-
mentation of the data gleaned about cancer-associated mutations. In terms of the clonal
evolution theory, the relevance of a mutation detected in a secondary (metastatic) tissue is
unclear in the absence of information about its presence in primary tumors. Moreover, in the
parallel evolution model, targeting this mutation for therapeutic treatment would have little
effect on treating the primary tumor, which would evolve independently.
Although cancer is a commonly understood as a single disease, this term more likely refers to a
growing group of more than 100 closely related complex diseases with diverse risk factors and
epidemiology [9]. Given the complexity of cancer and the diversity of its phenotypic outcome, it
is very unlikely that a single model can universally cover all aspects of these diseases. However,
it is plausible that both models are complementary (Figure 1.2, green pathway) and such an
integrated approach is supported by a recent study indicating that metastases could act as
repositories from which systemic tumor cell settlements could occur [33].
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Figure 1.2: Models of cancer evolution. The clonal evolution theory (blue arrows) is the prevailing
view to explain the successive steps of mutation and selection from normal tissue to a primary tumor
and metastasis. However, metastasis-generating cells can emerge relatively early in tumorigenesis and
seed distant tissues, thereby evolving in parallel with the primary tumor and defining the parallel
evolution model (red arrows). These two models can occur simultaneously, and metastatic deposits
may serve as sites from which additional metastases can be generated, thereby leading to an integrated
model of cancer evolution (green arrows). The microphotographs illustrate the paradigms modeled
(taken from Baudot et al. (2009) [13]).
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1.1.7 Mutations, protein kinases and cancer
Although about 1% of all human genes are known to contribute to cancer through acquired
mutations, the family of genes most frequently contributing to cancer is the protein kinase
superfamily [34]. Protein kinases are already a promising pharmaceutical target given that
they are involved in a large number of tumorigenic functions such as immune evasion,
proliferation, anti-apoptosis, metastasis and angiogenesis, possibly due to the simplicity of
the mechanism of attaching an ATP-derived phosphate to a substrate protein [35]. In fact,
a growing number of clinical drugs already target members of the protein kinase superfam-
ily [36, 37], the first of which was Fasudil, approved back in 1999. Originally developed to
treat cerebral vasospasm, Fasudil is a powerful competitive inhibitor of Rho kinase that binds
to the ATP-binding site. Nowadays, the most powerful compound to treat cancer is Imatinib
(Glivec), an inhibitor of the Abl tyrosine kinase used to treat Philadelphia chromosome-positive
chronic myeloid leukemia. Since the disease arises from a single mutation that leads to an
aberrant Abl kinase, this drug is fully effective if the disease is discovered at an early stage.
Interestingly, although this inhibitor binds in a competitive manner to the ATP-binding
pocket, its binding extends to a region behind the C-helix of the N-terminal lobe. However,
proper binding can only be achieved in the inactive conformation of the kinase. For this
reason, at an advanced stage of the disease when more mutations appear in the protein,
the drug is not so effective. In particular, a threonine to leucine mutation at a position
next to the C-helix pocket prevents Glivec binding and thus, it enables escape from the
protective action of the drug. This is not the only example where mutations affect protein
kinase function and indeed, there is now a plethora of kinase mutations that are thought to be
important for cancer onset and development. They will be discussed later in this doctoral thesis.
Another very interesting example of the role of kinases in cancer involves the cyclin-
dependent kinase (CDK). Progression through the cell cycle is screened by several checkpoints
that detect defects during chromosomal replication and segregation. If any of these control
points detects an error, the cell cycle is arrested, which enables the cell to attempt to repair
any defects found and prevent their transmission to its offspring. This arrest is mainly achieved
by modulating CDK activity (Figure 1.3).
Due to the crucial role of CDKs, their activity is intricately regulated. CDK activity requires the
binding of regulatory subunits known as cyclins, which are synthesized and destroyed at specific
times during the cell cycle to enable the CDKs to act so precisely. There are three interphase
CDKs (CDK2, CDK4 and CDK6) and a mitotic CDK (CDC2/CDK1), and in addition, there are
ten different cyclins grouped into four different classes (A, B, D and E). Several mutations have
been reported to de-regulate certain CDK-cyclin complexes, which result in either continued
cell proliferation or unscheduled re-entry into the cell cycle, both characteristics typical of
tumorigenic cells [26].
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Figure 1.3: CDK2 interaction with Cyclin A regulates the cell cycle. Active human CDK2 (orange)
in complex with Cyclin A (red). Time-regulated differential expression of cyclins and CDKs regulates
the cell cycle.
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1.2 The human kinome
1.2.1 Metabolic switches in the cell: protein kinases and phosphatases
“The conversion of phosphorylase b to a, as it occurs in cell-free muscle extracts, requires
a nucleotide containing high energy phosphate in addition to a divalent metal ion. Whether
this implies that during conversion there is a direct phosphorylation of the enzyme or the
formation of an active intermediate cannot be stated at this time.” Edmond H. Fischer and
Edwin G. Krebs stated this in 1955 when, for the first time, they introduced the concept of
reversible phosphorylation as a plausible mechanism to regulate protein function [38]. The
event they observed was the reaction in which glycogen phosphorylase was phosphorylated
by phosphorylase kinase. Phosphorylation switches the inactive glycogen phosphorylase to an
active state that is capable of catalyzing glycogen metabolism to provide the energy required
for muscle contraction.
It is a well-established dogma nowadays that reversible phosphorylation of proteins is a
versatile and recurrent mechanism of biological regulation. Furthermore, all protein families
are to some extent affected, directly or indirectly, by phosphorylation. The activity of proteins
with very diverse functions is controlled by reversible phosphorylation, from enzymes and
transcription factors to scaffolding proteins.
The phosphorylation mechanism is currently well understood. Protein kinases are a
family of enzymes that catalyze the transfer of a phosphate from ATP to a serine, threonine or
tyrosine hydroxyl group in the target protein. The change to a phosphorylated protein has very
different consequences of which activation or inhibition of an enzyme, alteration of interaction
surfaces, and conformational changes are among the most common. Due to the importance of
the processes regulated, protein kinases generally do not act alone but rather, they form part
of a finely tuned signaling cascade that is strictly controlled spatiotemporally. After a signal
has been transduced, the phosphate group is then required to be removed to yield an inactive
state. This action is performed by the counterparts of kinases, the phosphatases. Therefore,
both protein families are metaphorically referred to as the metabolic switches of the cell.
Although both superfamilies deserve detailed study and would provide very exciting ob-
servations, we will only focus on the protein kinase superfamily in this doctoral thesis. The
main reason for our choice is the growing number of studies that have thoroughly explored
the protein kinase superfamily and thus, the large amount of information available for this
superfamily. This is particularly relevant if we consider the ever increasing efforts to link
mutations in the protein kinase superfamily with cancer.
1.2.2 The human kinome
Protein kinases are one of the most ubiquitous families of signaling molecules in the human
cell, constituting approximately 2% of the proteins encoded by the human genome. The total
number of genes encoding kinases has been a matter of discussion in the last decade and for
instance, in 1998, Wang’s group predicted there are between 1000 and 2000 different kinases
in humans [39]. With the completion of the human genome, the current estimate is that 518
human genes encode protein kinases, corresponding to 1.7% of the total number of genes in
the human genome [40].
There are several different classifications of kinases from the main model organisms:
yeast [41], worm [42], fruit fly [43] and mouse [44]. The reference classification in humans
is KinBase [40], which has also been incorporated into UniProt [45], albeit with minor
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modifications.
According to KinBase, there are two different kinase superfamilies. A large superfamily
composed of 478 proteins with a eukaryotic protein kinase (ePK) domain and another
superfamily containing 40 atypical kinases that lack the conserved domain but that show
kinase activity. Additionally, eukaryotic protein kinases can be classified hierarchically into
groups, families and subfamilies, mainly based on sequence comparison of the catalytic domain
but also, according to the sequence similarity over the whole protein, the domain structure
outside the main domain, their known biological function, and other factors including similar
classifications in other model eukaryotic families such as yeast, worm and fruit fly. The
phylogenetic tree representing the 478 ePK genes and the fraction of kinases in each of the 8
major groups is shown in Figure 1.4.
Figure 1.4: Classification of the human kinome according to KinBase [40]
Panel A: Dendrogram of eukaryotic protein kinases as described in KinBase.
Panel B: Distribution of human eukaryotic protein kinases in the different KinBase groups.
The distribution of kinases in the different groups for human and commonly used animal models
is shown in Table 1.2. Of the 189 different human subfamilies, 51 are present in other model
organisms (namely yeast, worm and fruit fly), indicating their functions are important for the
eukaryotic cell. Moreover, 93 additional subfamilies are present in at least one of these model
organisms but absent in human, suggesting that they evolved to fulfill distinct functions in
metazoan evolution. It is interesting to highlight that more than 95% of the human kinases
have direct orthologs in mouse [40]. The complete dendrogram of the human protein kinase
superfamily is depicted in Figure 1.5.
1.2.3 A common feature of all protein kinases: the PK domain
Protein kinases share a common phylogenetic origin that is still evident in their common
structural core, the protein kinase (PK) domain. This common framework is flexible enough
to accommodate a considerable degree of specific structural variants, as well as a wide range of
sequence divergence and substrate specificities, while preserving the conserved basic catalytic
mechanism. Indeed, with a few exceptions, kinases share the molecular substructure for binding
the ATP-divalent cation complex, and the mechanism to transfer the terminal phosphate of
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Figure 1.5: The Human Kinome. The protein kinase superfamily as published in 2002 [40]
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Class Group Fams. Subfams. Yeast
Kinases
Worm
Kinases
FruitFly
Kinases
Human
Kinases
ePKs AGC 14 21 17 30 30 63
CAMK 17 33 21 46 32 74
CK1 3 5 4 85 10 12
CMGC 8 24 21 49 33 61
RGC 1 1 0 27 6 5
STE 3 13 14 25 18 47
TK 30 30 0 90 32 90
TKL 7 13 0 15 17 43
Other 37 39 38 67 45 83
aPKs PDHK 1 1 2 1 1 5
Alpha 1 2 0 4 1 6
RIO 1 3 2 3 3 3
A6 1 1 1 2 1 2
ABC1 1 1 3 3 3 5
BRD 1 1 0 1 1 4
PIKK 1 6 5 5 5 6
Other 7 7 2 1 2 9
TOTAL 134 201 130 454 240 518
Table 1.2: Distribution of kinases in human and model systems (adapted from Manning et al. (2002)).
ePKs: eukaryotic protein kinases, aPKs: atypical protein kinases. Fams. and Subfams. represent the
number of families and subfamilies in each of the groups.
the ATP to a serine, threonine or tyrosine residue in the target protein [46].
The structure of a canonical protein kinase (PK) domain has a basic two-lobe fold, the
N-terminal and C-terminal lobes, joined by a small hinge region. The N-terminal lobe is a set
of β-sheets plus a scaffolding α-helix (the conserved αC-helix), whereas the C-terminal lobe
is mainly a cluster of α-helices. Mn2+ and ATP bind to a conserved site between the two
lobes, and the substrate protein is recognized by interacting with the activation segment in the
C-terminal lobe.
Figure 1.6 highlights the most relevant structural elements common to all canonical
kinases, represented on the structure of the active conformation of human cyclin-dependent
kinase type II (CDK2). In addition to the basic two-lobe structure, there are other structural
elements of interest that are often present.
1.2.3.1 The P-loop
This is a small loop at the beginning of the N-terminal lobe that it is very often preceded by a
β-sheet and followed by an α-helix. It contains a glycine-rich motif (GxGxxG) that interacts
not only with the ATP but also, with the Mn2+ ion that coordinates the β- and γ- phosphates
in the ATP molecule. P-loop stands for phosphate-binding loop.
1.2.3.2 The αC-helix
This long helix in the N-terminal lobe acts as a backbone of this subdomain and has a role
in ATP binding [46]. In CDKs, this helix contains the evolutionarily conserved PSTAIRE
motif, which distinguishes them from other protein kinases and is thought to be involved in the
interaction with cyclins.
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Figure 1.6: Active conformation of human cyclin-dependent kinase type II (CDK2). Relevant struc-
tural features have been highlighted.
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1.2.3.3 The αF-helix
Similar to the C-helix, this helix acts as a backbone to the C-terminal domain and it is essential
for the assembly of the active conformation of the kinase [47].
1.2.3.4 The catalytic loop
This functionally important loop facilitates the binding and stabilization of ATP.
1.2.3.5 The activation loop (T-loop)
All kinases have a conserved activation loop involved in regulating kinase activity since it can
assume a large number of conformations depending on the phosphorylation state, which triggers
the active/inactive forms of the kinase. In the active form, the activation loop has an important
role in the conformation of the ATP-binding pocket. By contrast, the inactive conformation of
the loop blocks the binding of the substrate molecule to the substrate-binding groove. There
is a conserved and functionally important DFG motif at the N-terminal end of the activation
loop.
1.2.3.6 The P+1 loop
The P+1 loop is a small motif immediately downstream of the activation loop. Although
its biochemical mechanism is not yet fully understood, it has been reported to play a role in
recognizing the residues next to the tyrosine to be phosphorylated in the substrate [48,49]. This
loop contains the conserved APE motif.
1.2.3.7 The substrate-binding groove
A common feature of all protein kinases is that they phosphorylate polypeptide chains. The
substrate-binding structure is the part of the kinase where the substrate proteins dock and it
is formed by the catalytic loop, the P+1 loop and the αD-, αF-, αG- and αH-helices. This
structure positions the phosphorylation site in the substrate protein next to the γ-phosphate
of ATP.
1.2.3.8 The ATP-binding pocket
The active site is located between the two lobes, the small N-terminal lobe above the ATP
and the C-terminal lobe. The ATP-binding pocket has three differentiated parts: (1) a
cluster of hydrophobic residues around the adenosine of ATP; (2) a set of charged residues
around the γ-phosphate of ATP (namely the active site); and (3) a region of both polar
and hydrophobic residues in the C-terminal lobe. From a mechanistic point of view, the
hydrophobic area around the adenosine creates a binding pocket for ATP. The charged residues
in the active site bind and guide the γ-phosphate and the divalent cation (Mg2+/Mn2+),
and they participate in catalysis. The conserved residues in the C-terminal lobe help sta-
bilize the whole pocket and probably, they also participate in the interaction with the substrate.
Five conserved residues are critical for ATP binding, active-conformation stabilization
and catalysis (Figure 1.7). These are: (1) a lysine that interacts with the α- and β-phosphates
of ATP to stabilize it; (2) a glutamate in the αC-helix that forms a salt bridge with this lysine,
thereby increasing ATP stability; (3) an aspartate in the catalytic loop that is the catalytic
base that seeds phosphotransfer by deprotonating the corresponding acceptor (Ser, Thr or
Tyr) of the substrate peptide; (4) an asparagine that interacts with a secondary divalent
cation, placing the γ-phosphate in the correct position; and (5) an aspartate from the DFG
18 CHAPTER 1. INTRODUCTION
Figure 1.7: Detail of the ATP-binding
pocket of human CDK2. The five highly
conserved residues in the nucleotide-binding
pocket [46] are represented by sticks. These
are: (1) a lysine that interacts with the α-
and β-phosphates of ATP to stabilize it; (2)
a glutamate in the αC-helix that forms a
salt bridge with this lysine, thereby increas-
ing ATP stability; (3) an aspartate in the
catalytic loop that is the catalytic base that
seeds phosphotransfer by deprotonating the
corresponding acceptor (Ser, Thr or Tyr) of
the substrate peptide; (4) an asparagine that
interacts with a secondary divalent cation,
placing the γ-phosphate in the correct po-
sition; and (5) an aspartate from the DFG
motif of the activation loop that chelates the
primary divalent cation and hence, also po-
sitions the ATP molecule.
motif of the activation loop that chelates the primary divalent cation and hence, also positions
the ATP molecule [46].
1.2.4 Allosteric control of the activity of protein kinases
As already mentioned, protein kinases play a key role in cells as they regulate important
processes such as cell replication and signal transduction, among many others. Consequently,
the activity and specificity of protein kinases must be tightly regulated without substantially
interfering with the normal function of the proteins. Hence, protein kinases are often regulated
by allosteric mechanisms that include effector binding, phosphorylation and protein domain or
subunit interactions.
In the previous section, the structures commonly present in the PK domain were de-
scribed. Allosteric regulation of protein kinase activity involves the coupling of these
substructures through conformational rearrangements. Typically, this regulation involves
spatial repositioning of the αC-helix in the N-terminal lobe and the activation segment in the
C-terminal lobe. The mechanisms that control these events differ greatly, despite the closely
related sequences of the protein kinases and the similar active conformation adopted [50,51].
The most common allosteric regulation is the change in the orientation of the DFG mo-
tif that is tightly coupled to the phosphorylation events occurring in the activation loop.
In this conformation, the catalytic site is accessible to the nucleotide and the peptide
substrates. Conversely, in the inactive phosphorylated conformation, the activation loop
collapses into the active site and blocks substrate binding. Although slight differences exist,
this mechanism is shared by a large number of proteins, including the insulin receptor
kinase (IRK), c-SRC kinase, protein kinase A (PKA) and Abl kinase [51–56]. A phosphate
usually interacts with a conserved arginine that plays a key role in the rotation of the DFG
motif. Therefore, the whole catalytic loop is positioned in an optimal conformation for catalysis.
1.2. THE HUMAN KINOME 19
In addition to this activation mechanism, the αC-helix regulates kinase inhibition in
Src [54–56]. A Src homology 3 (SH3) domain interacts with a linker region between the protein
kinase and the SH2 domains, resulting in the rotation of the αC-helix and the disruption of the
lysine-glutamate pair. Phosphorylation of a tyrosine in the C-terminal tail inhibits the activity
of the protein by attaching the SH2 domain to the phosphorylated residue. This positions the
SH3 domain such that it interacts with the linker region in between the other two domains,
thereby inducing the linker to adopt a type II polyproline helical conformation. The SH3
domain and the linker can then stabilize the αC-helix in the inactive conformation.
Another recurrent example in the literature is the control by regulatory subunit bind-
ing. For instance, CDK2 requires the binding of certain cyclins, mainly A and E, to the
αC-helix [51,55]. The interaction with the cyclin forces the rotation of the helix and favors the
reorientation of the DFG motif in the activation loop, and the interaction of the conserved lysine
and glutamate important for the ATP-binding pocket [46]. The direct consequence of these
rearrangements is the shifting of the activation loop, which in turn facilitates the interaction
with cyclin-activating kinase (CAK). In Aurora kinase A, activation is boosted by binding of a
microtubule-associated protein, TPX2, in addition to the phosphorylation of a threonine in the
activation loop [51,57]. Similarly, Aurora kinase B binds to a centromeric protein, INCENP [58].
Dimerization is an alternative means of allosteric control [55], as exemplified by the epi-
dermal growth factor receptor (EGFR) that must homodimerize with a second subunit to
stabilize the active conformation [59]. Similarly, the interferon-induced, double-stranded RNA-
activated protein kinase (PKR) must undergo back-to-back dimerization of the N-terminal
lobes prior to activation [60,61].
1.2.5 Accessory domains in protein kinases
As mentioned before, protein kinases rarely act alone but rather, they are often part of tightly
regulated cascades. Signal transduction is generally modulated by a network of allosteric
and phosphorylation events (including auto-phosphorylation), whereby a number of kinases
activate their partners. While phosphorylation is mediated by the PK domain, other domains
regulate protein kinase activity by associating them with other signaling modules or localizing
the protein to the appropriate subcellular organelle. Studies [62, 63] in yeast have shown
that kinases can be very promiscuous, phosphorylating a large number of different protein
substrates while retaining remarkable specificity. This inconsistency suggests that kinases have
a region committed to regulating the general function of catalysis, with another customizable
region (or regions) that confer substrate specificity to the enzyme without any particular need
to alter folding, compromise ligand binding or modify the subsequent reaction mechanism.
This tightly regulated control mechanism is not unique to the protein kinase superfamily as
many other protein families control their activity by interacting with accessory domains [64–66].
260 kinases contain no additional domains other than the PK domain, and many are
indeed small proteins containing little more than this catalytic domain. For this reason, they
are often controlled by additional regulatory (external) subunits, as exemplified by the cyclins
when participating in controlling the cell cycle along with the activity of CDKs [23,26].
By contrast, 258 out of the 518 human kinases in KinBase contain additional domains,
and 83 different accessory domains other than the catalytic PK domain have been defined
(Table 1.3). Although the general trend is that members of the same kinase family share the
same domain structure, there are several cases where individual members of these families
have gained (or lost) a domain, possibly yielding a slightly different function.
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According to Manning et al. (2002) [40], the most common domains are those enabling
kinases to interact with other signaling proteins: 25 proteins express SH2 domains that bind to
phosphotyrosine residues; 38 have domains that are linked to small GTPase signaling proteins
(RhoGEF, RhoGAP, RBD, PBD, RGS, CNH, HR1 or TBC domains); 42 have domains that
are involved in lipid signaling (DAG PE, C2, PX or PH domains); 28 carry domains that are
associated with calcium signaling (CaM, IQ or OPR/PB1 domains); 7 proteins have domains
that target proteins to the cytoskeleton (spectrin, cofilin, myosin head or FCH domains); and
49 kinases contain domains that mediate interactions with other proteins or RNA, such as the
DEATH, SH3, SAM, LIM, ANK, RRM, DSRM or TUDOR domains.
Domain name Genes Doms. Function class
Protein kinase C terminal domain 44 44 Accessory domain
Immunoglobulin domain (Ig) 30 254 Extracellular, protein interactions
Fibronectin type III domain (FnIII) 28 194 Extracellular, protein interactions
SH2 domain 25 27 Adaptor, binds phosphotyrosine
SH3 domain 27 28 Adaptor, binds proline-rich motifs
PH domain 23 22 Signaling, phospholipid binding
Diacylglycerol binding (C1, DAG PE) 23 33 Phospholipid binding
Calmodulin-binding motif 23 25 Not a Pfam domain
Sterile alpha motif (SAM) domain 15 16 Dimerization domain
Ephrin receptor ligand binding domain 14 14 Ligand binding
CNH domain 12 12 Putative cytoskeletal
Activin receptor 11 11 Ligand binding
HEAT, armadillo/β-catenin repeats 10 27 Protein interaction
Ankyrin repeat (ANK) 9 59 Protein interaction
p21-Rho-binding domain (PBD,
CRIB)
9 9 GTPase interaction
Bromodomain 8 13 Acetyl-lysine (chromatin) binding
Regulator of G protein signaling (RGS) 7 7 GTPase interaction
PDZ/DHR/GLGF domain 7 7 Membrane targeting
Ubiquitin-associated domain A (UBA) 7 8 Protein degradation
Receptor L domain 7 14 Ligand binding
Furin-like cysteine rich region 7 21 Putative receptor dimerization
Phosphatidylinositol 3-kinase (PI3K) 6 6 Catalytic, protein kinase
FAT 6 6 Accessory domain for PI3K
FATC 6 6 Accessory domain for PI3K
Alpha kinase 6 6 Catalytic, atypical protein kinase
C2 domain 6 6 Ca2+, phospholipid binding
Death domain 6 6 Dimerization domain
Guanylate cyclase catalytic domain 5 5 Catalytic, cGMP production
HSP90-like ATPase 5 5 Catalytic, atypical protein kinase
ABC1 family 5 5 Catalytic, atypical protein kinase
Table 1.3: Most common Pfam domains in protein kinases apart from the PK domain. Adapted from
Manning et al. (2002) [40]. Only domains present in at least 5 genes are shown.
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1.3 Obtaining information about mutations
1.3.1 Resources that provide information about mutations
Currently, there is much effort being devoted to compiling and storing organized infor-
mation about mutations. The annotations that usually accompany the mutations provide
us with a powerful tool to understand the possible implications of the mutations in disease
and, in the best case scenario, the biochemical mechanisms underlying the aberrant phenotypes.
Different databases provide a diversity of information that reflects their distinct goals,
data sources, content, annotations and other issues. In fact, the scope of these databases is a
key feature since some of the resources provide information about mutations from a general
genome-wide perspective, while others provide detailed information on a protein family of
interest. As an example of the latter, we will centre our attention on resources that annotate
mutations affecting the protein kinase superfamily.
1.3.1.1 dbSNP
The dbSNP database [67] (www.ncbi.nlm.nih.gov/projects/SNP) catalogues and annotates
SNPs. Indeed, this resource constitutes the main source of information available on poly-
morphisms and their frequencies in different populations, sharing information with other state-
of-the-art resources such as Ensembl [68]. There is no requirement or assumption about the
minimum allele frequencies or functional neutrality for the polymorphisms in the database,
although the current level of activity in terms of the discovery of general sequence variations
suggests that SNP markers with unknown selective effects comprise most of the stored records.
There is also no requirement about the species, although most of the mutations correspond to
polymorphisms in humans or mice.
1.3.1.2 Ensembl
As described in its latest release [68] (www.ensembl.org), Ensembl seeks to promote genomic
science by providing high quality, integrated annotation on chordate and selected eukaryotic
genomes within a consistent and accessible infrastructure. All the species included have com-
prehensive, evidence-based gene annotations and a selected set of genomes has additional data
focusing on variation, comparative, evolutionary, functional and regulatory annotation. Cur-
rently, 56 species are supported including human and mouse.
1.3.1.3 The HapMap project
The HapMap project [69] (www.hapmap.org) is a catalog of common genetic variants in the human
genome. It describes these variants, their localization in the genome, and the allele frequencies
among people within populations and among populations. The populations include individuals
with African, Asian and European ancestry.
1.3.1.4 OMIM Online Mendelian Inheritance in Man
OMIM [70] (www.ncbi.nlm.nih.gov/omim) is a curated collection of human genes and genetic
disorders that was originally published as a book more than four decades ago. Afterward,
this information is stored as free text. Information from the biomedical literature, including
synopses and references is compiled manually. The lack of a structured database facilitates
the flexible description of a wide range of phenotypes and genes, although the lack of standard
format makes it more difficult to automatically search for information.
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1.3.1.5 SwissProt Variant pages and the ModSNP database
The SwissProt Variant pages [71] (http://expasy.org/swissvar) are an attempt to summarise
the available sequence information in conjunction with the additional structural information on
each human polymorphism in the SwissProt database [72]. The ModSNP database [71] maps
mutations from the SwissProt Variant pages onto three-dimensional protein structures, using
models generated by homology modeling when the referred proteins have not been crystallized
and stored in the Protein Data Bank [73].
1.3.1.6 SAAPdb
SAAPdb [74] (www.bioinf.org.uk/saap/db) is a resource for visualizing and analyzing the struc-
tural effects of mutations. The database classifies single amino acid polymorphisms into disease-
associated mutations (pathogenic deviations : PDs) and neutral polymorphisms (SNPs), and it
maps them onto structures in the Protein Data Bank [73]. In addition, the alteration of a set
of structural features is assessed for each mutation to provide clues as to the pathogenicity of
the variant allele. Neutral SNPs are mainly recovered from dbSNP [67] whereas pathogenic
deviations are mainly gathered from OMIM [70].
1.3.1.7 COSMIC: The Catalogue of Somatic Mutations in Cancer
The Catalogue of Somatic Mutations in Cancer [27] (www.sanger.ac.uk/genetics/CGP/cosmic)
is a database of somatic mutations in four genes in which genetic alterations have been asso-
ciated with cancer: BRAF, HRAS, KRAS2 and NRAS. The mutations, as well as tissue and
histological data, are recovered manually from the literature and included after curation.
1.3.1.8 KinMutBase
KinMutBase [75] (http://bioinf.uta.fi/KinMutBase/) is a plain-text database that stores
disease-causing mutations within protein kinase domains. The first release of KinMutBase
only contained information on protein tyrosine kinases while the second release also included,
as well as an update of the tyrosine kinases, serine/threonine protein kinases. The current
version contains 582 mutations in 20 tyrosine kinase domains and 13 serine/threonine kinase
domains.
1.3.1.9 MoKCa - Mutations of Kinases in Cancer
MoKCa [76] (http://strubiol.icr.ac.uk/extra/mokca) is a database that stores mutations in
protein kinases that are likely to be involved in cancer. These somatic mutations in the protein
kinase superfamily are recovered automatically from the literature, complemented with expert
manual annotation and other predictions (such as the probability of being pathogenic), and
then mapped onto the structures of the affected proteins.
1.3.2 Text mining techniques to extract kinase mutations from the
literature
As discussed, several databases are devoted to the compilation, annotation and characterization
of mutations occurring within the human kinome. Together they constitute a powerful resource
to understand disease association and the functional/structural properties of the mutations
that affect human protein kinases. However, compiling all the information available in
databases and the literature remains a time consuming task, since there is no global repository
covering all aspects of mutations.
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One reason for this is that the sizeable amount of information provided by large-scale
variation studies, and the growing efforts of databases and resources to store and curate this
information, are still not perfectly and fully connected. The same applies for the many efforts
dedicated to the detailed study of specific kinases in various biological systems published in
individual research papers. Resolving this problem still generally involves the manual in-
spection and curation of specific variation studies, although this requires considerable resources.
Several text mining techniques can be applied to the automatic extraction of entities
and their relationships from the existing literature, such as regular expressions, pattern
recognition and natural language processing, among others. Indeed, these approaches have
been successfully applied to other fields of research, for instance for the automatic extraction
of protein-protein interactions [77, 78] and in the annotation of genes and proteins [79, 80].
Despite the success of these methods, it must be born in mind that this technology does not
aim to replace manual curation and validation. Rather, text mining approaches are better
understood as systematic tools to assist the efforts of human curators by helping them to find
information, prioritize documents and highlight potentially relevant items [79,81].
The consistent nomenclature used to describe mutations in the literature makes these
entities especially amenable to this type of approach and accordingly, a growing number of
such methods have been described in the literature over the years. A summary of several of
these literature-mining tools to extract information on mutations is presented in Table 1.4.
Method Main Features Reference
MEMA Regular expressions, gene and protein men-
tions, co-mention proximity, OMIM valida-
tion.
Rebholz-Schuhmann
et al., 2004 [82]
MuteXt Regular expressions, GPCR and NR men-
tions detection, co-mention proximity, se-
quence check.
Horn et al., 2004 [83]
Yip Regular expressions, protein mentions detec-
tion, Swiss-Prot validation, sequence check
Yip et al., 2007 [84]
MutationGraB Regular expressions, protein mentions detec-
tion, graph shorted distance, sequence check
Lee et al., 2007 [85]
MutationMiner Regular expressions, protein mentions detec-
tion, sentence co-mention
Baker and Witte,
2006 [86]
MuGeX Regular expressions, protein mentions, pro-
tein and DNA mutation disambiguation
Erdogmus et al., 2007
[87]
VTag Machine learning detection of acquired se-
quence variation mentions detection (muta-
tions, translocations and deletions)
McDonald et al., 2004
[88]
OSIRIS Detection of human gene variations corre-
sponding to SNPs
Furlong et al., 2008
[89]
MutationFinder Regular expressions and patterns, protein mu-
tations mentions detection, complex language
expressions
Caporaso et al., 2007
[90]
Table 1.4: Summary of text mining implementations for mutation extraction.
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1.3.3 Methods to predict the pathogenicity of mutations
We mentioned earlier that high-throughput resequencing screenings represent a powerful set
of techniques to discover large numbers of mutations. Of these, only a small fraction are
causally implicated in disease onset and therefore, separating the wheat from the chaff is still
a major challenge [13]. For a small subset of the new mutations discovered, experimental
information is available regarding the relationship between the mutation and disease, and for
an even smaller number of cases the underlying biochemical mechanism is known. However,
there is no information for the remaining mutations. The requirement of a lot of resources,
time and money means that it is not feasible to experimentally test the association of all these
mutations to disease, and to characterize their functional effects. Nevertheless, this problem is
very amenable to in silico predictors.
Cline and Karchin [91] wisely described this approach as follows: “A bench biologist in-
terested in whether a mutation of interest impacts the transcription of a gene might perform
site-directed mutagenesis on genomic DNA, transfect mutated DNA into cell culture and use
readouts of the gene’s transcriptional activity to measure changes with respect to wild type.
In contrast, a bioinformatics approach typically involves computational analysis of the DNA
sequence surrounding the mutation, possibly supplemented with information from published
bench experiments.”
This is just one example of the very different methods available to predict the probabil-
ity of a newly discovered mutation being implicated in disease. Several interesting reviews
of this subject exist [13, 91, 92]. All predictors work under similar assumptions. Some make
use of several features to highlight crucial positions in a given protein, and hence, rules are
derived to predict the pathogenicity of mutations. Another group of methods assumes that
evolutionarily conserved protein residues [93] are important for protein structure, folding
and function, whereby mutations in these residues are considered deleterious. Variations
on this principle lead to methods that predict deleterious mutations by evaluating changes
in evolutionarily conserved Pfam motifs [94]. Moreover, a number of systems use protein
structures to characterize substitutions that significantly destabilize the folded state. There
are also methods that integrate prior knowledge in the form of both sequence-based and
structure-based features from a set of mutations (previously characterized as pathogenic or
neutral) to train an automatic machine learning system. After this training process, the system
can infer the pathogenicity of new mutations based on the knowledge acquired. The most
important predictors of pathogenicity are:
1.3.3.1 SIFT
SIFT [93] is a method based on position-specific sequence conservation. The algorithm can
be summarized as follows: (1) Search for similar sequences (PSI-BLAST); (2) Selection of
closely related sequences that supposedly share function; (3) Multiple sequence alignment of
PSI-BLAST results; (4) Calculate the normalized probabilities for all possible substitutions at
each position from the alignment; and (5) Substitutions with normalized probabilities less than
the cut-off (0.05) are predicted to be deleterious, otherwise they are tolerated.
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1.3.3.2 SNPs3D-stability
This method started as a rule-based system [95] but soon improved into a support vector
machine (SVM) learning approach [96,97]. A number of features affecting binding and stability
are analyzed:
• Protein stability.
– Loss of hydrogen bonds: distance donor-acceptor less than 2.5A˚ or angle at the
acceptor more than 90◦.
– Reduced hydrophobic interaction: loss of burial of more than 50A˚2 of non-polar area.
– Loss of a salt bridge: two oppositely charged groups closer than 4.5A˚ apart.
– Buried charge residue: introduction of an inaccessible charged residue.
– Over-packing: introduction of a large residue chain.
– Internal cavity: replacement of an inaccessible residue with a smaller residue chain.
– Electrostatic repulsion: two equally charged groups less than 4.5A˚ apart.
– Buried polar residue: polar groups with no accessibility and no hydrogen bonds.
– Disruption of metal binding: replacement by non-metal binding.
– Breakage of disulfide bonds: Cysteine replaced by non-cysteine.
– Backbone strain: Glycine changed to another residue outside Ramachandran plot.
– Backbone strain: Residue changed to proline with unfavorable torsion angles.
– Backbone strain: cysProline (ω=0±60◦) changed to another residue.
– Destabilization of a protein multimer: any of the above on a neighboring subunit.
• Ligand binding: any of the rules above where ligand atoms interact with the mutated side
chain.
• Catalysis: the residue is involved in catalysis.
• Allosteric regulation: the residue is involved in allosteric regulation.
• Post-translational modification: disruption of N-X-S/T pattern for glycosylation.
1.3.3.3 PolyPhen and PolyPhen II
PolyPhen [98] is a rule-based system that analyzes residue annotation, transmembrane and
coiled coil regions, signal peptide propensities, incompatible replacement of amino acids (PSIC
score), hydrogen bond disruption and hydrophobic or electrostatic interactions, disruption of
ligand binding, disruption of secondary structure or exposure of the protein core, uncommon
φ-ψ dihedral angles or untolerated regions of the Ramachandran map or normalized β-factors.
PolyPhen II [99] is an evolved version of the previous method, which relies on a na¨ıve
Bayesian classifier and a slightly modified set of features to predict the pathogenicity of
mutations. The most informative of these characterize how the amino acids of interest are
likely to occupy a given site according to the pattern of amino acid replacement in close
homologues. Moreover, it assesses how distant the protein harboring the deviation is with
respect to the protein from the human wild type allele, as well as whether the mutant allele
originated at a hypermutable site. In total, 8 sequence-based features and 3 structure-based
characteristics are evaluated.
26 CHAPTER 1. INTRODUCTION
1.3.3.4 Panther
The Panther [100] algorithm uses evolutionarily related sequences to estimate the probability
of a given amino acid at a particular position in a protein by calculating position specific
evolutionary conservation (PSEC) scores. subPSEC is the difference of values resulting from
the substitution of the wild type with mutant amino acids. The more negative the value, the
more deleterious the mutation is likely to be, and subPSEC values smaller than -3 are considered
deleterious.
1.3.3.5 Pfam LogRE-value
The Pfam LogRE-value [94] score predicts whether a change will alter protein function by
determining the difference in fit between the wild type version of the protein and a particular
Pfam model. Positive LogRE values indicate variants that reduce the fit of the protein and
that consequently, are potentially harmful.
1.3.3.6 PMut
PMut [101] relies on a neural network to predict the pathogenicity of mutations. To train the
system, the following features are assessed:
• Secondary structure.
• Solvent accessibility.
• Relative solvent accessibility.
• ProsaII differences in stability.
• Difference in surface potential.
• Difference in contact potential.
• Difference in the overall (weighted sum of the previous 2 potentials) potential.
• Blosum62 and PAM40 scores for the mutation.
• Residue volume change: van der Waals volume and volume of buried residues.
• Change in hydrophobicity: water/octanol free energy measurement and statistical poten-
tials.
• Change in secondary structure propensities: Chou-Fasman and Swindells analyses.
• Sequence environment potential: difference in the probabilities of observing residue rj at
position j given a sequence environment.
• Variability at the position: Shannon’s entropy and average of scoring matrices.
• Changes in the associated position specific scoring matrix values.
1.3.3.7 LS-SNP
LS-SNP [102] relies on an SVM implementing a radial basis function kernel. The following
features are analyzed: differences in solvent, violation of spatial restraints, introduction of
buried charges, evolutionary scores similar to subPSEC, Grantham values, changes in residue
volume, hydrophobicity and formal charges.
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1.3.3.8 SNPs3D-profile
This sequence-based algorithm [103] uses a SVM to evaluate the probability of substituting the
variant residue from the position specific scoring matrices (PSSM) , the conservation at that
position of the alignment (Shannon’s entropy), the mean entropy of the sequence, the standard
deviation of the entropies and the entropy at each position as a Z-score.
1.3.3.9 SNAP
SNAP [104] is probably the system that is currently producing the best results as demonstrated
in the latest CAGI experiment (http://genomeinterpretation.org) It consists of a neutral net-
work automatic machine learning predictor that evaluates the following features:
• Biochemical properties: Several properties are evaluated here. These include, the as-
sessment of the introduction of charged residues into a buried positions, the presence
of inflexible prolines in an α-helix, the replacement of hydrophilic amino acids with hy-
drophobic amino acids (or vice versa), the assessment of over-packing or the presence
cavities in the protein core, changes in Cβ-branching and the calculation of the mass of
the wild-type and mutant residues.
• Amino acid type.
• Transition frequencies.
• PSI-BLAST profiles (similar to subPSEC).
• PSIC score: Absolute PSIC score of wild-type and mutant residues, difference (subPSIC)
between wild-type and mutant PSIC score and a 3 state PSIC score (cut-offs at 0.5 and
1.5) are evaluated at this step.
• Secondary structure (PROFsec).
• Relative solvent accessibility (PROFacc).
• Predicted flexibility (PROFbval).
• PFAM annotation: Different properties are considered. The presence of domain bound-
aries at the position, the model score of the domain, whether the position is conserved or
whether the mutation is a better match with a consensus domain, the presence of domains
in the area are included.
• SwissProt annotation: Active residues, bonding residues, post-translational modifications,
variable residues and transmembrane regions are considered in the calculation.
• SIFT.
• PolyPhen.
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1.3.3.10 CanPredict
CanPredict [105, 106] is a random forest classifier that analyzes the scores from SIFT, Pfam-
based Log RE-value and Gene Ontology Similarity Score (GOSS) to provide a meta-prediction
of (cancer) pathogenicity.
1. SIFT: As described previously, this method uses the similarity between closely related
proteins to identify potentially deleterious changes (deleterious if SIFT score smaller than
0.05).
2. Pfam-based logRE-value: As described previously, score predicts whether a change will
alter protein function by determining the difference in fit between a wild-type version of
the protein and a particular Pfam model.
3. GOSS: uses Gene Ontology (GO) log odds to measure the similarity of the submitted
protein to other known cancer-causing genes. The sum of individual scores for each GO
term is considered. And each individual GO score is calculated as the logarithm of the
percentage of disease genes annotated with that GO respect to the percentage of neutral
genes annotated with that GO term.
1.3.3.11 Torkamani’s kinase specific predictor
This method [107] corresponds to an SVM implementing a radial basis function kernel. The
main particularity of this predictor is that it is trained specifically for the protein kinase super-
family. Indeed, the training vectors include features that are specific to this superfamily, such
as membership to a particular kinase group, which gives it a high discriminative power. The
complete list of features evaluated includes:
• Membership to a given kinase group.
• Wild type and mutant amino acids.
• Membership of the kinase domain, N-terminal and C-terminal lobe.
• subPSEC score (as in Panther).
• Change in biochemical properties: hydrophobicity, polarity and charge.
• Secondary structure prediction (Proteus server).
• Solvent accessibility (accessible, inaccessible and intermediate using Predict Protein).
• Change in flexibility.
• Difference in Kyte-Doolittle hydropathy.
• Difference in water/octanol partition energy.
• Difference in volume.
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1.3.3.12 SNPs&GO
SNPs&GO [108] is a genome-wide predictor of the pathogenicity of mutations. As most of the
best performing classifiers, it implements a SVM that relies on a radial basis kernel function for
the classification. The features implemented are completely sequence-based, which improves
the scope of the predictor, particularly for those proteins for which a crystal structure is not
yet resolved. The features analyzed include:
• Wild type and mutated amino acids
• Sequence environment (20 slots, accounting for the occurrence of each amino acid type in
a 19-residue window centered on the mutation at hand (9-x-9).
• Profile information: analysis of the conservation of the position in a multiple sequence
alignment. This is calculated as the frequency of the wild-type and mutant residues,
depth (number of sequences) at this position and conservation index.
• PANTHER prediction (as described before): Properties include the disease probability of
the mutation from Panther, probability of find the wild-type and the mutant residues and
the number of independent counts (a measure of the global diversity of the sequences at
this position).
• Gene Ontology Log-Odds ratio.
1.3.3.13 MutationAssessor
MutationAssessor [109] is a genome-wide predictor of the functional impact of non-synonymous
mutations. The prediction is based on earlier calculations of the differential evolutionary con-
servation of amino acids within protein subfamilies [110]. Protein subfamilies are determined
by clustering multiple sequence alignments of homologous sequences on a background of overall
function conservation.
1.3.3.14 Condel
Condel [111] is a genome-wide meta-predictor of the functional impact of missense mutations.
As a meta-predictor it integrates the output of 5 different methods: SIFT [93], MutationAssessor
[109], PolyPhen2 [99], Pfam LogRE-value [94] and MAPP [112].

Chapter 2
Goals and Objectives
2.1 Motivation
This doctoral thesis will focus on the analysis of mutations in the protein kinase superfamily.
Protein kinases are a good subject of study for a number of reasons. First, because of the
completeness of the information about their biochemical / cellular mechanisms. Second,
kinases are a large and complex superfamily, hence, they provides a rich source of information
for comparative analysis. And, third it is an important family, many of its members play a
crucial role in cancer and other diseases.
Most of the mutations published in the literature are tolerated and consequently, they
are apparently neutral to the cell. By contrast, only a small number of them are causally
associated with human diseases and cancer. The mechanisms by which pathogenic kinase
mutations lead to aberrant phenotypes have been explored in a number of relevant cases
for which the mechanism of action are relatively well understood. However, the biochemical
characterization of each single mutation requires an enormous effort, involving the dedication
of time and resources, which cannot keep up with the pace of high-throughput mutation
discovery technologies.
Thus, there is a clear need to broaden our understanding of the mechanisms by which
some mutations alter protein kinase function and cause disease. Such advances will help
to develop cost-efficient characterization protocols and, in parallel, prioritize the study of
mutations focusing on those that are most likely to play a direct role in human disease.
I have approached these problems using Computational Biology tools and methods. CB
provides a powerful framework to analyze vast amounts of complex and heterogeneous data.
Furthermore, CB methodologies are used to generalize previous observations and to use them
to predict the potential pathogenicity of newly discovered mutations.
In summary, the ultimate goals of this thesis are to understand the mechanisms by
which pathogenic mutations disrupt the structure and function of expressed protein kinases,
and to design a reliable methodology to identify mutations causally implicated in human
disease.
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2.2 Specific Objectives
This thesis is subdivided into four independent sections:
1. Mutations mapped onto the tertiary structures of proteins.
Here, we will tackle the technical problems of the integration of information from diverse
sources into a common repository and subsequently, transferring this primary sequence in-
formation to the tertiary structures of proteins. A public web-server, 3DSim, will display
the mutations and their annotations mapped onto representative structures. A public
web-server, 3DSim, will display the mutations and their annotations mapped onto repre-
sentative structures.
2. Text mining techniques to enhance knowledge of the kinase mutations.
The objective here is to compile information from existing data sources and in particular,
to automatically extract mutations from the literature. In addition, we will associate the
mutations with their original manuscripts, providing a summary of the evidence in the
literature that will help to link mutations with disease phenotypes.
3. Characterization of the residues that disrupt protein kinase function.
The goal is to identify the properties that distinguish pathogenic and neutral mutations.
For that, we will compare the distribution of selected features between neutral and poten-
tially pathogenic mutations, characterizing those that could be relevant to pathogenicity.
4. Prioritization of disease-associated kinase mutations.
The objective of this final task is to develop an automatic system to predict the pathogenic
nature of mutations based on the distribution of selected features. The new method will
be benchmarked against previously published approaches and it will be made publicly
available as a web server to facilitate the analysis of newly detected mutations.
Chapter 3
Materials and Methods
3.1 Mapping mutations from the sequence to the proteins’
tertiary structure
3.1.1 Obtaining mutations from SAAPdb
SAAPdb [74] is a database of single amino acid polymorphisms (SAAPs) from several resources,
such as dbSNP [67], ADABase [113], G6PD [114], HAMSTeRs [115], p53 Database [116],
LDLR [117], OMIM [70], OTC [118], SOD1db [119] and ZAP70Base [113]. Where possible,
these polymorphisms have been mapped to protein structures in the PDB [73]. As of
October 2008, SAAPdb contains 9,060 unique pathogenic deviations (PDs: SAAPs associ-
ated to a disease) and 2,532 unique single nucleotide polymorphisms (SNPs: SAAPs with
no known pathogenic effect) successfully mapped to the UniProtKB sequences in Gene3D [120].
Pathogenic deviations and neutral SNPs were only taken into account if the alteration
introduced is not silent, i.e. if it produces a change of amino acid from the wild-type. Since
SAAPdb integrates annotations from different sources there may be discrepancies in the
annotations for some mutations. These inaccuracies in the annotation are incompatible with
the analyses performed here and consequently, the mutations that were annotated as both
neutral and disease-associated were all considered as pathogenic deviations.
3.1.2 Generating groups of Gene3D sequences represented by the
same CATH domain
All CATH domains were recovered directly from the database for each of the 2,097 superfamilies
available in CATH [121] at the time of analysis (release 3.2 August, 2008), along with the
corresponding amino acid sequences. The sequences were grouped together by superfamily and
a total of 86,463 CATH domains were retrieved.
In order to assign the closest CATH domain to each of the Gene3D sequences in a
given CATH superfamily, we queried each of the sequences against the database of CATH
domains generated previously for that superfamily. Queries were performed using BLAST [122]
and the best match for each of the Gene3D sequences was considered the closest CATH
domain. Only cases where the identity between the hit and the query was greater than 20%
were considered and the resulting CATH domain was assigned as the structural representative
of this sequence. After performing this classification for the whole set of sequences, all Gene3D
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sequences represented by the same CATH domain were grouped together and all the sequences
within a group were considered to be similar. A total of 2,091 unique groups were generated.
3.1.3 Mapping SAAPdb mutations to representative CATH domain
structures
During the previous step of the pipeline, the sequences represented by the same CATH domain
were considered similar. However, in order to collapse all the mutations from the Gene3D
sequences onto the representative CATH domain sequences, the equivalence between pairs of
residues should be established. To perform this task the sequences were aligned using the
MUSCLE [123] package and the resulting alignments were used to transfer the mutations, both
pathogenic deviations and neutral SNPs, from the sequences in Gene3D to the corresponding
representative CATH structures.
3.2 Characterization of the residues that disrupt protein
kinase function
3.2.1 Classification of the human kinome according to KinBase
The KinBase [40] resource (www.kinase.com/kinbase) is a repository storing the currently ac-
cepted classification of eukaryotic protein kinases. At the time of the analysis, KinBase con-
tained 620 human protein sequences, excluding pseudogenes, of which 518 correspond to protein
kinases. KinBase does not directly map its entries to Uniprot and consequently, we used BLAST
to search each KinBase sequence against a custom database containing all human sequences
annotated with a protein kinase domain in Uniprot [72]. After this mapping step, we were able
to assign 488 KinBase identifiers to a valid Uniprot entry, 474 of them (97.13%) at sequence
identity levels ≥95%.
3.2.2 Selection and classification of somatic mutations
Large-scale systematic genotyping studies have been carried out to identify mutated genes in
human cancer genomes. These studies focused on different tumor types (Colon and breast) or
on the protein kinase superfamily [14,16], and they led to the identification of more than 3,500
somatic mutations. Further statistical analysis based on mutation rates or synonymous versus
non-synonymous mutation ratios have been used to classify genes as drivers, those causally
involved in oncogenesis, or passengers, those incidentally involved in oncogenesis and that
probably arise during tumor development.
The analysis performed in this doctoral thesis focuses on the protein kinase catalytic
domain. The protein kinase domain subset comprises 140 mutations, 73 (52%) drivers and
67 (48%) passenger mutations. We stored these mutations along with the corresponding
amino acid change, their nature as a driver or passenger, and their sequence and structural
positions. The mapping of sequence and structure positions was calculated with the SPICE
DAS server [124], a resource originally developed to visualize sequence-based annotations in
protein structures.
3.2.3 Selection and classification of germline mutations
SAAPdb [74] is a database of single amino acid polymorphisms (SAAPs) mapped to protein
structures. SAAPdb aims to define potential structural consequences of mutations and to iden-
tify differences in the structures that may be associated with neutral and pathogenic mutations.
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The disease dataset, pathogenic deviations, is mostly derived from OMIM [70], whereas the neu-
tral dataset comes from dbSNP [67]. Within the Protein Kinase domain of the 488 kinases we
could map to Uniprot identifiers, SAAPdb contains 130 pathogenic deviations and 200 neutral
SNPs. Of these 130 PDs, 62 were successfully mapped to a residue in a resolved PDB structure.
Similarly, of the 200 SNPs mapped to the sequence, 36 were mapped to a PDB structure. A
unique mutation was defined by the combination of four parameters: UniProtKB accession
number; sequence position; native amino acid; and mutated amino acid. We excluded nonsense
and synonymous mutations assuming that they have a known truncating effect or no effect on
the protein structure, respectively.
3.2.4 Calculation of sequence conservation
Two different measures of sequence conservation were used.
First, for each position in the multiple sequence alignments, conservation was measured
in terms of Shannon’s entropy [125], a measure of the variability in the distribution of elements
in a set described by the formula:
−
n∑
i=1
p(xi) · log2p(xi)
Where p(xi) is the probability of having element xi in bin i for that distribution.
Conservation was measured in the context of identity, using 1 bin for each amino acid
and an extra bin for gaps, giving a total of 21 bins. The positions in the alignment were
labeled as conserved if the Shannon’s entropy was <0.20. Positions with more than 75% gaps
in the corresponding multiple sequence alignments were labeled directly as unconserved.
Second, we used the weighted sequence conservation implemented in AL2CO [126]. AL2CO is a
program that calculates a conservation index for each position in a multiple sequence alignment
using diverse methods that share a common principle, whereby amino acid frequencies at each
position are estimated and the conservation index is calculated for these frequencies. We used
the implementation to weight sequences in order to correct for the unequal distances between
different sequence pairs in the alignment and the matrix score that gives the most common
position occupied by residues with similar physicochemical properties. Those residues with a
normalized conservation index of ≥70% were considered to be conserved.
3.2.5 Calculation of the solvent accessibility with Naccess
Naccess (Hubbard et al., unpublished) is a stand-alone program that calculates the solvent
accessible area by rolling a probe with a van der Waals radius over the surface of the molecule.
We defined residues as buried if their relative accessible surface area exposed to the probe is
less than or equal to 16% of the total surface of the residue.
3.2.6 Defining the ATP binding site with FireDB
The FireDB database [127] contains a comprehensive curated set of substrate-binding and
catalytic residues, extracted directly from PDB [73] or from the Catalytic Site Atlas [128].
FireDB binding residues for the various kinases were mapped into the general model using the
corresponding multiple structure alignment.
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3.2.7 Defining specificity determining positions with S3Det
Specificity Determining Positions (SDPs) are the positions within a family of homologous
proteins characteristic of the internal organization into subfamilies. Hence, SDPs typically
correspond to positions in a multiple sequence alignment where the type of amino acid is
differentially conserved among subfamilies. Subfamilies and SDPs have previously been
associated with important features of protein functional subspecificity, such as catalytic
activity, small ligand binding, protein-protein interactions, DNA/RNA binding, etc. [129–131]
Here we predict SDPs with S3det [131], an in-house novel implementation of the Se-
quence Space approach [129] that relies on Multiple Correspondence Analysis [132]. The
procedure implemented in S3det is summarized in Figure 3.1.
Using this technology, S3det vectorizes the initial multiple sequence alignment in order
to produce two linked spaces, namely a protein space and a residue space. These two spaces
can be represented simultaneously: in the protein space similar sequences are located in the
same region of the space, whereas the residues characteristic of those sequences map to an
equivalent region in the residue space. Through automatic clustering in the sequence space,
S3det detects groups of sequences that correspond to the family’s subfamily composition.
These subfamilies are then mapped to the residue space through the vector that represents the
center of their masses. This procedure permits the set of residues that uniquely characterize
each subfamily to be determined automatically, defining the SDPs. SDPs determine the
segregation into subfamilies and they are responsible for the specific functional features of the
subfamily.
Figure 3.1: Summary of the method to identify specificity determining positions (SDPs) implemented
in S3det. [131]
3.2.8 Xd analysis
To assess the significance of the proximity of different sets of mutations to specific areas of
the protein (buried, functional, conserved, etc), we used the harmonic deviation introduced
previously, Xd [133–135]. The most relevant characteristic of this measure of the differences
between distributions is that it more heavily weights those positions in bins proximal to the
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features studied, instead of considering the complete distribution of distances to be equally
informative. In other words, it gives more importance to differences in the distribution of
residues close to the important regions than to differences located in more distant regions.
Xd =
n∑
i=1
Pic − Pia
di · n
Where n is the number of distance bins in the distributions, di is the upper limit for each bin,
Pic is the percentage of residues with a distance between di and di+1, and Pia is the same
percentage for all the residues in the protein.
Defined in this way, positive values of Xd would indicate that the population of residues shifts
to smaller distances with respect to the population of all residues. In practice, we use an
arbitrary value of 0.5 for the difference of Xd (∆Xd) to indicate distributions of residues that
are sufficiently distinct in terms of their proximity to the chosen areas of the protein.
3.3 A prediction server to determine the pathogenicity of
a mutation
3.3.1 Mutation Dataset
The mutation data used here was derived directly from Uniprot [72] (release 2011 01; Jan 11,
2011) after applying the following constraints:
1. The protein is annotated as a protein kinase in UniProt.
2. It is a human protein.
3. The mutation corresponds to non-synonymous, non-truncating single point coding mu-
tations. Other mutation types such as insertions, deletions, copy number alterations,
truncating and silent mutations were not considered in this analysis.
The use of a Uniprot derived dataset has recently been benchmarked for a number of classifiers
with satisfactory results [136].
Following this pre-filtering step, we classified the mutations as disease or neutral muta-
tions according to the annotation in Uniprot. There is a third group in Uniprot that aggregates
the mutations for which insufficient information is available, mutations that were ruled out of
this analysis. After the whole selection process, the ‘disease dataset’ that includes mutations
for which there is experimental evidence of their disease association, contained 865 mutations
in 65 human kinases. By contrast, the ‘neutral dataset’ that contains mutations with no
experimental proof of association to disease, contained 2,627 mutations in 447 human protein
kinases.
3.3.2 Implementation of the classifier
To implement the Support Vector Machine classifier we used the SVMLight (http://www.cs.
cornell.edu/people/tj/svm_light/) package with a radial basic function (RBF) kernel:
K(xi, xj) = exp(−G||xi − xj ||2))
In this manner, two parameters are crucial to the performance of the classifier: the soft-margin
penalty (C) and the radius (γ). An exhaustive evaluation of the parameters was carried out for
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values ranging between 0 ≤ C ≤ 8 in 1 unit steps, and 10−4 ≤ γ ≤ 10−2 increasing by 5 · 10−4
after each run. In order to decide which pair of parameters performs best, the average f-score
across the entire set of k-folds was chosen as the scoring function for the optimization.
3.3.3 Evaluation of performance
The classification obtained from our classifier was evaluated using a 10-fold cross-validation
approach where 80% of the mutation data is used to train the classifier, another 10% to
validate and optimize the parameters, and the remaining 10% is used to evaluate the classifier.
The process is repeated enough times to ensure that all subsets of mutations are used for each
purpose. The classifier’s performance is averaged across all combinations in order to avoid
over-interpreting the quality of the method. The efficiency of the classifier can be assessed in
many ways and here we describe the most illustrative ones.
Hereafter, we will refer to the following abbreviations:
TP True positives, correctly predicted disease-associated mutations.
FP False positives, neutral mutations predicted as disease prone.
TN True negatives, correctly predicted neutral mutations.
FN False negatives, disease-associated mutations predicted as neutral.
Accuracy, often referred to as Q2, accounts for the fraction of mutations correctly predicted in
function of the total number of mutations.
Accuracy =
Correctly Predicted
All Predicted
=
(TP + FN)
(TP + TN + FP + FN)
Recall, also referred to as sensitivity by other authors, accounts for the proportion of correctly
predicted disease-associated mutations in function of all the disease-associated mutations in the
dataset.
Recall =
Correctly Predicted (disease)
Observed Mutations (disease)
=
(TP )
(TP + FN)
Precision accounts for the proportion of correctly predicted disease-associated mutations with
respect to all the predicted disease-associated mutations.
Precision =
Correctly Predicted (disease)
Predicted Mutations (disease)
=
(TP )
(TP + FP )
The F-score is a measure of the accuracy of the classification. It considers both the precision
and the recall in a single representative score for evaluation purposes.
F − score = 21
Precision +
1
Recall
The Matthews Correlation Coefficient (MCC) was calculated according to the following formula:
MCC =
(TP · TN)− (FP · FN)√
(TP + FN)(TP + FP )(TN + FP )(TN + FN)
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3.3.4 Classification Feature: membership to a Kinase group
In order to cluster the kinases according to the groups they belong to, two different clas-
sification schemes were used. The KinBase resource [40] constitutes the currently accepted
classification scheme of eukaryotic protein kinases. According to KinBase, kinases are catego-
rized as ‘conventional’ protein kinases (ePKs) or ‘atypical’ protein kinases (aPKs). The ePKs
form the largest group and they have been subdivided into 8 groups according to sequence
similarity, the presence of accessory domains and by considering different modes of regulation.
The eight ePK groups defined in KinBase correspond to: the AGC group (including cyclic-
nucleotide and calcium-phospholipid-dependent kinases, ribosomal S6-phosphorylating kinases,
G protein-coupled kinases and close relatives of these kinases); the CAMKs (calmodulin-
regulated kinases); the CK1 group (casein kinase 1 and close relatives); the CMGC group
(including cyclin-dependent kinases, mitogen-activated protein kinases, CDK-like kinases and
glycogen synthase kinase); the RGC group (receptor guanylate cyclase kinases); the STE group
(MAPK cascade kinases); the TK (tyrosine kinase) and the TKL (TK-like), which are a group
of serine-threonine kinases resembling TKs. Another broad miscellaneous group, called ‘Other’,
is also considered for those proteins that do not fit in any of these predefined categories. By
contrast, Uniprot [72] provides a classification scheme that includes the same groups included
in KinBase along with the additional groups, NEK and STG, making a total of 11 groups.
The vector of features submitted to the classifier contains a position for each of the groups in
the latter scheme. The values are encoded as 1 for the group to which the kinase housing the
mutation belongs to, and 0 for the rest. A similar approach was followed by Torkamani and
Schork [107].
3.3.5 Classification Feature: Gene Ontology Log Odds Ratio
The Gene Ontology Log Odds Ratio (GOLOR) was used to classify the mutations as pathogenic
(disease-associated) or neutral according to the annotations regarding the function of the genes
in which they exist. To compute the score, we retrieved all the terms associated to the kinases
in our dataset from the 3 sub-ontologies in Gene Ontology [137] (Molecular Function, Biological
Process, Cell Component). The ontologies were followed towards the root of each ontology in
order to include all parental terms in the calculation. Note that ‘part-of’ relationships were
discarded and only ‘is-a’ links were considered. For each of the kinase genes, the sum of the
Gene Ontology Log Odds Ratio (sumGOLOR) was computed as follows:
sumGOLOR =
∑
log2
% kinase genes annotated with GOi in the disease set
% kinase genes annotated with GOi in the neutral set
Where disease-associated kinase genes are those with at least one reported disease-associated
mutation and neutral kinase genes are those with no reported disease-associated mutation.
In order to resolve undetermined ratios, frequencies equal to 0 were artificially set to 10−9.
A similar approach with slight changes in the algorithm is followed in two other methods:
CanPredict [105,106] and SNPs&GO [108].
3.3.6 Classification Feature: PFAM domains
The position of the different domains in the sequence of the human protein kinome was ex-
tracted from the swisspfam file in PFAM [138]. A binary position in the vector was created
for each of the 117 different domains in the protein kinase family, where 1 means that the
mutation is in a position that was characterized as part of that domain, and otherwise it is
attributed a value 0. An additional binary position in the vector, pfam any, was created to
record whether the position belongs to at least one PFAM domain. This is a simplified version
of the implementation by other authors [104,105,107].
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3.3.7 Classification Feature: Amino acid type and change in hy-
drophobicity
Each amino acid type was encoded at 20 positions in the vector, where the wild-type residue
is encoded as 1 and its mutant counterpart is encoded as -1. The rest of values remain as 0
for classification purposes. An additional position was encoded to represent the change in the
Kyte-Doolittle hydrophobicity index [139].
3.3.8 Classification Feature: Uniprot Annotation
Uniprot [72] provides a detailed description of the residues for a number of proteins in the
database. We considered 5 different classes of residue annotation to be relevant:
1. Catalytic site (including residues annotated as SITE, BINDING, ACT SITE, METAL and
NP BIND: refer to the Uniprot help pages for a detailed description of the annotations)
2. Disulfide bond (DISULFID)
3. Post-Translational Modifications (MOD RES, SIGNAL)
4. Residues with special interest (MUTAGEN)
5. Transmembrane regions (TRANSMEM).
A binary input corresponding to each of these categories was added to the classification vector.
In addition, two additional positions were added: one that corresponds to a positive match in
at least one category from the catalytic site class, while the other corresponds to a positive
match in at least one of the categories described above. A similar approach was followed
previously [98,104,140,141].
3.3.9 Classification Feature: Phosphorylation sites
PhosphoELM [142] is a database of eukaryotic phosphorylation sites. This resource includes
manually curated information derived from the literature, as well as high-throughput analyses
for 1,232 phosphorylation sites in 287 human kinases present in our dataset. Since out of the
20 potential residues only 3 can be phosphorylated (Ser, Tyr, Thr), this feature was encoded
for the classifier according to 3 different states: 1 represents a reported residue amenable for
phosphorylation, 0 if the residue is a Ser, Thr or Tyr that is not phosphorylated, and -1 for the
remaining residues.
3.3.10 Classification Feature: Catalytic sites
FireDB [127] is a database of known functionally relevant residues. It includes both biologically
relevant data filtered from the close atomic contacts in 3D crystal structures and manually
annotated catalytic residues. The presence of a mutation in the catalytic site of a protein was
encoded in the classifier as a binary input, whereby 1 means that the mutation is part of the
catalytic site, 0 otherwise.
3.3.11 Classification Feature: Evolutionary Information
In order to capture the similarity between closely related proteins and thereby identify poten-
tially deleterious changes, we included the SIFT score in our feature vector [93]. This method
relies on the normalized probabilities for all possible residue substitutions at each position of
a multiple sequence alignment of homologous proteins. The score can be easily translated into
a binary output where values <0.05 are considered deleterious. Consequently, both the binary
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and the continuous versions of the score were computed in order to provide more discriminating
results. Additionally, the number of sequences in the alignment at the position of interest was
also considered. Since it was introduced in 2001, this method has been successfully incorporated
in several predictors of pathogenicity [104,105,107,141].
3.3.12 Classification Feature: Specificity Determining Positions
Those positions occupied by conserved residues within groups of proteins in a family sharing a
common general specificity that differs between groups can be used as a proxy for the regions
accounting for subfamily specificity. SDPs, also referred as tree-determinants on occasion, were
calculated using a simplified version of the in-house S3Det predictor [131]. In our implemen-
tation, the f-score associated to the wild-type and mutant residues in the classification of the
subfamilies calculated from the sequences in the PFAM alignments was encoded in the classifi-
cation vector. An additional third position represented the difference between these two scores.
This difference represents the change (increase or decrease) in agreement with the subfamily
introduced by the mutation.

Chapter 4
Results
4.1 Mapping mutations: From the protein sequence to its
tertiary structure
This thesis was conceived in order to address the need to transfer information about mutations
from databases and other sources to the corresponding protein sequences and structures.
We needed a system that could handle the heterogeneous information available regarding
mutations and, very importantly, a system that could transfer the coordinates of the mutations
and the associated meta-information between protein sequences, and their corresponding
structures and structural families.
As a framework for our development we used the CATH database developed by the
group of Christine Orengo at the University College London [121]. CATH is a manually-
curated hierarchical classification of protein domain structures. In CATH each protein
structure is partitioned into domains and assigned to superfamilies, with each superfamily
representing groups of domains that share a common evolutionary origin. CATH is coupled
to Gene3D [120], a resource that assigns protein sequences to the CATH hierarchy and that
fills the sequence-structure gap. In the CATH framework, the representative structure of each
CATH domain is a proxy of all the associated sequences. Therefore, the system makes it
possible to fulfill our need, transfering the coordinates of the mutations and the associated
meta-information between sequences and structures of the same superfamily.
4.1.1 3DSim in a nutshell
3DSim [143] is a method to map single amino acid polymorphisms onto protein structures.
In the current implementation (See Introduction for a detailed description) mutation data
is obtained from SAAPdb [74], sequence information from Gene3D [120] and the protein
structures correspond to the superfamily representatives in CATH [121]. The system permits
the mutations to be mapped onto the protein structures and it facilitates the dynamic
visualization of the mutations within the structures. Relevant annotations about the mutations
are summarized, including information regarding the wild type and mutant sequences, the
predicted structural implications of the mutations and their characterization as neutral or
pathogenic according to these predictions. The information is provided together with the links
to the original sources of information, such as UniProt, Gene3D, SAAPdb, CATH, Modbase,
etc. . .
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The algorithm behind the server is described in detail in Figure 4.1 and it can be sum-
marized as follows:
1. Each mutation in SAAPdb (either neutral or pathogenic) was located in the corresponding
Gene3D sequence, which acts as a mediator between the sequence and structure databases.
The mapping between SAAPdb and Gene3D included 11,904 sequences.
2. Gene3D sequences were clustered according to their closest representative CATH domain
based on homology. This ensured that all sequences were associated with a unique CATH
domain, even if their own protein structures were not resolved. The closest relative found
was used to cluster the sequences (i.e., the one with the lowest e-value and highest sequence
identity in a BLAST search). This process yielded 2,091 different groups.
3. All sequences corresponding to the same CATH domain were aligned to the sequence
of the CATH domain’s representative using the multiple sequence alignment package
MUSCLE [123].
4. The multiple sequence alignments were used to identify the equivalent sequence to struc-
ture positions, which were then used to transfer the mutations in SAAPdb from each of the
Gene3D sequences onto the structures of corresponding CATH domain representatives.
At the end of the whole pipeline, we collected information on 6,514 point mutations; 4,865 of
them are known to be associated with disease and map to 396 CATH superfamilies.
Figure 4.1: Schematic view of the algorithm that 3DSim uses to map mutations in SAAPdb from the
sequences onto the structures of the family representatives in CATH.
4.1. 3DSIM: MAPPING MUTATIONS ONTO STRUCTURES 45
4.1.2 Implementation of the application as a web server
To make the information generated available to the scientific community, we decided to
implement our mutation sequence-to-structure mapping pipeline as a web server. Thus,
3DSim [143] is publicly available at http://3dsim.bioinfo.cnio.es. The most important
features of this web server are displayed in Figure 4.2.
3DSim can be queried in many different ways, although the simplest input is a CATH
superfamily identifier to retrieve information on mapped mutations. Accordingly, the user can
either manually introduce the desired superfamily identifier in the provided form or the com-
plete list of superfamilies in CATH can be browsed to access the information (Figure 4.2, panel
A). The database can be searched with UniProt accession numbers or CATH domain identifiers.
Once the CATH superfamily of interest is chosen, relevant information is displayed along
with the list of CATH domains for which information is available regarding the mutations in
SAAPdb. The number of pathogenic mutations is also reported for any CATH domain (Figure
4.2, panel B).
After a CATH domain of interest has been selected, 3DSim loads the main page for
that specific domain. On this page, the server displays both an interactive Jmol plug-in that
shows the mutations projected onto the 3D structure of the representative CATH domain and
a ‘mutation information table’ (Figure 4.2, panel C) that contains all the information available
for that given domain. This information includes the mutations available, the position of
the mutations in the sequence and structure, their pathogenicity, and the similarity (BLAST
sequence identity) between the sequences in Gene3D and the representative CATH domain
sequence. Importantly, this similarity index provides the user with clues to the reliability of
the homology-based transfer of mutations from the sequences in Gene3D to the structures in
CATH. As a rule of thumb the stronger the similarity the more reliable the mutation transfer.
By default, the server rejects mutations transferred from sequences with a BLAST sequence
identity less than 20%, although due to the interactive approach of the server the user can
establish more stringent constraints depending on the case under study.
3DSim also provides links to several external annotation sources where additional infor-
mation about the mutations, proteins and structures can be obtained, including CATH [121],
Gene3D [120], SAAPdb [74], Modbase [144], PDBsum [145] and UniProt [72]. Among these,
the information SAAPdb may provide about the structural consequences of mutations is
particularly interesting. Indeed, in some cases this information can help to understand the
pathogenic characteristic of the mutations and provide an insight into the protein’s function.
4.1.3 Access to the information: web services
Although punctual access to the information contained in the server is sufficient for most users,
recursive programmatic access to the information is often necessary in genome-wide studies. To
allow remote access to the resource, we developed nine SOAP web services that permit users
to retrieve:
1. All known mutations for a given CATH domain grouped by a UniProt identifier.
2. The total number of mutations in a CATH domain.
3. All the CATH domains associated with a given UniProt identifier.
4. The amino acid sequence of a given CATH domain.
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Figure 4.2: Schematic summary of the capabilities of 3DSim [143].
Panel A: Browsable list of superfamilies for which mutations exist.
Panel B: Example of a structure displaying known pathogenic mutations.
Panel C: An explanatory table that displays relevant information about the mutations in the chosen
CATH domain.
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5. All CATH domains in a CATH superfamily.
6. The superfamily to which a given CATH domain belongs.
7. The description and representative structure of a CATH superfamily.
8. All the mutations in SAAPdb for a given UniProt accession number.
9. The total number of mutations in SAAPdb for a given UniProt accession number.
These services were designed to facilitate the construction of elaborated computational
pipelines. For example, a user starting from the UniProt accession number of a particular
protein could retrieve a list of all the domains found in that protein and by chaining together
four web service calls, the CATH superfamilies each domain belongs to, all the other domains
that usually accompany the domain, and all the known mutations in the related domains can
be found.
4.1.4 Example of the capabilities of 3DSim: the protein kinase super-
family
The protein kinase superfamily is subdivided into two different CATH superfamilies, each
corresponding to a different structural lobe (Figure 4.3). The C-terminal lobe of the kinase is
represented by the 1.10.510.10 CATH superfamily, which corresponds to the phosphotransferase
domain I homology group in CATH, and it includes 73 different representative subdomains
harboring mutations. Of them, subdomain 1rw8A02 (Figure 4.3, panel A) contains the largest
number of mutations, 29 mutations that correspond to 22 different residues in the protein struc-
ture. Of these 29 mutations, only 3 come from a sequence, namely P36897, which maps directly
onto the domain. The remaining 26 correspond to homologous sequences with 40-82% sequence
identity according to Gene3D. The ability to increase the number of mutations in a given
structure by homology-based transfer is probably the most important added value of the server.
Interestingly, the pathogenic mutations reported in 3DSim for the human TGF-β recep-
tor type I (M318R, D400G and R487P) have already been associated with Loeys-Dietz
syndrome type 1A, an aortic aneurysm syndrome with widespread systemic involvement [146].
This disorder is characterized by arterial tortuosity, aneurysms, craniosynostosis, hypertelorism
and bifid uvula (cleft palate). Exotropy, micrognathia, retrognathia, structural brain abnor-
malities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and
aneurysm with dissection throughout the arterial tree have also been reported.
The structure of TGF-β receptor type I (1rw8) can be seen along with the pathogenic
deviations from SAAPdb (Figure 4.3, panel A), and a similar image can be obtained directly
from our server and is one of the main features available to analyze the distribution of
mutations within structures. This figure reveals that pathogenic deviations tend to cluster
around important structural features, such as the catalytic loop or the substrate-binding groove.
The N-terminal lobe of the protein kinase superfamily is represented by the CATH su-
perfamily 3.30.200.20, which contains 21 different subdomains with at least one reported
mutation. The one with most mutations is 1uwjA01 (Figure 4.3, panel B), accounting for
8 pathogenic deviations in 6 different residues. Interestingly, none of these mutations corre-
sponds directly to the structure of the representative protein but rather, to structurally similar
proteins in the same subdomain classification that have been transferred by our algorithm.
The mutations inherited at 95% identity from the human serine/threonine-protein kinase
B-raf are particularly noteworthy, a well-known proto-oncogene involved in the transduction
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of mitogenic signals from the cell membrane to the nucleus. Mutations in this gene cause
cardiofaciocutaneous syndrome and a wide number of diseases such as lung cancer, colon
cancer, melanoma and several types of cancers affecting the immune system, including
non-Hodgkin lymphoma. As a matter of fact, the mutations reported in our server have been
linked to colorectal cancer (R462I, I463S and G464E) [147], lung cancer (G466V) [148] and
non-Hodgkin lymphoma (G469A, G469R/V) [149].
From the structure of B-raf and the pathogenic mutations reported in the database
(Figure 4.3, panel B), it is evident that the mutations are located near an important structural
element, such as the P-loop, which is involved in ATP binding. In fact, some of the mutations
target Gly-464, Gly-466 and Gly-469, the highly conserved amino acids in the glycine-rich
motif GxGxxG that interacts with the β- and γ-phosphates of ATP.
Figure 4.3: Examples of mutations mapped onto representative members of the protein kinase super-
family.
Panel A: Pathogenic mutations mapped onto the structure of the TGF-β receptor type I (1rw8A). Mu-
tations transferred from other proteins with the same structural representative have been highlighted
in yellow, whereas the pathogenic mutations occurring directly in the structure of the TGF-β receptor
have been highlighted as follows: M318R in violet, D400G in red and R487P in orange.
Panel B: Pathogenic mutations in B-raf (1uwjA). Cancer-associated mutations in the P-loop have been
highlighted: R462I in cyan, I463S in yellow, G464E in orange, G466V in magenta and G469A/R/V in
blue.
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4.2 Automatic literature-mining
Mutations discovered from either high-throughput genome wide studies or from detailed
studies of specific kinases in various biological systems are often recorded in state-of-the-art
databases, such as the SwissProt Variant Pages [71], COSMIC [27] or KinMutBase [75].
However, large-scale human variation studies generate a vast amount of information that is
not properly resourced to store, annotate and curate. Most of the existing manually-curated
mutation annotation resources rely on reading a subset of all published articles, while existing
automated systems are mainly based on (subsets of) PubMed abstracts or small (but broader
than the manual ones) collections of full-text articles [150]. Please refer to the Introduction for
a review of these resources.
Therefore, many mutations are not stored in databases. When annotations are lacking,
it is not easy to recover functional information even when the experimental results have been
published. Whereas manual inspection of the literature, curation and annotation of mutations
is possible for very specific singular cases, it becomes practically unfeasible for large sets of
proteins and/or documents.
Thus, we tackled the difficulties in obtaining generalized information about mutations
in the protein kinase superfamily, which represents a large superfamily with a growing number
of published reports. Accordingly, we needed a system capable of recovering kinase mutations
from the literature in a fully automated manner. We implemented a pipeline that integrated
article retrieval, the detection of mutations mentioned in the literature, and a final validation
of the mutations linked to their corresponding protein sources [150]. Although the pipeline
is focused on mutations within the protein kinase domain, it constitutes a prototype that
might be easily applied to any other superfamily. This pipeline (Figure 4.4) includes the
construction of a kinase-relevant article collection that considers both abstracts and full-text
articles from PubMed, the detection of mutation mentions, the predictive classification of
mutations into induced or natural, the linking of mutations to corresponding protein sequences,
and comparisons to existing databases.
4.2.1 Mutation mention extraction and disambiguation
Our mutation extraction pipeline was applied to two different document sets, one containing
the whole collection of PubMed abstracts and the other, a collection of 19,404 full-text articles.
The full-text articles were automatically downloaded using an in-house retrieval system [79]
following three different criteria:
1. Relevance of the abstract: information contained in the corresponding abstracts such
as the mention of mutations, mention of human kinases and a combination of keywords
(including ‘human kinase mutation’).
2. A priori relevance of the articles: extracting all the PubMed references for human kinases
contained in multiple databases (e.g., SwissProt, MINT and IntAct).
3. Relevance of the journal: based on analyzing a fraction of mutation-mentioning abstracts
of each journal and prioritizing a set of journals (and thus their articles) to retrieve their
full-text articles. These journals included the American Journal of Human Genetics,
European Journal of Human Genetics, Human Genetics, Human Mutation and Human
Molecular Genetics.
Both abstracts and full-text articles were then pre-processed by applying an in-house rule-based
sentence boundary detection system that we optimized for PubMed abstracts [79].
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Figure 4.4: Flow chart of the literature-mining pipeline for mutation extraction presented, giving an
overview of the different processing steps to extract interesting mutations in the human kinome.
For the initial extraction of single amino acid substitutions we used MutationFinder [90], a
software for point mutation literature-mining based on regular expressions and patterns. Its
main function is to detect the mention of mutations in a given set of manuscripts and it relies
on language expressions used to describe mutation events. This system is very competitive
for recall and precision when compared to other strategies [84], and it has been evaluated
using a manually-generated gold standard collection of abstracts. In addition to the raw
results provided by MutationFinder, we designed an approach to target mutation pattern sense
disambiguation and the filtering of mentions that do not correspond to protein mutations. To
determine whether a candidate mutation mention corresponds to a mutation or an artifact, we
designed a module that filters false positive mentions through a combination of named entity
recognition, dictionary look-up and rule-based methods. Most false positive mutation mentions
corresponded to one of the following three semantic types:
1. Cell lines or cell types. Several frequently mentioned cell lines resembled mutation men-
tions, including the human glioblastoma cell line T98G, the T-cell line M14T, the adreno-
cortical cell line H295R, and other commonly used cell lines such as T47D or T24C.
2. Taxonomic entities. Certain taxa, especially bacterial strains, cloning vectors and some
mouse models displayed names that were similar to single letter mutation mentions e.g.,
Escherichia coli K12S, Actinomyces viscosus T14V, Pneumocystis pneumoniae R36A,
Actinomyces naeslundii T14V, Mycoplasma sp. G145T and the yeast strain S288C. Clone
identifiers (e.g., W12I and W12E) or plasmids (e.g., E. coli plasmids P15A) can also cause
false positive mutation identification. A special case of ambiguous mutation mentions are
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transgenic mouse models like G93A transgenic mice. Although they are a strain express-
ing a G93A mutant of the human SOD1 protein, these mice are usually mentioned in the
literature as the strain rather than as a reference to the particular mutation.
3. Protein, gene and drug names. Several protein names match the patterns used to identify
mutations from the literature. Although some of them correspond to human proteins,
like S100D and S100E, a considerable fraction are viral gene names (e.g., vaccinia viral
A10L, variola viral A11L or the poxvirus protein A52R). We found some additional cases
of wrongly tagged mutations that could be classified as drugs or compounds (e.g., the
antibiotic A83586C, the immunogen A27L or the antifungal antibiotic A9145C). To de-
termine the semantic class of a given mutation, we explored the use of knowledge-based
methods relying on machine-readable dictionaries (MRDs) for sense disambiguation based
on local context analysis.
4.2.2 Linking mutation mentions to human kinase sequences
Linking mutations that appear in the literature to their corresponding protein sequences and
database records is crucial to characterize the putative structural implication of the mutations.
This also allows direct comparison of the mutations retrieved to manually-curated functional
annotation of protein mutations contained in dedicated databases, as well as the integration
of the literature mentions into large-scale experimental genotyping studies. Here, we focused
on the association of the literature-extracted mutation mentions with human protein kinases.
More specifically, we restricted our analysis to mutations occurring within the protein kinase
domain defined in KinBase [40].
To link mutation mentions and the sequences of human kinases, we assumed that the
corresponding protein names were co-mentioned in the articles. After extracting mutation
mentions from PubMed abstracts and a large collection of full-text articles, these two data
sets were explored for mentions of human protein kinases. We applied a dictionary look-up
approach to detect any mentions of kinase proteins, similar to strategies that were successfully
used in the gene normalization 1 task of BioCreative II [151]. To take into account inter-
and intra-species protein name ambiguity, instead of using very strict protein-organism source
co-mention criteria based on relative textual distances, we calculated two scores for each
article reflecting: (1) the contextual similarity of the article to the SwissProt protein record;
and (2), the overall association of the article with human species terms from the total set of
tagged species terms. This high recall protein normalization scoring strategy was followed
by a stricter sequence validation that detected links between the mutations and proteins by
checking whether the mutation mentions could be confirmed by the presence of the residues at
the precise sequence positions.
To enhance the recall of the basic sequence look-up validation method, we implemented
five complementary mutation-sequence mapping strategies. These took into account errors
resulting from the wrong detection of the actual directionality of the extracted mutation with
respect to wild type and mutant residues, as well as inconsistencies and alternative sequence
counting between the article and the database kinase sequence. The criteria are summarized
as follows:
1. Basic mutation to sequence position mapping. Basic validation system as described pre-
viously where the algorithm looks for the wild type residue of an extracted mutation
mention at the corresponding protein sequence position.
1In the text-mining domain normalization is the task of linking entities (i.e. protein names), to a common
reference (i.e. a protein database entry)
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2. Alternative mutation directionality look-up. To account for errors in the automatic ex-
traction of the mutation mention directionality (i.e., a mutant residue is considered wild
type by the pipeline), we examined whether the mutant residue could be matched to the
corresponding sequence position.
3. Relative mutation patterns. We considered a sliding window algorithm that searches for a
pattern of mutations in a sequence, in addition to the exact position co-occurrences within
the sequence presented previously. The algorithm recursively scans each position in the
sequence and searches for co-occurrence of the other mutations mentioned in the same
abstract in positions relative to the start, which is used instead of the exact positions
provided to consider the distance between all the mutations in sequence terms. Thus,
this approach has to deal with the different ways the starting position of a protein can
be defined, the most clear being the presence or absence of a signal peptide, but other
examples may arise (e.g., sequencing errors or discrepancies, inclusion of promoter regions,
etc. . . ). Since finding a profile by chance is quite easy for trivial results (the easiest being
patterns comprising just one mutation), a limitation in the complexity of the pattern was
established, taking into consideration only patterns with at least 3 mutations at different
sequence positions.
4. Pro-peptides and mature protein mutation mapping. To handle alternative residue count-
ing when a signal peptide is present, we looked for the wild type residue in a map that
considers the additional length of existing N-terminal signal peptides.
5. Methionine cleavage start site counting. We mapped a mutation by taking into account
putative methionine cleavage and neglecting the N-terminal methionine.
A total of 567 triplets (i.e., article-mutation mention-protein associations) derived from the
abstract corpus was validated by the basic wild type to position mapping. By applying the
additional 4 matching strategies, we recovered 437 additional hits, corresponding to 43.53 %
of the total set of sequence-validated protein-mutation pairs. This added up to a total of 1,004
triplets from 714 abstracts.
When the full-text corpus was considered, the total number of triplets detected by the
basic mapping was 3,911, while another 3,917 triplets were recovered by the additional
sequence mapping methods. This resulted in 7,828 triplets from 3,496 full-text articles.
The average number of sequence-validated mutations in the protein kinase domain was 1.41
and 2.24 for each abstract and full-text article, respectively, implying that each paper often
describes more than one mutation.
When we considered unique mutation-protein pairs irrespective of the number of times
this pair was recovered from the literature, a total of 643 kinase domain mutations from
128 different protein kinases were extracted from PubMed abstracts. When considering the
full-text collection, this number increased considerably and 6,970 mutation-protein pairs were
obtained from 325 protein kinases. Therefore, using full-text articles significantly increased the
mutations recovered (more than 10 times more mutation-protein pairs when compared to those
obtained from the abstracts) and also increased the recall of proteins for which mutations had
been extracted (more than doubling the initial number derived from abstracts alone). The
increased recall with full-text papers justified the computational effort required to retrieve and
pre-process them.
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4.2.3 Manual validation of a representative subset of mutation men-
tions
To determine to what extent the information extracted could be trusted as a source of
potentially missing mutations that still needed to be annotated in the databases, we manually
validated a random sample of 100 mutation mentions from PubMed abstracts.
We found (Figure 4.5) that for 23% of the mutations, there was a confirmed record in
at least one of the analyzed knowledge bases (we will discuss this aspect more thoroughly
below). Moreover, 41% of the results corresponded to correct protein-mutation assignments
obtained by our extraction pipeline that were missing in the repositories studied. In addition,
8% of the mutations were examples of mentions from orthologues of human proteins having
the same amino acid at the specified position. These results can also be considered positive
hits since they mostly correspond to animal models for the indirect analysis of human kinases.
Interestingly, a small proportion (2%) of the records corresponded to mutations too ambiguous
even for human curators and therefore, they were inherently unpredictable for the automated
methods.
We estimate that around three quarters (72%) of the mutations that we extracted with
our automated text-mining pipeline corresponded to correct mutation mentions in the liter-
ature. These correct predictions integrate mutation mentions that correspond to previously
annotated mutations, and reliable novel mutations published in the literature but not recorded
in the knowledge bases for both humans and closely orthologous models.
4.2.4 Evaluation of the mutation extraction pipeline by comparison
to existing repositories of experimentally curated data
We assessed whether the mutations recovered from the literature by our system were already
present in commonly used databases or if they were newly recovered. Accordingly, we studied
the overlap between the mutations in the protein kinase domain recorded in some representative
state-of-the-art knowledge bases and the mutation mentions automatically retrieved by our
literature-mining pipeline.
Moreover, we wanted to assess how many mutations we could recover from a combined
dataset of mutations from all the studied repositories in order to determine our extraction
pipeline’s coverage of existing knowledge. We built a non-redundant set with 1,265 mutations
in 317 different kinases, which also highlighted that the different knowledge bases were
unevenly represented depending on the purpose of each database. The weight of each database
is reported in Table 4.1, where the overlap between the different databases is assessed.
Out of the 1,265 mutations in the combined dataset, 148 (11.70%) were found by our
automated pipeline when the PubMed abstracts were scanned. By contrast, 354 (27.98%)
mutations were recovered when full-text articles were considered and 399 (31.54%) when the
combined abstract/full-text dataset was used. The recall of mutations from the databases is a
way to measure the capacity of the methodology and it provides additional information in the
form of descriptive sentences about the recorded mutations, which clearly justifies the computa-
tional effort required. This aspect of the extraction pipeline will be discussed thoroughly below.
Interestingly, only a small fraction of the mutations detected in the datasets of high-
throughput genotyping studies (COSMIC [27] and Greenman/Wood [14, 16]) corresponded to
previously identified mutations mentioned in the literature. This is consistent with the fact
that mutations from high-throughput projects are generally not studied in detail and they are
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Figure 4.5: Success estimate of the extraction pipeline by expert human manual validation. These
percentages were calculated by a manual sampling and validation protocol carried out on 100 abstracts.
The categories are described as follows:
Correct - Database Confirmed: These are the mutations that have already been found in at least one of
the mutation repositories analyzed (Uniprot, SAAPdb, COSMIC, KinMutBase or Greenman/Wood).
Correct - Manual Validation: This subset corresponds to the mutation-protein pairs that were found
to be correct after manual validation of 100 abstracts.
Correct - Orthologue: This subset corresponds to the cases where mapping is confirmed by manual
validation and the mutation is mapped to a non-human orthologue.
Incorrect mutation to protein assignment: This corresponds to the cases where at least 2 proteins in the
same text share the same amino acid at the mutated position and the algorithm confuses the pairing.
Incorrect mutation assignment: These are cases where the mutation is not properly identified.
Too ambiguous even for human experts: These are cases that lack enough supporting information even
for human curators.
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therefore not reported in the literature.
The results for the neutral subset of SAAPdb [74] are particularly striking. Except for
a couple of cases, we did not find references to mutations from this set in the literature,
regardless of the type of collection analyzed. This is probably because a considerable fraction
of these mutations have a neutral phenotype and thus, they are not mentioned further in
the literature. Another interesting observation was that contrasting results were obtained for
natural variants and induced mutations in the SwissProt Variant database [84]. We observed
differences in the percentage overlap of mutations recovered from abstracts and full-text
articles when the two types of mutations were considered individually. This result suggests
that experimentally-induced mutations annotated in SwissProt are usually not mentioned in
the abstracts but rather, they only appear in the full-text articles, while the converse is true
for natural variants. This agrees with the underlying idea of natural variants being primary
discoveries in their respective papers, whereas induced mutations are usually reported for
experiments whose goal is not to report novel mutations but biochemically characterize the
wild type residues.
There were mutation records that we could not find any evidence of in the literature
and among the reasons why our system could not detect them, the most plausible are:
1. Lack of accessibility to full-text articles or additional materials.
2. General limitations in terms of recall of the mutation mention extraction methods.
3. Limitations in protein normalization.
4. Limitations in the association of mutations with corresponding sequences.
Knowledge base Muts. Weight Abstract Full-text Combined
SwissProt; all 710 56.13% 134 [18.87%] 328 [46.20%] 365 [51.41%]
SwissProt; natural variants 459 36.28% 99 [21.57%] 196 [42.70%] 230 [50.11%]
SwissProt; mutagenesis 251 19.84% 35 [13.94%] 132 [52.59%] 135 [53.78%]
SAAPdb; all 610 48.22% 65 [10.66%] 106 [17.38%] 125 [20.49%]
SAAPdb; pathogenic deviations 323 25.53% 64 [19.81%] 105 [32.51%] 123 [38.08%]
SAAPdb; neutral SNPs 287 22.69% 1 [0.35%] 1 [0.35%] 2 [0.70%]
Greenman/Wood; all 254 20.08% 4 [1.57%] 12 [4.72%] 13 [5.12%]
Greenman/Wood; driver 119 9.04% 3 [2.52%] 9 [7.56%] 9 [7.56%]
Greenman/Wood; passenger 135 10.67% 1 [0.74%] 3 [2.22%] 4 [2.96%]
COSMIC 200 15.81% 4 [2.00%] 11 [5.50%] 12 [6.00%]
KinMutBase 83 6.56% 32 [38.55%] 32 [38.55%] 43 [51.81%]
All databases 1265 - 148 [11.70%] 354 [27.98%] 399 [31.54%]
Table 4.1: Coverage in the existing knowledge bases of the mutations extracted from the literature.
The percentages in brackets show the fraction of each database recovered by our text-mining pipeline.
4.2.5 Phylogenetic distribution of the extracted mutations
We analyzed putative biases in the distribution of the mutation mentions by superimposing the
topology of the protein kinase superfamily defined by KinBase [40] onto the results presented
above (please refer to the Introduction for a more detailed description of the different kinase
groups). There are large differences in the total number of mutations in each of the clades,
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with more than half of the mutations in either the TK or CMGC groups (the distribution of
mutations across the different kinase groups is shown in Figure 4.6, panel A). Interestingly, our
system could extract mutations from all the groups using either PubMed abstracts or full-text
articles.
The normalized distribution of mutations in the different protein kinase domains de-
fined by KinBase was established when either abstracts or full-text articles were used (Figure
4.6, panel B). It is clear that no matter which dataset was used, abstract or full-text articles,
the distributions were very similar and independent of the absolute number of each dataset.
4.2.6 Location of the extracted mutation mentions in the protein ki-
nase domain
Intuitively, relevant regions in the protein structure would accumulate more mutation mentions
and conversely, the number of times a particular mutation is mentioned would indicate the
relevance of that mutation for protein function. Thus, we considered the mutation density
distribution within a consensus protein kinase domain model (Figure 4.7). Although mutations
were scattered all around the consensus structure of the kinase domain, a higher mutation
density was found close to functionally relevant elements, such as the ATP-binding pocket or
the DFG motif in the activation loop. In fact, the ATP-binding Lys-64 is associated with most
mutations, with a total of 65 mutations, followed by several regions in the activation segment
with up to 39 mutations per residue. By contrast, regions with a low mutation density are not
functionally relevant.
4.2.7 The other side of the coin: from mutations to the literature
We described earlier the importance of our system in retrieving mutations from the literature
that are not reported in the databases. A second application of the method that is at least
equally importantly is its use as an information repository. The added value of our system
is the vast amount of manuscript references and sentences that describe the experimental
conditions and the implications of the mutations. The latter constitute an important source of
information to help assess the pathogenicity of mutations, and in the best possible scenario,
the biochemical mechanism and/or phenotypic consequences.
Mutations in the epidermal growth factor receptor (EGFR) provide a working example
of such a utility. EGFR is a protein kinase involved in controlling cell growth and dif-
ferentiation, which has been linked to breast cancer development. EGFR ligation elicits
dimerization, internalization of the binary complex, induction of tyrosine kinase activity,
stimulation of cell DNA synthesis and cell proliferation. Several well-known mutations in this
protein are present in the current state-of-the-art databases: SwissProt [84], COSMIC [27],
Greenman/Wood [14,16], KinMutBase [75], and SAAPdb [74]. In some cases, the contribution
of these mutations to disease has been studied and annotated in the corresponding databases.
For instance, the somatic mutations G719S, L858R and T790M have already been associated
with lung cancer [14,152].
Our system recalled a further 32 novel mutation mentions from the literature that have
not been reported in the databases. To better understand the effect of these new mutations,
our approach provided contextual information to help interpret the role played by the muta-
tions. For example, in the case of Y845F (transformed to Y869F due to the presence of a signal
peptide) we found the following sentences: ‘Furthermore, transient expression of a Y845F
variant EGFR in murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis
to non-stimulated levels.’ (PubMed:10075741); ‘Stably transfected B82L cells with a point
4.2. AUTOMATIC LITERATURE-MINING 57
Figure 4.6: Distribution of literature-extracted mutations in the groups defined by KinBase [40].
Panel A: Number of mutations from the literature housed in the different protein kinase domain groups
defined by KinBase when either abstracts or full-text articles are used.
Panel B: Normalized distribution of mutations in the topology of the protein kinase superfamily when
either the abstract or the full-text collection is considered.
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Figure 4.7: Density of mutations
extracted from the literature within
the structure of a consensus pro-
tein kinase domain model. The
ATP-binding pocket is represented by
sticks. The residue with the high-
est density of mutations is the ATP-
binding Lys-64 (red sticks), with a
total of 65 mentions, followed by
residues in the activation segment (up
to 39 mutations per residue) and oth-
ers in the ATP-binding pocket. The
DFG motif (activation segment es-
sential for kinase function) accumu-
lates many mutations. The light
brown asparagine (central part of the
figure) in the inter-lobe region has
more than 10 mutations.
mutation of the EGFR at Tyr-845 (B82L-Y845F) exhibited only basal Ras activity following
exposure to Zn2+’ (PubMed:11983694); and ‘In contrast, LPA-elicited DNA synthesis and
migration were augmented in cells expressing EGFR, EGFR(K721A), or EGFR(Y845F), but
not EGFR(Y5F), although the PDGF responses were indistinguishable’ (PubMed:15364923).
The information retrieved suggests that Tyr-845 is involved in DNA synthesis provoked by
EGF binding to the receptor.
Our system also retrieved functionally neutral results that are often discarded and not
stored in the databases, despite containing useful information for the contextual interpretation
of the involvement of specific residues in protein function: ‘Unexpectedly, the Y845F mutant
EGFR was found to retain its full kinase activity and its ability to activate the adapter protein
SHC and extracellular signal-regulated kinase ERK2 in response to EGF, demonstrating that
the mitogenic pathway involving phosphorylation of Y845 is independent of ERK2-activation’
(PubMed:9990038). The structural model of this protein and a summary of the information
gathered from the literature by our system regarding specific residues and mutations are
represented in Figure 4.8.
4.3 Characterization of the residues that disrupt protein
kinase function
In the examples analyzed above, we found that pathogenic mutations targeted structurally
and functionally important residues, while neutral polymorphisms were scattered throughout
the protein (Figure 4.9). To further explore this issue, we assessed whether there was a
preferential distribution of the amino acids according to their pathogenicity and to what extent
the pathogenicity of the mutations was explained by the relevance of the residues harboring
them. In this study we focused on protein kinases, a well-studied set of proteins associated
with cancer onset and progression.
We mapped the different types of mutations onto a consensus structural model repre-
senting the whole protein kinase superfamily and analyzed their distribution at evolutionary
conserved positions and known functional regions (buried, functional and conserved). Two
4.3. RESIDUES THAT DISRUPT PROTEIN KINASE FUNCTION 59
Figure 4.8: Mock-up of the structural model of the epidermal growth factor receptor (EGFR, pdb
1m17) together with a summary of the residue and mutation information gathered from the literature
by our automatic literature-mining pipeline.
different groups of datasets were used for the comparison, one with disease-associated mutations
and the other with neutral polymorphisms. Driver somatic mutations (those predicted to be
involved in cancer onset) were compared to passenger ones (supposedly neutral) [13, 14, 16],
while pathogenic germline deviations (mutations with structural evidence linking them to
disease) from SAAPdb [74] were compared with neutral polymorphisms.
In the Introduction, we elaborated on the differences between these two separate groups
of mutations. Germline mutations are inherited and therefore, they are present in every cell of
the individual, whereas somatic mutations are acquired after conception, mainly induced by
external agents or duplication errors. Consequently, somatic mutations do not occur in all the
cells of an individual and they are not transmitted to the offspring.
Irrespective of the dataset, the significance of the proximity of different sets of muta-
tions to specific areas of the protein was assessed through the Xd measure [133]. We chose
this weighted measure of distance distributions to prioritize the differences in regions closer to
the regions studied (for example, binding sites) as opposed to differences in the distribution
of residues far from the regions of interest. The Xd value has been used as a standard to
measure the difference between the distribution of predicted residues in the context of the
CASP challenge [134,135,153]. For full details see the Methods section.
To provide a single measure that summarizes the behavior of the whole superfamily
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while accounting for a reasonable number of mutations capable of achieving reliable statistical
significance, we transferred the mutations from each specific protein kinase onto a consensus
model that we considered a good proxy for the common structural features of the superfamily
(Figure 4.9). The protein kinase superfamily is amenable for this type of approach due to the
structural similarities among its members [154,155].
4.3.1 A consensus model of the protein kinase superfamily
A consensus model of the basic structure of the kinase domain was constructed, representing
the average structure of a large number of kinases in the human kinome and capturing the
common characteristics of these proteins in a single structure. To build the model, we first
selected MAP3K1 as a standard representative sequence of the family from a manually-curated
multiple sequence alignment of the human kinome constructed with MUSCLE [123]. A model
of the sequence selected was built with Modeller [156], which assembled all the closely related
PDB template structures returned from a BLAST search [122]. The consensus model and some
of the most important functional regions are shown in Figure 4.9.
4.3.2 Distribution of somatic driver and passenger mutations
In this experiment, the datasets used corresponded to the somatic mutations discovered in
cancer resequencing projects [14, 16] and that were located within the protein kinase domain.
The pathogenic dataset corresponded to the somatic mutations classified as ‘drivers’ (those
that are more probably disease-associated), while the neutral dataset consisted of ‘passenger’
mutations (those not thought to be pathogenic).
We assessed the significance of the proximity of different sets of mutations to specific
areas of the protein using the harmonic deviation, Xd [133]. This was performed to prioritize
the differences in the regions near to the studied regions (for example, binding sites) over
the differences in the distribution of residues in positions far from the regions of interest.
To compare the two distributions, ∆Xd was calculated as the difference of Xdpassengers and
Xddrivers. Greater positive values indicated that passengers localize closer than drivers (on
average) to the residues annotated with the feature studied, while greater negative values
indicated that drivers co-localize with the regions under study. For explanatory purposes,
an arbitrary threshold of 0.5 was chosen to consider the two distributions of distances to be
sufficiently different. The results of these analyses are displayed in Table 4.2.
Mean Dist.
drivers (A˚)
Mean Dist.
passengers (A˚)
XddriverXdpass ∆Xd
Seq. conservation, Shannon 7.26 7.43 1.27 0.04 -1.23
Seq. conservation, AL2CO 8.46 8.51 1.42 0.54 -0.88
Accessibility 3.88 3.77 -0.88 -0.87 -0.01
Catalytic site, FireDB [127] 11.36 10.80 0.56 -0.39 -0.95
Catalytic site, Knight [46] 14.34 13.85 0.55 0.00 -0.55
Tree-determinants 6.50 6.71 1.25 -0.30 -1.55
Table 4.2: Distribution of driver and passenger somatic mutations in regions that are evolutionary
conserved, that display structural conservation or that retain functionality.
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Figure 4.9: Our model structure of a human protein kinase domain based on MAP3K1. The model
shows the basic two-lobe kinase fold, with the N- and C-terminal (cyan and orange, respectively) lobes
joined by a hinge region (magenta). Recognition of the substrate protein is mainly through interaction
with the activation segment (green), a region in the C-terminal lobe. ATP binds at a site between
the two lobes, where five highly conserved residues guide the positioning of the molecule: K74, E96,
D171, N176 and D190 (yellow, numbers corresponding to positions in the generated structural model).
The substrate-binding groove is located between the catalytic loop, the P+1 loop (activation segment),
helix D, helix F, helix G and helix H.
4.3.2.1 Cancer mutations in relation to sequence-conserved regions
We examined the distribution of the distances between mutated residues and conserved regions
in the different protein kinases using two different definitions of sequence conservation. First,
a simplistic approach was used based on Shannon’s entropy [125] in the context of identity.
Accordingly, 21 bins were characterized that each reflected an amino acid, with an extra bin
for gaps. The positions in the multiple sequence alignment were labeled as conserved if their
Shannon’s entropy was less than 0.20. Additionally, to avoid unreliable results, alignment
positions with more than 75% gaps were automatically discarded. Thus, a total of 20 fulfilled
the requirements to be considered conserved and 6 of them were driver mutations. Figure
4.10 shows that drivers tended to locate closer to conserved regions than passenger mutations,
which was also reflected in the Xd values: ∆Xd = -1.23, Table 4.2.
We also considered an alternative measure of sequence conservation, AL2CO [126]. An advan-
tage of this program over the earlier method is that AL2CO weights the sequences in order to
correct for the unequal distances between the sequences in the alignment, and it uses a scoring
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Figure 4.10: Driver and passenger mutations at the conserved sequence regions calculated in terms
of Shannon’s entropy.
Panel A: Driver mutations (red) and conserved positions (blue) mapped onto the consensus structural
model. Positions with both a driver mutation and a conserved residue are displayed in magenta.
Panel B: The histograms show the distribution of distances between conserved positions and driver
(red) or passenger (green) mutations.
matrix to consider the most common positions occupied by residues with similar physicochemi-
cal properties. As residues with a normalized conservation index threshold of 70% were deemed
to be conserved, there were in total 14 conserved residues, of which 4 were driver mutations
(Figure 4.11, panel A displays the position of these conserved residues and the driver mutations,
with driver mutations tending to locate close to the conserved positions). Moreover, we observed
that drivers were nearer to the conserved positions than passenger mutations (∆Xd = −0.88,
Table 4.2 and Figure 4.11, panel B).
4.3.2.2 Cancer mutations and solvent accessibility
We analyzed the distribution of the mutated positions with respect to ‘buried’ residues, which
were defined as those with a relative solvent accessibility score of less than 16% when mea-
sured with Naccess (Hubbard, unpublished). Out of the 99 buried residues in the protein kinase
domain, 16 and 17 residues coincided with driver and passenger mutations, respectively. More-
over, we found no differences in the weighted distribution of the distances between the two
kinds of mutations (∆Xd = −0.01, Table 4.2).
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Figure 4.11: Driver and passenger mutations at the conserved positions calculated with AL2CO [126].
Panel A: Driver mutations (red) and conserved positions (blue) mapped onto the consensus model struc-
ture. Positions containing both a driver mutation and a conserved residue are displayed in magenta.
Panel B: The histograms show the distribution of distances between the conserved positions and the
driver (red) or passenger (green) mutations.
4.3.2.3 Cancer mutations and the ATP-binding site
The functionally active region of protein kinases was defined in the Introduction. However, it
is worth remembering that the ATP-binding pocket has three main parts:
1. A region of hydrophobic residues clustered around the adenosine of ATP;
2. An area around the γ-phosphate of ATP and the divalent cation (the catalytic site) that
is primarily enclosed by charged residues;
3. A region in the large lobe composed of both hydrophobic and polar residues below the
ATP that stabilizes this region and that may mediate substrate interactions.
There are 32 residues in FireDB [127] that describe the consensus ATP-binding pocket of
the protein kinase superfamily (Figure 4.12), while others have limited the catalytic region of
the kinases to a subset of these residues [46], considering only the five highly conserved residues
that are responsible for ATP positioning and for stabilizing the active conformation in the
catalytic mechanism:
64 CHAPTER 4. RESULTS
1. Lys-74, which interacts with the alpha- and beta-phosphates of ATP and stabilizes it.
2. Glu-96, which forms a salt bridge with Lys-74 and increases the stability of this network.
3. Asp-171, which serves as the catalytic base, initiating phosphotransfer by deprotonating
the acceptor serine, threonine or tyrosine.
4. Asn-176, which interacts with a secondary divalent cation, thereby positioning the γ-
phosphate of ATP.
5. Asp-190, which chelates the primary divalent cation and indirectly positions ATP.
Driver mutations appeared near the ATP-binding pocket (Figure 4.12, panel A) and indeed,
8 out of the 32 residues in this pocket correspond to positions with a driver mutation. When
the distance distribution of point mutations was examined (Figure 4.12, panels B and C),
driver mutations were closer to the positions forming the ATP-binding pocket than passenger
mutations, whether this pocket was defined by either FireDB or Knight and coworkers [46].
Nevertheless, this trend was stronger for the residues in direct contact with the substrate
identified by FireDB, as supported by the differences in the harmonic deviations ∆XdFireDB =
−0.95 and ∆XdKnight = −0.55 (Table 4.2) for the ATP-binding site.
Figure 4.12: Driver and passenger mutations in the ATP-binding pocket.
Panel A: Driver mutations (red) mapped onto the ATP-binding pocket (blue). Positions that have a
driver mutation and are part of the catalytic site are displayed in magenta. We have used the set of
binding residues extracted from FireDB as an operational definition of the consensus ATP binding site
of the kinases. This definition includes the five highly conserved residues mentioned by Knight [46]:
K74, E96, E171, N176 and E190 (represented by sticks).
Panel B: The histograms show the distribution of distances between residues forming the ATP-binding
pocket, according to FireDB [127], and driver (red) or passenger (green) mutations.
Panel C: The histograms show the distribution of distances between residues forming the ATP-binding
pocket, according to Knight and coworkers [46], and driver (red) or passenger (green) mutations.
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4.3.2.4 Cancer mutations and tree-determinants
We define tree-determinants as residues putatively involved in binding specificity. They are
often used as a proxy for functionally important regions in protein kinases, particularly those
related to the specific functions of each of the groups, and therefore, they are also referred to
as specificity-determining positions (SDPs) [129, 131, 157]. Residues differentially conserved in
the various groups of protein kinases were identified for each of the 8 groups KinBase uses to
categorize the human kinome [40] using the S3Det method [131]. We identified 35 residues
as sufficient to differentiate between the groups, i.e., residues that are conserved within a
specific kinase group but different from those of the rest of the groups. The most statistically
significant tree-determinants were distributed among the kinase groups as follows: 4 in the
AGC, 4 in CK1, 8 in CMGC and 9 in STE.
Tree-determinants were mapped onto the representative structure (Figure 4.13, panel A)
and while a representative set of tree-determinants clustered near the ATP-binding pocket,
others were found around the bundle of helices that form the C-lobe. This region is known
to bind substrates, interact with other protein partners and participate in intermolecular
signaling [158]. The distribution of point mutations with respect to the positions of the
tree-determinants was determined (Figure 4.13, panel B) and the corresponding Xd values
were compared (∆Xd = −1.55, Table 4.2). Drivers were closer than passenger mutations to
positions that are important in determining kinase group sub-specificity.
Figure 4.13: Driver and passenger mutations in specificity regions.
Panel A: Driver mutations (red) and tree-determinants (blue) mapped onto the consensus structural
model. Positions with both a driver mutation and a tree-determinant are displayed in magenta. While
a representative set of the Tree-Determinants clustered near the ATP binding pocket of the protein,
others could be found around the bundle of helices that conform the C-lobe. This region is known
to bind substrates, interact with other protein partners and to participate in intermolecular signaling
events.
Panel B: The histograms show the distribution of distances between residues determining the kinase
group sub-specificity and driver (red) or passenger (green) mutations.
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4.3.3 Distribution of pathogenic germline mutations
Following a similar approach to the one previously reported for the driver and passenger
somatic mutations, we mapped different types of germline mutations onto a representative
structural model of the protein kinase superfamily and analyzed their distribution relative
to evolutionary conserved positions and known functional regions. The two datasets used to
compare pathogenic and neutral mutations were downloaded from SAAPdb. The pathogenic
dataset corresponded to germline mutations classified as ‘pathogenic deviations’ (PDs) and
more likely to be associated with disease, while the neutral dataset consisted of ‘neutral SNPs’
that are widespread in the population and not likely to be pathogenic. Both datasets were
limited to mutations within the protein kinase domain.
Figure 4.14: Our model structure of the human protein kinase domain based on MAP3K1. 47
positions with at least one pathogenic mutation (red), those that correspond to residues that are
putatively associated with disease. By contrast, 27 positions had neutral SNPs (green).
We mapped 47 positions containing at least one PD and 27 positions with at least one SNP
onto the consensus model described previously (Figure 4.14. We calculated the Xd scores of the
distribution of distances [133] to prioritize the differences in regions closer to those studied (for
example binding sites) over the differences in the distribution of residues at positions far from
the regions of interest. We undertook a similar approach to analyse somatic mutations. Again,
to compare the two distributions, the ∆Xd was calculated as the difference of the XdSNP
and XdPD. Greater negative values indicated that the PDs and the positions under study
co-localize, while greater positive values indicated the contrary. An arbitrary threshold of 0.5
was chosen as sufficient to discern between the classes (the results of these analyses are shown
in Table 4.3).
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Mean Dist.
PDs (A˚)
Mean Dist.
SNPs (A˚)
XdPD XdSNP ∆Xd
Seq. conservation, Shannon 7.17 6.71 -0.01 -0.14 -0.13
Seq. conservation, AL2CO 8.49 10.49 1.07 0.55 -0.52
Accessibility 2.94 3.63 1.84 1.01 -0.83
Catalytic site, FireDB [127] 8.69 12.66 3.92 -0.84 -4.76
Catalytic site, Knight [46] 11.89 16.26 1.35 -0.98 -2.33
Tree-determinants 6.99 7.94 0.31 -1.67 -1.98
Table 4.3: Distribution of PDs and SNPs in regions that are evolutionary conserved, display structural
conservation or retain functionality
4.3.3.1 Germline mutations and sequence conservation
Sequence conservation was evaluated with AL2CO [126] and as in the protocol described
earlier for driver and passenger somatic mutations, residues with a normalized conservation
index threshold of 70% were labeled as conserved. This analysis revealed that 3 out of the
14 conserved residues coincided with PDs and two with neutral SNPs. Indeed, conserved
positions tended to be surrounded by PDs even if there were not many exact coincidences of
conserved residues and PDs (Figure 4.15, panel A). In the histograms showing the distribution
of the distances between mutated and conserved positions for PDs and neutral polymorphisms
(Figure 4.15, panel B), in general PDs in the protein kinase domain were closer to conserved
residues than neutral polymorphisms, as further supported by the ∆Xd of -0.52 (Table 4.3).
A similar trend was observed when analyzing Shannon’s entropy. Positions in a multiple se-
quence alignment were deemed to be conserved if their Shannon’s entropy was less than 0.20,
and to ensure the results were more reliable, the alignment positions with more than 75% gaps
were discarded. Under these constraints, 20 residues were identified as conserved and 4 of them
coincided with the position of a PD, including the three residues observed with AL2CO and a
glycine in the glycine-rich loop. In addition, the same two neutral SNPs were highly conserved
(Figure 4.16, panel A). In the histograms of the distribution of the distances between mutated
and conserved positions (Figure 4.16, panel B), the PDs in the protein kinase domain tended to
be slightly closer to the conserved residues than neutral polymorphisms. The ∆Xd was small
at only -0.13 (Table 4.3), corroborating that this trend was not very strong.
4.3.3.2 Germline mutations and accessibility to the solvent
We identified 99 residues as inaccessible to the solvent under the same constraints defined for
the driver and passenger somatic mutations, i.e., relative residue solvent accessibility score of
less than 16% measured with Naccess (Hubbard, unpublished). Out of these 99 buried residues,
20 were PDs (Figure 4.17, panel A) and 12 were neutral SNPs. The distribution of distances
(Figure 4.17, panel B) clearly demonstrates PDs being closer to buried residues in the protein
core. Analyzing the distance between mutated positions and solvent-inaccessible residues re-
vealed that PDs were closer to buried residues than neutral polymorphisms, supported by an
Xd difference of -0.83 (Table 4.3).
4.3.3.3 Germline mutations and catalytic sites
The ATP-binding pocket of the kinase superfamily was defined as the set of residues extracted
from FireDB [127], including the 32 residues (Figure 4.18, panel A) that directly contact ATP in
the binding pocket. This definition includes the five highly conserved residues that play a critical
role in positioning ATP and stabilizing the active conformation in the catalytic mechanism [46].
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Figure 4.15: Pathogenic deviations (PD) and neutral polymorphisms (SNP) at conserved positions
in the protein kinase domain calculated with AL2CO [126].
Panel A: Pathogenic deviations (red) and conserved positions (blue) mapped onto the consensus model
structure. Positions with both a pathogenic mutation and a conserved residue are displayed in magenta.
Panel B: The histograms show the distribution of distances between conserved positions and pathogenic
deviations (red) or neutral SNPs (green).
Regardless of the definition used (FireDB or Knight), PDs tended to locate in the cat-
alytic region or at least around it. Indeed, 13 out of the 32 residues were annotated as PDs,
whereas only 3 were neutral SNPs. Moreover, two of the five residues thought to be essential
for the correct functioning of the ATP-binding pocket [46] were annotated as PDs. Both
the distance distribution histograms (Figure 4.18, panels B and C) and the ∆Xd results
(∆XdFireDB = −4.76 and ∆XdKnight = −2.33, Table 4.3) support this trend.
4.3.3.4 Germline mutations and regions of functional sub-specificity
As for driver and passenger somatic mutations, we also investigated the relationship between
tree-determinants and germline mutations. Tree-determinants are a proxy for functionally
important regions in protein kinases, particularly those related with the specific functions of
each one of the eight groups in which KinBase classifies the human kinome [40]. Consequently,
they are often referred as subspecificity determining positions (SDPs) [129, 131, 157]. Our
recent automation of the sequence-space approach, S3Ddet [131], identified 32 unique positions
as discriminative between kinase specificity groups. A number of these residues clustered close
to the ATP-binding pocket, while others were concentrated around the bundle of helices in the
C-lobe, which is known to bind substrates, interact with other protein partners and participate
in intermolecular signaling [158].
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Figure 4.16: Pathogenic deviations (PD) and neutral polymorphisms (SNP) at conserved positions
in the protein kinase domain calculated in terms of Shannon’s entropy [159].
Panel A: Pathogenic deviations (red) and conserved positions (blue) mapped onto the consensus model
structure. Positions with both a pathogenic mutation and a conserved residue are displayed in magenta.
Panel B: The histograms show the distribution of distances between conserved positions and pathogenic
deviations (red) or neutral SNPs (green).
Pathogenic deviations located closer to tree-determinant positions than neutral SNPs.
PDs, if not exactly in positions that were annotated as tree-determinants, clustered around
specificity residues. In fact, out of the 32 tree-determinants mapped onto the consensus model,
five were annotated as pathogenic and only two as neutral. This is especially relevant for
residues around the ATP-binding pocket but it was also appreciable in the other function spe-
cific tree-determinants (Figure 4.19, panel A depicts the localization of pathogenic deviations
and kinase specificity-determining residues). There was also a clear difference in Xd values
(∆Xd = −1.98, Table 4.3) and the histograms showing the distribution of distances (Figure
4.19, panel B), indicating that significant differences between PDs and SNPs exist regarding
their proximity to positions characterized as important for kinase function and sub-specificity.
4.3.4 Assessing the possible functional role of relevant kinase muta-
tions by their sequence-structure characteristics
In the previous section, we mapped all the knowledge accumulated for the protein kinase do-
main onto a consensus model under the assumption that regions important for kinase structure
and function can be used as a reference to interpret the mutations in this superfamily. The
accumulation of information clearly increases the significance of the results provided and makes
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Figure 4.17: Pathogenic deviations (PD) and neutral polymorphisms (SNP) in regions of the protein
that are solvent-inaccessible and form the core of the protein.
Panel A: Pathogenic deviations (red) and buried positions (blue) mapped onto the consensus structural
model. Positions with both a pathogenic mutation and a buried residue are displayed in magenta.
Panel B: The histograms show the distribution of distances between solvent-inaccessible positions and
pathogenic deviations (red) or neutral SNPs (green).
the distribution of polymorphisms more reliable and accurate. Once the relevance of the ana-
lyzed regions in the structure was understood, our approach also provided an insight into the
specific biomedical implications of individual kinase mutations.
4.3.4.1 Diabetes, acanthosis nigricans and mutations in the insulin receptor
Mutations in the human insulin receptor gene (INSR) have been associated with disease and
defects in the INSR have been linked to patients suffering from insulin-resistant diabetes
mellitus associated with acanthosis nigricans type A (IRAN type A, MIM: 610549). IRAN
type A is characterized by severe insulin resistance manifesting as marked hyperinsulinemia,
no response to exogenous insulin, ovarian hyperandrogenism in adolescent female patients and
the skin lesion acanthosis nigricans. The relationship between this disease and the mutations
in kinases is reflected in OMIM and the literature [150]. Recent studies further characterized
this relationship between insulin resistance and disease [160], while acanthosis nigricans has
been linked to mutations in other kinases, such as fibroblast growth factor receptors II and
III [161–163].
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Figure 4.18: Pathogenic deviations (PD) and neutral polymorphisms (SNP) in the ATP-binding
pocket.
Panel A: Pathogenic deviations (red) and conserved positions (blue) mapped onto the consensus model
structure. Positions with both a pathogenic mutation and a buried residue are displayed in magenta.
We used the set of residues extracted from FireDB as an operational definition of the binding site. This
definition includes the five highly conserved residues mentioned in Knight et al. (2007) [46]: K74, E96,
E171, N176 and E190 (represented by sticks).
Panel B: The histograms show the distribution of distances between residues forming the ATP-binding
pocket, according to FireDB [127], and pathogenic deviations (red) or neutral SNPs (green).
Panel C: The histograms show the distribution of distances between residues forming the ATP-binding
pocket, according to Knight and co-workers [46], and pathogenic deviations (red) or neutral SNPs
(green).
We were interested in identifying disease-prone mutations based on the accumulation of
pathogenic factors in the position of the mutations. For instance, we identified A1161T, a
mutation that introduces an alanine-threonine shift in the INSR. This mutation is at a catalytic
residue according to FireDB [127] and it is important for family specificity [131]. Perturbing
the ATP-binding pocket might impair phosphorylation and reduce enzymatic activity, thereby
producing an aberrant phenotype. To corroborate this prediction, we found that this mutation
has been defined in SAAPdb [74] as a pathogenic deviation.
4.3.4.2 The carcinogenic role of mutations in B-raf
Another interesting example is the mutation D594G in B-raf proto-oncogene. The RAF gene
family has three members (ARAF1, BRAF and RAF1), each encoding a serine/threonine
kinase that is regulated by binding to RAS, as component of the RAS-RAF-MEK-ERK-MAP
kinase pathway that plays a critical role in cell proliferation. B-raf is frequently activated in
cancer cells, especially in non-Hodgkin lymphoma (NHL) and mutated B-raf proteins have
been shown to have greater kinase activity [148], indicating that the RAS-RAF kinase pathway
is probably regulated by somatic mutations of B-raf in some cancers.
Here, we identified D594G as a pathogenic mutation that introduces an Asp/Gly change in
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Figure 4.19: Pathogenic deviations (PD) and neutral polymorphisms (SNP) in regions of kinase-
group sub-specificity.
Panel A: Pathogenic deviations (red) and tree-determinants (blue) mapped onto the consensus model
structure. Positions with both a pathogenic mutation and a specificity-determining residue are dis-
played in magenta.
Panel B: The histograms show the distribution of distances between tree-determinants and pathogenic
deviations (red) or neutral SNPs (green).
the activation loop of the kinase family. Our analysis highlighted the importance of this
amino acid in ATP binding, as described by FireDB [127], and as a residue conferring family
sub-specificity [131]. From these descriptions, we derived the hypothetical role of this mutation
in the development of NHL as described above. To confirm this hypothesis, SAAPdb [74]
and our text-mining pipeline [150] indicated that this mutation is pathogenic and involved in
the disruption of the binding site, interacting surface, quaternary structure and the essential
scaffolding of hydrogen bonds.
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4.4 Prioritizing pathogenic mutations in the protein ki-
nase superfamily
Human protein kinases fulfill a wide variety of physiological functions and while most muta-
tions described in this family are tolerated without significantly disrupting the corresponding
structures or functions, some have been linked to a variety of human diseases, including cancer.
We have already discussed the preferential distribution of germline pathogenic deviations [155]
and driver somatic mutations [154] to regions of functional and structural importance. Here,
we present the basis for the development of a computational method to predict the impact of
mutations on the function of protein kinases based on these features.
We explored the significance of disease-associated mutations in terms of sequence-derived
characteristics at different levels:
1. At the gene level: membership to a KinBase group and Gene Ontology terms.
2. At the domain level: the occurrence of the mutation inside a PFAM domain.
3. At the residue level: several properties including amino acid types, functional annotations
from SwissProt and FireDB, and specificity-determining positions (SDPs).
Accordingly, we analyzed the independent significance of these properties and their combination
with a support vector machine (SVM).
4.4.1 Construction of the disease and neutral datasets
The method was trained and evaluated using a dataset derived from UniProt [72], which has
been benchmarked for a number of classifiers with satisfactory results [136]. After the filtering
pipeline described in the Methods, 865 mutations in 65 human kinases formed the ‘disease
dataset’, whereas the ‘neutral dataset’ consisted of 2,627 mutations in 447 human kinases.
4.4.2 Optimization of the prediction method
To classify the mutations in the human kinome as disease-associated or neutral according to
the sequence features of the mutations, we used a Support Vector Machine (SVM). This type
of approach has previously been widely used to automatically prioritize disease-associated
mutations [102,107,108,140,164] and it has been demonstrated to outperform other approaches
such as Bayesian classifiers and neural networks [107].
Our implementation of the SVM relied on a radial basis function kernel. Two parame-
ters are crucial for the performance of the classifier, the soft-margin penalty (C) and the
radius (γ): C represents the amount of errors allowed during the training and evaluation steps,
while γ represents the width of the SVM radial function. These parameters can be optimized
to improve the predictions and consequently, the parameters were exhaustively evaluated for
values ranging between 0 ≤ C ≤ 8 and 10−4 ≤ γ ≤ 10−2 (Figure 4.20). To decide which
parameters predict with the best performance, the average f-score across the entire set of
k-folds was chosen as a scoring function for optimization (the whole procedure is described in
the Methods). The optimal values used during the analyses were C = 8 and γ = 6 · 10−4
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Figure 4.20: Grid optimization of the predictive power of the classifier. We exhaustively tested the
two most critical parameters of the SVM’s radial basis kernel: soft-margin (C) and radius (γ). The
average f-score across the entire set of k-folds was chosen as a scoring function for the optimization.
The optimal values used for the analyses were C = 8 and γ = 6 · 10−4 when all groups in the kinase
superfamily were considered.
4.4.3 Evaluation of the performance of the classifier
We avoided over-fitting the classifier by applying a 10-fold cross-validation approach where 8
random sets were used during the training step, one for the validation phase and one for the
evaluation. This process was repeated 10 times to allow all the sets to be used during the
evaluation. Although the optimization of the kernel relies on the f-score, the performance of
the classifier is assessed by several additional measures, such as accuracy, precision, recall and
the Matthew’s correlation coefficient (MCC).
On average, the classifier predicted the pathogenicity of kinase mutations very accu-
rately. Different threshold values could modulate the output of the classifier, as summarized
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in Table 4.4, and selecting an appropriate threshold is a critical step in developing a classifier.
Relaxed thresholds, such as -0.75, enable the detection of more disease-associated mutations
(increased recall), albeit at the cost of a larger number of false positives (reduced precision).
Conversely, higher thresholds of conservative classifiers, such as -0.5, reduce the frequency of a
mutation being classified as pathogenic, consequently predicting a smaller set of more reliable
disease-associated mutations. For the sake of accuracy, we analyzed our results according
to the conservative threshold of -0.5, whereby which the classifier predicted 83.29% of the
mutations correctly. Regarding the pathogenic dataset, 75.17% of the observed mutations were
recovered on average across all k-folds with a precision of 60.03%. The average MCC was 0.58.
SVM threshold Accuracy (%) Precision (%) Recall (%) MCC
-1.00 74.33 46.52 89.14 0.65
-0.75 80.91 56.12 79.84 0.62
-0.5 83.29 60.03 75.17 0.58
-0.25 80.55 59.98 66.14 0.51
0.00 82.26 58.56 47.19 0.38
Table 4.4: Performance of the classifier depending on the SVM classification thresholds applied using
all kinase groups.
4.4.4 Evaluation of the results in a data populated subset
There is a clear bias in the distribution of mutations across the kinase groups, since
a small number of groups contain most of the mutations (Figure 4.21). Consequently, we
evaluated the dependence of the results on the amount of disease-associated mutations available.
When the different groups in which the protein kinase superfamily is divided were superimposed
(Figure 4.21), we observed differences in the number of mutations that populated the groups.
This observation is consistent with the phylogenetic distribution of the literature-extracted
mutations we discussed earlier (Figure 4.6). A small number of these groups contain most of
the mutations, while others lack or contain very few disease-associated mutations (Table 4.5).
For the mutations in these less populated groups, only group membership suffices to consider
them as neutral and this neutrality is likely an artifact due to the lack of experiments assessing
the pathogenicity of the mutations.
A second dataset was generated with only the highly populated groups: TK, TKL, Atyp-
ical PI3-PI4, CAMK, RGC, CMGC, AGC and Atypical ADCK. Under this constraint the
‘disease dataset’ consisted of 814 mutations in 54 human kinases, while the neutral dataset
contained 1,775 in 297 proteins.
When only the groups sufficiently populated with disease-associated mutations were
considered, on average we correctly predicted 76.81% of the remaining mutations across all
k-folds, with the optimized values of C = 8 and γ = 10−4 (Figure 4.22).
With respect to the pathogenic dataset, we recovered 73.26% of the disease-associated mutations
with a precision of 64.68% (MCC: 0.53, Table 4.6), comparable to that obtained when all the
mutations from all the kinase groups were considered, thereby confirming that the bias in the
data does not significantly affect the results.
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Figure 4.21: Mutations in each of the groups in which UniProt divides the protein kinase superfamily.
The number of pathogenic (red) and neutral (blue) mutations is also represented. Differences in the
number of mutations that populated the groups can be observed.
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Figure 4.22: Grid optimization of the predictive power of the classifier when only the groups with
a reasonable number of reported disease-associated mutations are considered. We exhaustively tested
soft-margin (C) and γ. The average f-score across the entire set of k-folds was chosen as the scoring
function for the optimization. The optimal values used during the analyses were C = 8 and γ = 10−4.
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Group Disease Neutral Total
TK † 496 565 1061
TKL † 172 151 323
Atypical PI3-PI4 † 49 138 187
CAMK † 40 518 558
Other 36 411 447
RGC † 23 35 58
CMGC † 18 178 196
AGC † 16 190 206
STE 7 222 229
Atypical ADCK 6 14 20
Atypical Alpha-type 1 88 89
CK1 1 52 53
NEK 0 45 45
Atypical RIO 0 14 14
Atypical PDK-BCKDK 0 5 5
Atypical FAST 0 1 1
Table 4.5: Number of mutations in each of the groups in which UniProt divides the protein kinase
superfamily. The groups enriched in disease-associated mutations are highlighted by †.
SVM threshold Accuracy (%) Precision (%) Recall (%) MCC
-1.000 71.50 51.43 88.93 0.61
-0.750 77.06 61.72 81.55 0.60
-0.500 76.81 64.68 73.26 0.53
-0.250 79.44 68.15 69.93 0.50
0.000 71.57 60.66 56.32 0.37
Table 4.6: Performance of the classifier depending on the SVM classification thresholds applied when
using groups highly populated in disease mutations only.
However, clear differences were observed when the groups were compared individually (Table
4.7). For the groups with a reasonable number of mutations, the performance of the classifier
was considerably better than with the less populated groups. This was especially clear for
the precision of the predictions, which was consistent with the fact that the use of a sufficient
number of support vectors helps the classifier learn how to discern disease-associated mutations
properly.
4.4.5 Analysis of the most relevant features for classification
To evaluate the contribution of each individual feature to the classification, the features were
ranked according to the variation in the module of the weight vector of the trained SVM
(‖ ω ‖2) when each feature was removed from the set of support vectors. The feature whose
removal minimized the variation in module was considered to contribute the least to the
hyperplane that separates the two classes of examples (pathogenic/neutral) with a maximum
margin (this ranking is shown in Table 4.8). The ranking derived from the SVMs has been
applied for variable selection in many classification problems [165, 166]. According to the
SVM-based criteria, the top ranked features are only based on the subset of support vectors
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Group Accuracy (%) Precision (%) Recall (%) MCC
CMGC † 91.5 87.5 8.64 0.08
TKL † 68.7 70.47 70.93 0.37
TK † 71.3 69.68 68.32 0.42
RGC † 58.24 47.92 61.35 0.19
Atypical PI3-PI4 † 70.59 47.12 100 0.78
STE 96.85 43.75 11.11 0.11
AGC † 90.78 43.35 61.11 0.55
Other 88.86 41.64 95.37 0.89
CK1 97.69 33.33 22.22 0.21
Atypical Alpha-type 89.89 9.09 88.89 0.83
CAMK † 55.48 8.31 51.94 0.1
Atypical ADCK 70 0 0 0
NEK 100 0 0 0
Atypical RIO 100 0 0 0
Atypical PDK-BCKDK 100 0 0 0
Atypical FAST 100 0 0 0
Table 4.7: Performance of the classifier when the groups in which UniProt divides the protein kinase
superfamily are considered individually. Groups enriched in disease-associated mutations are indicated
by †.
that are ‘borderline’ cases.
Interestingly, Gene Ontology (GO) functional annotations were the most relevant fea-
ture for the classification, which corresponds to a classification at the gene level since all the
mutations in a gene display the same score. This information is encoded as the sum of GO
terms log-odds ratio, sumGOLOR, to be able to compare between the classes. This measure
represents the proportion of disease-associated and neutral kinase genes that are annotated
with a particular GO term, and it can be used to identify the GO terms characteristic of
neutral or disease-prone genes.
If the individual terms from the biological process sub-ontology are analyzed, interesting
trends can be observed. For example, the most pathogenic biological processes are enriched in
terms associated with protein localization, cell proliferation and tissue development, all aspects
related to disease and particularly cancers. Pathogenic and neutral genes are differentially
enriched in terms from the molecular function sub-ontology. While neutral genes are associated
with basic kinase activity functions, disease-associated genes are enriched in terms associated
with hormone binding, co-factors and interaction partners.
The most representative GO terms for each of the classes are shown in Table 4.9 for
neutral genes and Table 4.10 for disease-associated ones.
The next group of features in the order of relevance for the predictor is linked to the
positions that confer specificity at the family level (i.e., the tree-determinants). The cal-
culation of this score is based on our in-house implementation of the S3Det method [131].
However, the current implementation of the method did not provide a continuous measure
of tree-determinant characteristics and thus, we implemented this additional possibility. The
coincidence of a given residue with the alignment of the rest of the family members, and the
differences regarding the sequences outside the subfamily, were measured with an f-score as
described in the Methods. Three different scores were calculated: the f-score for the wild type
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Rank Feature Description Rank Feature Description
1 sumGOLOR 21 pfam PF07714 (PKinase tyr)
2 TDs fscore diff 22 phosphoelm
3 TDs fscore wt 23 class CK1
4 Diff KD hydrophobicity 24 swannot disulfid
5 TDs fscore mt 25 SIFTscore
6 aatypeL 26 aatypeE
7 pfam any 27 aatypeW
8 SIFTscore binned 28 aatypeF
9 aatypeA 29 pfam PF00041 (Fibronectin)
10 class TK 30 class TKL
11 aatypeV 31 class Atypical Alpha-type
12 aatypeR 32 aatypeQ
13 aatypeS 33 firedb
14 aatypeK 34 aatypeD
15 swannot any 35 class Atypical ADCK
16 aatypeH 36 aatypeI
17 aatypeN 37 pfam PF00023 (Ank)
18 aatypeM 38 pfam PF01403 (Sema)
19 class CAMK 39 class Atypical PI3-PI4
20 aatypeT 40 aatypeG
Table 4.8: Ranking of the features according to their contribution to the classification. The features
are ranked according to the variation in the module of the weight vector of the trained SVM (‖ ω ‖2)
when each feature is removed from the set of support vectors [165,166]. See the Methods section for a
detailed description of these features.
amino acid; the f-score for the mutant residue; and the difference between these two scores as
a measure of the relevance of the change introduced.
Following these two important features of the predictor is the Kyte-Doolittle hydropho-
bicity change, the presence of a PFAM domain (in particular the tyrosine kinase domain),
the functional annotation of the residues in SwissProt [72] and PhosphoELM [142], and the
evolutionary SIFT score [93] or the amino acid types involved in the change.
Interestingly, among the genome-wide features, some kinase-specific features also emerged as
being relevant. For instance, to reinforce the important role of gene-level characterization,
classifying kinases into the different groups in KinBase [40] was an important feature (par-
ticularly TK, CAMK, CK1 and TKL among the canonical protein kinases, and Alpha-type,
ADCK or PI3-PI3 among the atypical ones), as observed previously [107].
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GO term %dis %neu GOLOR Description
GO:0019901 0 4.62 -32.1 (MF) protein kinase binding
GO:0046328 0 4.62 -32.1 (BP) regulation of JNK cascade
GO:0070302 0 4.62 -32.1 (BP) regulation of stress-activated protein kinase signaling cascade
GO:0005083 0 3.85 -31.84 (MF) small GTPase regulator activity
GO:0043506 0 3.85 -31.84 (BP) regulation of JUN kinase activity
GO:0008134 0 3.59 -31.74 (MF) transcription factor binding
GO:0043507 0 3.59 -31.74 (BP) positive regulation of JUN kinase activity
GO:0005794 0 3.08 -31.52 (CC) Golgi apparatus
GO:0007257 0 3.08 -31.52 (BP) activation of JUN kinase activity
GO:0051098 0 3.08 -31.52 (BP) regulation of binding
GO:0030528 0 2.56 -31.26 (MF) transcription regulator activity
GO:0051090 0 2.56 -31.26 (BP) regulation of transcription factor activity
GO:0051101 0 2.56 -31.26 (BP) regulation of DNA binding
GO:0090046 0 2.56 -31.26 (BP) regulation of transcription regulator activity
GO:0004707 0 2.31 -31.1 (MF) MAP kinase activity
GO:0019207 0 2.31 -31.1 (MF) kinase regulator activity
GO:0019887 0 2.31 -31.1 (MF) protein kinase regulator activity
Table 4.9: Most representative GO terms (according to the log-odds ratio) to classify kinase genes as neutral. %dis, %neu: Percentage of disease-associated
and neutral genes annotated with a given GO term. MF: Molecular Function, BP: Biological Process, CC: Cellular Component.
82
C
H
A
P
T
E
R
4.
R
E
S
U
L
T
S
GO term %dis %neu GOLOR Description
GO:0048646 7.81 0 32.86 (BP) anatomical structure formation involved in morphogenesis
GO:0007389 6.25 0 32.54 (BP) pattern specification process
GO:0010594 6.25 0 32.54 (BP) regulation of endothelial cell migration
GO:0050431 6.25 0 32.54 (MF) transforming growth factor beta binding
GO:0050679 6.25 0 32.54 (BP) positive regulation of epithelial cell proliferation
GO:0051896 6.25 0 32.54 (BP) regulation of protein kinase B signaling cascade
GO:0051897 6.25 0 32.54 (BP) positive regulation of protein kinase B signaling cascade
GO:0001525 4.69 0 32.13 (BP) angiogenesis
GO:0001871 4.69 0 32.13 (MF) pattern binding
GO:0003002 4.69 0 32.13 (BP) regionalization
GO:0005539 4.69 0 32.13 (MF) glycosaminoglycan binding
GO:0009952 4.69 0 32.13 (BP) anterior/posterior pattern formation
GO:0030246 4.69 0 32.13 (MF) carbohydrate binding
GO:0030247 4.69 0 32.13 (MF) polysaccharide binding
GO:0032388 4.69 0 32.13 (BP) positive regulation of intracellular transport
GO:0033158 4.69 0 32.13 (BP) regulation of protein import into nucleus, translocation
GO:0033160 4.69 0 32.13 (BP) positive regulation of protein import into nucleus, translocation
GO:0042306 4.69 0 32.13 (BP) regulation of protein import into nucleus
GO:0042562 4.69 0 32.13 (MF) hormone binding
GO:0045428 4.69 0 32.13 (BP) regulation of nitric oxide biosynthetic process
GO:0045429 4.69 0 32.13 (BP) positive regulation of nitric oxide biosynthetic process
GO:0048729 4.69 0 32.13 (BP) tissue morphogenesis
GO:0051222 4.69 0 32.13 (BP) positive regulation of protein transport
GO:0090316 4.69 0 32.13 (BP) positive regulation of intracellular protein transport
Table 4.10: Most representative GO terms (according to the log-odds ratio) to classify kinase genes as disease-associated. %dis, %neu: Percentage of
disease-associated and neutral genes annotated with a given GO term. MF: Molecular Function, BP: Biological Process
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4.4.6 Benchmark of the classifiers against other methods
To test the performance of our classifiers, we compared our results with those of four
well-established predictors of pathogenicity: SIFT [93], SNAP [104], SNPs&GO [108] and a
kinase-specific method [107]. This set of classifiers represents a wide variety of approaches and
scopes: genome-wide and kinase-specific classifiers, different classification approaches (rule-
based, neural networks, linear SVMs and radial basis SVMs) and a broad set of classification
features.
Unfortunately, making a fair comparison of the predictive capabilities is not an easy
task [91] and many technical difficulties arise. Choosing an objective testing dataset is
the most difficult, especially when the datasets used in the original publications are not
equivalent. Increased predictive capabilities would be expected if the testing dataset had
already been presented to the classifier during the learning process. This is very likely the case
for the kinase dataset, which is a strict subset of the most commonly used training dataset [136].
The results of this benchmark are shown in Table 4.11. The two genome-wide classi-
fiers SNPs&GO and SIFT included an evaluation using the same dataset as that used to train
and evaluate our own. Interestingly, when these methods were evaluated with the protein
kinase dataset, performance dropped significantly compared to those reported in the original
publications for a wider range of protein families. It is worth noting that this decrease in the
overall performance demonstrates that the protein kinase superfamily is a challenging scenario,
justifying the need for kinase-specific classifiers at the cost of scope. For a genomic-wide
scenario, general classifiers such as SNAP or SNPs&GO perform better.
Our predictor generated results with the kinase dataset comparable to those obtained
by the best predictor, SNPs&GO. Our method was also better than SIFT, a reference method
used by many others including ours. Given that we achieved results similar to those of the best
classifier is particularly interesting since some increased prediction is expected if the kinase
dataset had already been presented to the classifier during the training process.
The results of our predictor are also comparable to those of the kinase-specific method
proposed by Torkamani and co-workers, the only method against which a direct comparison
can be made. Unfortunately, the original publication did not provide information about recall,
precision and the pathogenic mutations resulting from their method. Hence, this method was
only compared for accuracy and MCC. Our results are more accurate as we correctly predicted
83.29% of the cases compared to the 77% predicted by the other method. In addition, the
correlation coefficient was slightly better in our case, 0.58 compared to 0.55. These results
indicate that our choice of features concentrated more predictive power.
4.4.7 Implementation of the predictor as a web server
We implemented our pipeline to predict mutation pathogenicity in the protein kinase super-
family as a web server, KinMut, which is publicly available at http://kinmut.bioinfo.cnio.es.
The most important features of this web server are displayed in Figure 4.23. The server displays
the mutations and the SVM score for each prediction. Mutations with an SVM score greater
than -0.5 are considered damaging, according to the threshold discussed above.
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Method Scope Accuracy (%) Precision (%) Recall (%) MCC
KinMut Kinase 83.29 60.03 75.17 0.58
SNPs&GO [108] Kinase† 82.28 62.76 77.45 0.64
Torkamani [107] Kinase 77.00 - - 0.55
SIFT [93] Kinase† 77.63 37.83 27.88 0.17
SNPs&GO [108] Genome-wide 82.00 83.00 78.00 0.68
SNAP [104] Genome-wide 78.20 76.70 80.20 -
SIFT [93] Genome-wide 68.33 66.11 56.51 0.35
Table 4.11: Summary of the performance of other state-of-the-art classifiers of mutations, either
general or kinase-specific. Performance was measured in terms of overall accuracy, recall and the
Matthews correlation coefficient. General methods with which the prediction was run with our dataset
are marked with †. The remaining results for the classifiers displayed here were taken directly from
their original publications
Figure 4.23: Schematic summary of the capabilities of KinMut.
Chapter 5
Discussion
This thesis focuses on analyzing mutations in the human kinome, a subset of the genome
chosen due to its key role in cancer and the large amount of information available on its
biochemical properties. We aimed to specifically shed light on two related aspects of these
mutations.
First, we wanted to characterize the mutations that disrupt the structure and function
of protein kinases, focusing on the properties that contribute to differentiate pathogenic and
non-pathogenic mutations. These features include the solvent accessibility, sequence and
structure conservation, and the relevance of the residues for enzymatic activity or family
sub-specificity.
Second, we aimed to apply the knowledge acquired to predict the consequences of mu-
tations for human disease, and cancer in particular, using the properties associated with the
mutations and the corresponding phenotypes as the input.
We approached these scientific questions from the perspective of Computational Biology.
This discipline provides us with the methodology to identify mutations and their properties,
link them to annotations from heterogeneous information sources, classify the mutations based
on the features selected and according to the information available, and use this classification
to predict the effects of newly discovered mutations.
5.1 3Dsim: Structural implications of mutations
One of the initial steps taken in this thesis was to implement the 3DSim method [143] to
interactively map single amino acid polymorphisms onto protein structures. In addition,
3DSim summarizes several sources of information into a single repository and it displays an-
notations about the mutations, such as wild-type and mutant sequences, predicted structural
implications of the mutations, and their characterization as neutral or pathogenic according to
these predictions. To enhance the potential to use this information, the system also provides
links to the original repositories: UniProt [45], Gene3D [120], SAAPdb [74], CATH [121] and
Modbase [144] among many others.
Successful attempts to map and display mutations, along with their annotations onto a
protein structure, had been completed previously (see Table 2 in Uzun et al. (2007) [167] for a
detailed review). However, the method discussed here presents several unique and interesting
features that are not available in earlier implementations.
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First, the similar treatment of SNPs, and the less common and more harmful pathogenic
deviations (PDs), allows the users to inspect and compare both kinds of mutations through
the same interface, including explanatory annotations where available.
Second, the localization of mutations within the CATH hierarchy allows users to query
and explore the distribution of the mutations at different levels of the structural classification.
Third, it is possible to transfer mutations and annotations from protein sequences to
related three-dimensional structures, even when no structures are available. In such cases,
we use CATH [121] and Gene3D [120] to assign a representative structure that can be used
as a proxy for the real structure. The possibility of using an alternative structure as a
representative of the mutated sequence has been successfully employed by other methods, such
as those of LS-SNP [102], stSNP [167] and Modbase [144], although with slight differences in
terms of implementation. The main difference is that the earlier methods used a structure
calculated with MODELLER [156], whereas in our implementation the representative structure
corresponds to one of the manually curated domain representatives in CATH that is chosen
by a sequence-similarity search (see the Methods section for a detailed description of our
algorithm).
Finally, the availability of data via web services and databases enables users to include
this information efficiently into their own analyses. These facilities allow the independent
integration of our data into any other pipeline or workflow.
5.2 Automatic extraction of human kinase mutations
from the literature
To test the performance of our methodology, we compared the mutations extracted by our
pipeline to those from the most frequently used annotation databases and a compilation of data
from genotyping studies. Through this comparison, we concluded that our pipeline increased
the total number of database records by extracting mutation mentions from the literature.
Moreover, automated mutation extraction systems were demonstrated to be a valuable resource
to assist manual curation by providing direct pointers to sentences of mutation evidence that
can be rapidly examined by experts.
One such example is the Y845F mutation in the epidermal growth factor receptor (EGFR).
Y845F is one of the 32 mutations in this protein that was extracted from the literature
and that was not present in the databases queried. We recovered a number of sentences
mentioning this mutation: ‘Furthermore, transient expression of a Y845F variant EGFR in
murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis to non-stimulated
levels.’ (PubMed:10075741); ‘Stably transfected B82L cells with a point mutation of the
EGFR at Tyr-845 (B82L-Y845F) exhibited only basal Ras activity following exposure to
Zn2+’ (PubMed:11983694); and ‘In contrast, LPA-elicited DNA synthesis and migration were
augmented in cells expressing EGFR, EGFR(K721A), or EGFR(Y845F), but not EGFR(Y5F),
although the PDGF responses were indistinguishable’ (PubMed:15364923). The information
retrieved is sufficient to suggest to the experts that Tyr-845 might be involved in DNA
synthesis triggered by EGF binding to its receptor. In this case, it is also important to provide
the expert with additional information regarding this residue, for example, that it actually
maps to position 869 in the protein sequence due to a signal peptide that was not considered
by the authors of the publication.
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In the Introduction to this thesis, we presented other methods for the automatic extrac-
tion of mutations from the literature. The added value of our system in comparison to
those methods is the inclusion of a multi-layer pipeline to corroborate the presence of the
extracted mutations in the protein sequences. This validation pipeline not only includes a basic
comparison of the mutations to the reference sequence in UniProt but also, more intricate
strategies such as a sliding window algorithm that searches for a pattern of mutations along
the sequences instead of at exact positions, and the consideration of alternative starting points
due to signal peptides or methionine cleavage (this pipeline is described in detail in the Results
section).
We retrieved approximately one third of the mutations present in the most commonly
used databases and genotyping studies. It is most likely that the remaining mutations were
not obtained as there is insufficient evidence in the text, probably due to:
1. Missing accessibility to the original reference, full-text articles or additional materials.
Little can be done from our side with respect to this issue. This is especially evident in
older publications that are not necessarily digitalized, although there are currently efforts
to digitalize the literature that only exists as print copies. Nevertheless, this issue will
continue to be unsolved unless the publishing houses make their archives openly accessible
and, from a technical point of view, the formats and repositories comply with the needs
of the automatic extraction pipelines.
2. General methodological limitations of mutation mention extraction, such as those asso-
ciated with MutationFinder [90] in our case. This is especially relevant in terms of the
number of mutations retrieved (recall) and the reduction in the number of incorrect mu-
tation mentions (false positives). We expect that better mutation extraction methods will
be available in the near future.
3. Limitations in protein normalization and mutation to sequence annotation. We plan
to improve our extraction pipeline in several ways. Thus, future implementations of our
system will very likely include mutation-protein proximity analysis, examination of species
and organism source ambiguity, and analysis of the probability of finding a given mutation
within a target sequence by considering the observed residue composition of the proteins,
and particularly kinases.
4. Improvement of the sequence validation pipeline. Our system currently includes a multi-
step pipeline to validate the mutation mentions extracted and to reduce the number of false
positives. Basically, we corroborate the existence of the residues at a given position of the
reference sequence in UniProt [45] and correct for alternative starting points, i.e., due to
the presence of the initial methionine or signal peptides. However, multiple improvements
to this pipeline can be made, the most straightforward of which is the consideration of
alternative isoforms. As different splicing isoforms skip or include exons, the numbering
of the positions change downstream of the splicing event. These alternative counting
possibilities need to be included in further developments.
The scope of this work is not only limited the identification of mutations for which evidence
in the literature exists but there are no records in the databases. Even more interestingly, the
work presented here proves that the extraction of mutations from full-text articles is feasible
and that it is a powerful resource to characterize and annotate mutations. Indeed, one of the
strengths of the system is the possibility of linking mutations with supporting experimental
evidence from the literature. This additional information usually includes crucial data such
as experimental conditions, organisms, evidence of association with disease or phenotype and,
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in the best case scenario, a description of the underlying biochemical mechanisms affected.
This background information is very valuable and consequently, we think that systems such
as personalized medicine platforms or pathogenicity prediction pipelines may benefit from the
information contained in our system.
Although we focused on the extraction of mutations within the protein kinase super-
family, nothing impedes the application of the described methodology to the whole set of
full-text articles in PubMed. Despite representing a computationally expensive task, the huge
amount of information that would be gathered greatly justifies this effort. Nevertheless, this
approach is definitely not intended to substitute human curation and expert validation but
rather, it is a complement and guide, helping prioritize the efforts of manual curators. See
Leitner et al., 2010 and Krallinger et al., 2011 for a detailed description of the efforts to
integrate text mining in database pipelines and manual curation [81,168].
5.3 Preferential distribution of disease-associated kinase
mutations
We compared here the distribution of point mutations in protein kinases in order to char-
acterize the structural and functional consequences of the different types of mutations. In
particular, we focused on the protein kinase domain. The human kinome is particularly
amenable for this type of analysis because it represents one of the best characterized protein
superfamilies [40, 43, 46, 55, 169, 170], and because a growing number of drugs already target
members of the protein kinase family [36, 37]. Therefore, many efforts have been made to
crystallize kinase protein structures and a large number of mutations are currently available as
discussed above [14, 27, 71, 74, 75, 171]. Furthermore, the underlying biochemical mechanisms
have also been characterized for a growing subset of these mutations.
To cover all aspects of kinase mutations and their relationship to disease, we analyzed
somatic and germline mutations [154,155]. Germline mutations are inherited from parents and
transmitted to offspring, while somatic mutations are acquired variations that differ from the
progenitors’ fertilized eggs [9]. It is important to understand this difference and the implication
it has in understanding the link between kinase mutations and disease. Hence, while germline
mutations cause inherited diseases [70] and kinasopathies [171], cancers typically arise due to
somatically acquired mutations [9, 14,16].
We analyzed a number of features relevant to protein kinases, including: (a) sequence
conservation as an indicator of evolutionary important regions; (b) localization in the buried
core of the protein; (c) organization of mutations with respect to regions relevant for enzymatic
activity; and (d) specificity-determining positions.
We first analyzed the distribution of somatic mutations with respect to these features [154]
and classified the mutations into two different types: drivers and passengers. Driver mutations
correspond to those causally implicated in oncogenesis as they confer growth advantage on the
cancer cell. These mutations are positively selected in the microenvironment of the tissue in
which the cancer arises. By contrast, passengers do not confer any clonal growth advantage or
contribute to cancer development.
Driver and passenger somatic mutations display clear differences in their distributions in
the protein kinases [154]. Driver mutations tend to occur close to regions important for
protein function and structure, such as the ATP- and substrate-binding sites, residues that
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confer subfamily specificity, conserved residues and the hydrophobic core of the protein. This
distribution is consistent with their association with disease and their putative role in the
development of tumors. By contrast, passenger mutations do not occur in buried or conserved
residues and they are not usually clustered around functionally relevant sites. The neutral role
of these mutations is attributable to their localization in these regions with mild effects.
In a related experiment, we characterized the preferential distribution of germline muta-
tions with respect to functional and structural features, and according to their propensity to
be involved in disease. Thus, we classified the mutations as pathogenic deviations or neutral
polymorphisms. There were significant differences between the two types of germline mutations
in terms of conservation, accessibility and distance to the residues forming the ATP-binding
site or the regions that provide family sub-specificity. In fact, the behavior of these mutations
mimicked that previously discussed for driver and passenger mutations (Table 5.1).
Feature Somatic Germline
Sequence conservation, Shannon’s entropy [125] Drivers PDs (Slightly)
Sequence conservation, AL2CO [126] Drivers PDs
Accessibility No difference PDs
Catalytic site, FireDB [127] Drivers PDs
Catalytic site, Knight [46] Drivers PDs
Tree determinants Drivers PDs
Table 5.1: Summary of the preferential distribution of kinase mutations with respect to the features
analyzed. Disease-associated mutations, drivers and pathogenic deviations (PDs) tend to occur closer
to the important regions of the protein than their neutral counterparts.
Interestingly, despite the similar location of the mutations, both datasets are non-redundant
and indeed, only four mutations are common to the driver and pathogenic datasets, all of
which are found in the B-raf proto-oncogene. This is consistent with the very different nature
(germline and somatic) of the mutations in each of the disease-prone datasets.
The results presented here confirm the functional and structural relevance of the disease-prone
sets of mutations: the germline pathogenic deviations and somatic driver mutations. The fact
that driver mutations behave similarly to other pathogenic mutations could indirectly support
the categorization of mutations into drivers and passengers, and enable them to be used as a
proxy to study the involvement of somatic mutations in cancer biology.
Moreover, these results constitute a necessary step towards developing a predictor that
uses machine learning techniques. Some of the features described here would be able to predict
the pathogenicity of any novel kinase mutation. This predictor has been introduced in the
Results section and its implications will be addressed below.
The trends observed in our experiments for both germline and somatic mutations are
consistent with those defined previously [172]. In those studies, the authors classified inherited
germline mutations with a customized machine learning approach and ranked the features that
contributed most to the classification. In addition, the mutations were mapped onto structural
elements of the protein kinase domain. The conclusion of these studies was that mutations
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predicted to be disease-associated tended to map to regulatory and substrate-binding regions.
The results we obtained suggest a similar tendency. Thus, both sets of results demonstrate
the relationship between disease-associated amino acid changes and key regions of protein
structure and function, although from slightly different perspectives.
The analyses performed here have some limitations. The experimental information available is
currently very limited and the majority is derived from high-throughput genetic studies that
lack further validation. The biochemical characterization of mutations cannot keep up with
the pace of the techniques to discover mutations, since the study of a single mutation out
of the millions identified requires an enormous amount of effort, time and resources. This is
especially difficult for protein kinases, which are regulated by tightly controlled cascades where
changes in one protein can elicit phenotypes that are often identified as disease or altered
states associated with downstream or negative signaling components. This is the case, for
example, of mutations in the protein tyrosine phosphatase that activates the kinase signaling
pathway in Noonan syndrome [173].
Moreover, at the functional level there is an important difference between gain-of-function
and loss-of-function mutations. Changes in function occur at various levels, from the protein
level where the changes in a residue directly perturb protein function, to the system level
where the mutations can affect the whole cell and/or organism. For example, a mutation that
perturbs the function of a protein kinase that is part of a signaling cascade might disrupt the
activity of the proteins downstream in the same cascade, and in turn, the cellular functions
dependent on that signaling event. In this case, the predicting the pathogenicity of a mutation
based on the mechanistic understanding of the function of the signaling cascade requires a
detailed knowledge of the full system, and the application of an adequate system simulation
strategy. Even if progress in this area of Systems Biology is made, reliable methods connecting
mutations and system response are still not available and they are beyond the scope of this
thesis.
A gain-of-function mutation constitutively increases kinase activity, sometimes leading
to unrestrained signaling, and it may trigger oncogenesis or cause rare inherited dominant
phenotypes. This is the case of the somatic mutation V600E in B-raf that is associated with
non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma and lung
carcinoma [148, 174, 175]. By contrast, loss-of-function mutations may lead to a decline in
cell signaling, which can in turn affect cell growth and normal tissue development. This is
exemplified by mutations in the proto-oncogene RET, which are associated with Hirschsprung
disease, a type of congenital intestinal aganglionosis affecting the enteric ganglia in the
intestinal tract [176, 177]. Another interesting example of a loss-of-function mutation is the
B-raf kinase, where there is a link between the deactivating mutations E501G and G596V,
and CFC syndrome [175]. Please refer to Lahiry et al. (2010) [171] for an interesting review
on this subject. In addition to their important relationship with disease, the over-activation
or over-repression of kinase activity could provide insights that might help characterize the
biochemical mechanisms governing kinase activity.
Although the results presented here focus on the mutations in the protein kinase super-
family, the methodology described here to analyze the distribution of mutations according to
a fixed set of features can be applied to any other protein family of interest. Indeed, it would
be an interesting forthcoming project to analyze other protein families at a genome-wide scale
to corroborate the extent to which the trends observed for the protein kinase subfamily can be
extrapolated to the whole human genome.
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5.4 Features that determine the pathogenicity of kinase
mutations
The majority of protein kinase mutations are tolerated without producing significant effects,
while only a small subset is causally associated with disease. In cases where the mechanistic
interpretation of the consequences of the mutations on phenotypes is not feasible, current
research aims to identify correlations between mutations and human diseases, particularly
cancer. Current advances in automatic machine learning enable the rules to be generalized
based on prior observations, which can then be used to assess the probability of a mutation
being harmful. It is in this context that we propose KinMut, a computational method that
predicts the impact of mutations on protein kinase function from basic sequence information.
Based on the knowledge acquired through our experiments to study the preferential dis-
tribution of neutral and pathogenic kinase mutations with respect to certain types of residues,
we linked a number of sequence-derived features to disease-associated kinase mutations,
including: (a) membership of a KinBase group and Gene Ontology terms at the gene level;
(b) the occurrence of the mutation inside a PFAM domain at the domain level; and (c)
several other properties including amino acid type, functional annotations from SwissProt
and FireDB, and specificity-determining positions at the residue level. We examined the
independent significance of these properties and their combination using a support vector
machine (SVM).
Good features are those that can discriminate between pathogenic and neutral muta-
tions. To decide which of these are the most adequate, smart feature selection must have a
wide collection of mutations from both categories (pathogenic and neutral) and a representa-
tive variety of possible values within both categories. The underlying assumption is that the
collection is large enough and includes a sufficient representation of the variation in each of the
classes. If the collection is too small, not representative of the pathogenic or neutral classes,
or too contaminated with mislabeled mutations (truly pathogenic mutations labeled as neutral
or vice versa), we will not be able to classify the mutations properly.
Our classifier relies solely on sequence-based features. We are aware that a myriad of
available protein features exists and that it is unfeasible to integrate all of them and all
their combinations into a classifier. For instance, other methods include structure-based
features in their calculations [99, 102, 103, 141, 178, 179]. It is evident that protein structures
retains a huge amount of relevant information. Concomitantly, the protein space of the
prediction is limited to only those proteins for which a structure has been properly determined,
or at least for which a reliable enough model can be obtained. For a broader coverage,
we designed our classifier around sequence-based features and demonstrated its ability to
achieve a reasonable level of accuracy. It is worth noting that, in the future, when the gaps
in the structure-space are complete, the detection of pathogenic mutations will very likely
benefit from the inclusion of structure-based features without risking the scope of the prediction.
The selection of the training dataset is crucial. Previous methods have used a variety of training
sets to construct their pathogenic and neutral catalogues. Disease-associated mutations are
usually collected from databases such as the SwissProt variant pages [71,99,105,108,109,178],
OMIM [107, 180], COSMIC [27, 105], KinMutBase [75, 107], HGMD [95, 103, 107, 164, 181], or
from clinical or functional studies. Generally, these mutations refer to Mendelian or monogenic
diseases [91]. The neutral dataset is usually gathered from the SwissProt variant pages as well,
but also from dbSNP [67, 95, 105, 107, 164], HapMap [69, 164], HGVbase [98, 182], or generated
artificially from the equivalent amino acids in closely related species [164, 178, 183]. Many
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early predictors undertook a different approach and used the results of saturation mutagenesis
experiments in bacterial and viral proteins [93, 184]. Another approach is to use all the
available information about possible deleterious/neutral amino acid substitutions (human
disease databases and systematic functional assays among others) in order to construct large
benchmark sets, such as differences between two closely-related functional enzymes that can
be considered neutral [104]. In a recent benchmarking of several training datasets [136], it was
concluded that the SwissProt variant pages provided the most accurate results to predict the
pathogenic effect of human non-synonymous mutations. Consequently, we derived our datasets
from this repository.
Nevertheless, several issues have to be considered in data analysis. Common to any of
these benchmark sets is the underlying assumption that a cause-and-effect relationship exists
between the mutation and the elicited phenotype, which may be debatable. In addition, the
pathogenic dataset assumes a simple one-to-one relationship between mutation and disease. In
complex diseases such as cancer, the reality is that the mutations act as a contributing rather
than a causal factor.
5.5 Performance of the classifier and the benefits of
family-specific prediction
Our KinMut predictor achieves a level of performance similar to that obtained by the best
predictors, SNPs&GO [108] and Torkamani’s kinase-specific [107] method, and it outperforms
other reference methods such as SIFT [93] when evaluated within the framework of the kinase
dataset.
Interestingly, we achieved results comparable to the best classifier, SNPs&GO, whose
capability we probably overestimated due to a technical artifact. SNPs&GO has been trained
with all the mutations in UniProt, which are very likely to be included in our subset of kinase
mutations. When this set was presented to SNPs&GO for classification in order to compare
its performance with that of KinMut, SNPs&GO was given some advantage since the classifier
had already been presented with the mutations. Thus, it is not possible to compare the
classifiers without training the predictor from scratch without the kinase mutations, which
would nevertheless yield an unfair comparison as well. Therefore, we assume this artifact to be
acceptable for our qualitative analysis.
Probably, the similarity in the performance is given by the use of GO terms since both
methods - even though they differ in their scope and implementation - benefit from functional
information encoded as GO terms at the gene level, which is the most discriminative feature
for our classifier.
Our predictor performs beyond the capabilities of the only method against which an ut-
terly fair comparison can be conducted, Torkamani’s kinase-specific predictor [172], at least in
terms of accuracy and correlation. Unfortunately, the authors of this method did not provide
information about its recall, precision and output, to enable a better comparison to have been
made. Interestingly, Torkamani’s and our classifiers share several properties: amino acid types;
kinase group membership, which the authors state to be critical for classification; biochemical
properties such as the Kyte-Doolittle hydrophobicity index; and evolutionary conservation. In
spite of these similarities, Torkamani’s method does not benefit from intra-family specificity
positions or from GO annotations, which we have shown to be crucial for prediction (see
above). This might have caused the differences in performance observed.
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During the writing of this thesis, another method was published that takes into account
specificity-determining positions [109]. Hence, we are looking forward to evaluating the
performance of this classifier with our dataset in order to compare different implementations
with a very similar concept.
Current genome-wide predictors of mutation pathogenicity perform well on average, probably
because they can use the huge amount of mutation data available. However, most of these
predictors only exploit a small proportion of the possible characteristics for the sake of
coverage, the subset of features that could be generalized to the entire range of protein families
in the human proteome, which constitutes an intrinsic limitation. By contrast, family-specific
predictors, such as the method presented here for the protein kinase superfamily, can overcome
this limitation and benefit from features that apply only to the protein family of interest.
These family-specific features might capture aspects of pathogenicity that are unique to that
given protein family. We explored the basis of using kinase-specific features, such as kinase
group membership, annotation with certain GO terms and the presence of determined Pfam
domains, which are relevant for predicting pathogenicity in the protein kinase superfamily.
Accordingly, the performance of genome-wide methods decreases when they are confronted
with the set of kinase mutations.
Indeed, the family-specific nature of our method allowed us to explore features that are
unique to the protein kinase superfamily, retaining valuable information on mutation
pathogenicity. In our case, membership to a particular kinase group and the occurrence of
mutations in the catalytic protein kinase domain were important features that are unique
to the protein kinase superfamily. This is in full agreement with previous observations that
reached similar conclusions [107,172].
The results provided here reinforce the idea that for well-studied families like the kinase
superfamily, family-specific classifiers can use unique features that are only valid in the context
of this specific superfamily, thereby improving performance over general purpose methods.
Regarding the dissimilarities between the different branches of the kinase phylogenetic tree,
we demonstrated that more accurate results were obtained for groups with sufficient data that
allowed the classifier to learn to weight the importance of the individual contribution of the
features precisely. Moreover, this group membership was one of the most triggering features of
our classification.
There are groups in which very few (or even no) pathogenic mutations have been de-
scribed and as such, in these cases group membership is a powerful means to predict neutral
mutations. However, since the mutational landscape is far from complete, we cannot discern
whether this is a reliable scenario (where these kinase groups do not elicit pathogenicity) or
rather an artifact due to a gap in our current knowledge that will be filled when new mutations
are discovered.
Indeed, the uneven, heterogenic, distribution of experimental evidence regarding the dif-
ferent kinase groups does not only affect the number of mutations discovered but also, the
quality and thoroughness of features such as GO or UniProt annotations, which is very likely
to influence the predictive capacity of our system.
In the near future, ongoing genomic projects will help us understand the links between
mutations in all the kinase groups and disease, thereby boosting the capability of kinase-
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specific prediction methods beyond the limits of current highly populated groups.
5.6 Prioritization of pathogenic mutations for experimen-
tal characterization
Our method was not conceived for direct use in a clinical situation. Indeed, currently no
in silico method can achieve the required accuracy to be a substitute for laboratory experiments.
Even if the method we have developed performs at a level similar to that of the best
methods available, the results are still of limited direct use. Indeed, the most direct practical
use in our case is as a component of a system that ranks mutations generated in cancer genome
studies for further experimental validation.
Additionally, the development of the system opens new possibilities to study the rela-
tive importance of the features used by the classifier, information that could help to investigate
the underlying molecular events linking mutations, biochemical/cellular events and pathogen-
esis.
A limitation common to all current predictors of pathogenicity, including ours, is that
they only provide results for missense variations. New methods are necessary to evaluate the
functional impact of synonymous mutations and small insertions/deletions (commonly referred
to as indels). Methods that determine the impact of mutations occurring outside of the coding
fraction of the genome are also needed. Although in these cases no aberrant protein product is
expressed, promoter regions, transcription factors and splicing sites may still be affected, along
with other important non-coding regions.
5.7 Pathogenicity prediction and personalized medicine
One of the most interesting applications of the methodology presented here is its use in
prioritizing mutations for personalized medicine platforms.
The purpose of personalized medicine is to provide each patient customized treatment
that takes into account the predicted response to drug therapy, instead of administering a
universal treatment based on trends observed in the whole population. Personalized prediction
of drug response is founded on the sequencing of the patient’s genome. Our group recently
developed a prototype to help clinicians choose personalized cancer treatment according to
the patient’s genomic profile. The objective of this platform is two-fold: prioritize somatic
mutations in the genome of the patient according to their role in tumor onset and progression;
and suggest candidate drugs for personalized treatment. Our predictor of pathogenicity might
represent a valuable tool for prioritizing somatic mutations.
The pipeline of the initial personalized medicine prototype can be described as follows.
For each somatic mutation obtained in a full-exon sequencing of the patient’s genome, the
system automatically collects information about mutated genes, the corresponding proteins
and the pathways involved. The application also predicts the potential functional effect of
the mutations using several state-of-the-art predictors of the mutation pathogenicity such as
SIFT [93], Polyphen II [99] and SNPs&GO [108].
It is evident that other information sources will be added in the future to further de-
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velop this analysis platform. In particular, the development of the KinMut predictor described
here fits perfectly with the need to predict the consequences of mutations in protein kinases,
as they are frequently mutated in cancer [14, 27, 71, 74, 75, 171] and they are common clinical
targets of a number of cancer drugs [35,36].
5.8 Future developments and perspectives
In addition to its incorporation into a personalized medicine platform, a number of other
extensions and improvements of the predictor presented here are envisaged.
From a technical point of view, the most straightforward future task regards the main-
tenance of the server. The performance of the classifier correlates with the amount of input
information and the number of experimentally characterized mutations. Therefore, the
classifier would need to be re-trained and re-evaluated with each new release of the mutation
databases. Thus, an obvious future objective is to design a protocol for the automatic
maintenance of the predictor whenever mutation databases are updated.
From a conceptual perspective, future plans include the introduction of structure-based features
to complement the sequence-based features used in our prediction pipeline, such as protein
flexibility [104,107], structural conservation [185] and allosteric regulation [50,51,55,164]. The
3DSim method [143] introduced in this thesis will be an important part of this development,
since it will provide the means to map the position of the mutations onto corresponding protein
structures. Hopefully in the near future, more structures, including reliable models, will be
available. With the completion of the structure-space, we will be able to include new features
that can be scaled up to a large number of structures, and study more intricate processes, such
as the implication of mutations in protein-protein interaction or drug binding.
We are also interested in extending the work started here with the protein kinase su-
perfamily towards other protein families of interest in cancer biology, such as phosphatases,
caspases and small GTPases.
With the growing number of families to be analyzed, this project would require the de-
velopment of automatic pipelines to fulfill the tasks that were completed manually here. Thus,
different kinds of pipelines would be required.
First, we would need to retrieve the mutations and classify them as pathogenic or neu-
tral. The text mining system for the extraction of kinase mutations that we discussed
previously can be adapted to retrieve the necessary information. Detecting mutation mentions
and mapping them onto proteins outside the protein kinase superfamily would not be a problem
for the system as it is. However, the detection of the classification of the proteins would require
a development similar to that implemented in our previous work, where a machine learning
approach was used to detect the natural or mutagenic character of the kinase mutations (data
not shown, [150]).
Second, we need to calculate the support vectors that describe each of the mutations in
the terms of the selected features. These include pipelines for aligning sequences, calculating
conservation, extracting catalytic sites from FireDB, gathering annotations from UniProt and
calculating specificity-determining positions, among the general features. This can be achieved
with the current development of the system and no additional issues would be expected.
However, one of the main difficulties we will face is the systematic selection of family-specific
features for mutation classification. As we discussed previously, one of the strongest aspects of
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our kinase-specific predictor is the presence of customized features that are only valid in the
context of the protein kinase superfamily. Thus, the automatic selection of specific features
still needs to be solved.
Finally, to evaluate which features would be the most informative, we would need an
automatic self-assessing system, and since the number of features is relatively small, an
exhaustive search will be sufficient. If the number of possibilities grows beyond reasonable
limits, other implementations can be tested, such as the Monte Carlo approach where the
individual contribution of inserting a given feature is evaluated.
In the future, we plan to cover the entire protein-space and train classifiers for the re-
maining protein families, integrating and validating these information sources in the automatic
machine learning framework initially developed for the protein kinase superfamily. With
the completion of the family-space, we will address whether the trend of disease-associated
mutations to localize near important residues is general or a particularity of the protein kinase
superfamily, and whether the definition of driver somatic mutations is valid for other protein
families.
Chapter 6
Conclusions
1. We have developed a system, 3Dsim, to transfer mutations and annotations from sequence
coordinates to the corresponding three-dimensional protein structure. The system exploits
the capabilities of CATH and Gene3D to assign a representative structure to the query
sequences.
2. We have implemented an automatic pipeline that can extract mentions of mutations in
protein kinases from abstracts and full-text articles and map them onto corresponding
protein sequences. Almost one half of these mutations were not previously recorded in
public databases. The extracted mutations are a useful information repository.
3. We have demonstrated that automatic extraction pipelines are valuable for linking
protein kinase mutations and their mentions in the literature. These pipelines are useful
in assisting manual curation of mutations, e.g., by providing experimental conditions,
functional evidence and the associated phenotypes.
4. Differences exist in the distribution of somatic mutations with respect to important
regions in the structure of human protein kinases. Potential cancer-associated mutations
(drivers) tend to occur near conserved and functionally relevant regions, such as the
ATP-binding pocket and subfamily specificity positions relevant for effector binding.
5. Germline mutations associated with disease (pathogenic deviations) tend to be located
close to conserved solvent-inaccessible regions, the ATP-binding pocket and family
specificity-determining positions.
6. Somatic driver and germline pathogenic mutations have a similar distribution in impor-
tant regions of protein kinase structures. This might be interpreted as supporting the
classification of pathogenic somatic mutations as cancer drivers, since their distribution
is similar to mutations known to be able to elicit disease.
7. We have implemented an automatic system to predict the pathogenicity of mutations in
the protein kinase superfamily. This system integrates general and family-specific infor-
mation, including sequence-based features and experimentally-derived functional annota-
tions. The results support the use of family-specific predictors and justifies its extension
to other protein families.
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Resumen
Las superfamilia de las prote´ına quinasas constituye una prometedora diana farmacolo´gica
debido a que estas prote´ınas esta´n involucradas en gran nu´mero de procesos tumorige´nicos
tales como evasio´n del sistema inmune, proliferacio´n, anti-apoptosis, meta´stasis y angioge´nesis.
La mayor´ıa de las mutaciones descritas en prote´ına quinasas son perfectamente toleradas y
no se conoce que sean causa de enfermedad o fenotipo adverso alguno. Consecuentemente,
podemos suponer que son neutras para la funcio´n y estructura de las prote´ınas. Por el contrario,
para un reducido nu´mero de mutaciones es patente su implicacio´n directa en alguna enfermedad.
Los mecanismos mediante los cuales las mutaciones dan lugar a fenotipos adversos han
sido estudiados y caracterizados bioqu´ımicamente en muchos de estos casos y algunas de
las relaciones causa-efecto esta´n ampliamente estudiadas en la actualidad. Sin embargo, la
caracterizacio´n en te´rminos bioqu´ımicos de las mutaciones requiere semejante cantidad de
recursos que no es factible en te´rminos pra´cticos mantener el ritmo impuesto por las tecnolog´ıas
de alto rendimiento que existen en la actualidad para la identificacio´n de nuevas mutaciones.
Es necesario, por tanto, ampliar nuestro conocimiento sobre los mecanismos mediante
los cuales las mutaciones alteran la funcio´n de las prote´ınas y dan lugar a enfermedad. Esto
nos permitira´ desarrollar protocolos mas eficientes para la caracterizacio´n y priorizacio´n de
mutaciones, de tal forma que los esfuerzos de la comunidad cient´ıfica se orienten hacia aquellas
mutaciones que ma´s probablemente jueguen un papel causal en el desarrollo de enfermedades.
El objetivo de esta Tesis Doctoral es ampliar nuestro conocimiento acerca de los mecan-
ismos mediante los cuales las mutaciones patoge´nicas interfieren con el normal funcionamiento
de las prote´ına quinasas, dando lugar a enfermedad as´ı como desarrollar una plataforma
para identificar aquellas mutaciones en prote´ına quinasas que presenten una alta probabilidad
de estar involucradas en enfermedad. Al centrar nuestros esfuerzos en la superfamilia de
las prote´ına quinasas podemos utilizar me´todos e ideas espec´ıcos para su organizacion y su
evolucio´n en familias de prote´ınas.
Estas interesantes cuestiones cient´ıficas se tratan en esta Tesis Doctoral desde la per-
spectiva de la Biolog´ıa Computacional. Dicha disciplina proporciona el entorno necesario
para el ana´lisis integrado de grandes cantidades de informacio´n provenientes de diferentes
fuentes. Adema´s, los avances en bioestad´ıstica y en aprendizaje automa´tico posibilitan
la generalizacio´n de reglas basadas en observacio´n del comportamiento de las mutaciones
previamente caracterizas. Dichas reglas permiten la estimacio´n teo´rica de la probabilidad de
que una mutacio´n dada altere la funcio´n de la prote´ına y resulte desencadentante de alguna
tipo de enfermedad.
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Conclusiones
1. Hemos desarrollado un sistema, 3DSim, que permite la transferencia de mutaciones y
sus anotaciones desde las secuencias a las estructuras tridimensionales de las prote´ınas.
El sistema hace uso de CATH y Gene3D para asignar estructuras representativas a las
secuencias si es necesario.
2. Hemos implementado un protocolo automa´tico para la extraccio´n de mutaciones en
prote´ına quinasas mencionadas en art´ıculos cient´ıficos y para mapear dichas menciones
a sus secuencias proteicas correspondientes. Casi la mitad de las mutaciones recuperadas
de esta forma no estaban presentes en las bases de datos publicas y constituyen, por
tanto, un nuevo repositorio de utilidad reseable.
3. Hemos demostrado que la extraccio´n automa´tica de mutaciones en el a´mbito de las
prote´ına quinasas constituye un recurso va´lido para la asociacio´n de mutaciones con sus
menciones en la literatura. Este tipo de herramientas facilitan la curacio´n manual de
las mutaciones y proporcionan informacio´n adicional como, por ejemplo, las condiciones
experimentales, las funciones de las prote´ınas o los fenotipos asociados.
4. Existen diferencias en la distribucio´n de las mutaciones soma´ticas con respecto a
regiones importantes en la estructura de las prote´ına quinasas humanas. Las mutaciones
potencialmente asociadas con ca´ncer (drivers) tienden a localizarse cerca de posiciones
conservadas y regiones relevantes para la funcio´n como el sitio de unio´n de ATP, las
regiones de unio´n a efectores y ligandos o los residuos que confieren especificidad dentro
de las subfamilias de quinasas. Esta asociacio´n es coherente con el papel potencial de
estas mutaciones en los primeros estadios del desarrollo de tumores.
5. Estas diferencias tambie´n existen en la distribucio´n de las mutaciones germinales con
respecto a las regiones importantes en la estructura de las quinasas humanas. Las
mutaciones patoge´nicas, aquellas para las que existe una validacio´n experimental de su
asociacio´n a enfermedad, tienden a encontrarse cerca de regiones conservadas, en regiones
inaccesibles para el solvente, cerca del sitio de unio´n de ATP o en posiciones importantes
para la especificidad de subfamilias o la unio´n de efectores.
6. Tanto mutaciones soma´ticas como germinales presentan una distribucio´n parecida con
respecto a las posiciones importantes para la estructura del dominio quinasa. Esta obser-
vacio´n se puede interpretar como un argumento a favor de la controvertida categorizacio´n
de las mutaciones soma´ticas en drivers y passengers y su uso como un modelo para el
estudio del papel de las mutaciones soma´ticas en la biolog´ıa del ca´ncer.
7. Hemos implementado un sistema automa´tico para la prediccio´n de la patogenicidad de las
mutaciones en la superfamilia de las prote´ına quinasas. Este sistema integra tanto infor-
macio´n general como espec´ıfica de familia. Esta informacio´n incluye propiedades basadas
en secuencia y anotaciones funcionales obtenidas experimentalmente. Los resultados pre-
sentados avalan el desarrollo de predictores espec´ıficos de familia y la extensio´n de este
trabajo a otras familias mas alla´ de las prote´ınas quinasas.
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Abstract
Background: The phenotypic effects of sequence variations in protein-coding regions come about
primarily via their effects on the resulting structures, for example by disrupting active sites or affecting
structural stability. In order better to understand the mechanisms behind known mutant phenotypes, and
predict the effects of novel variations, biologists need tools to gauge the impacts of DNA mutations in terms
of their structural manifestation. Although many mutations occur within domains whose structure has been
solved, many more occur within genes whose protein products have not been structurally characterized.
Results: Here we present 3DSim (3D Structural Implication of Mutations), a database and web application
facilitating the localization and visualization of single amino acid polymorphisms (SAAPs) mapped to protein
structures even where the structure of the protein of interest is unknown. The server displays information
on 6514 point mutations, 4865 of them known to be associated with disease. These polymorphisms are
drawn from SAAPdb, which aggregates data from various sources including dbSNP and several pathogenic
mutation databases. While the SAAPdb interface displays mutations on known structures, 3DSim projects
mutations onto known sequence domains in Gene3D. This resource contains sequences annotated with
domains predicted to belong to structural families in the CATH database. Mappings between domain
sequences in Gene3D and known structures in CATH are obtained using a MUSCLE alignment. 1210 three-
dimensional structures corresponding to CATH structural domains are currently included in 3DSim; these
domains are distributed across 396 CATH superfamilies, and provide a comprehensive overview of the
distribution of mutations in structural space.
Conclusion: The server is publicly available at http://3DSim.bioinfo.cnio.es/. In addition, the database
containing the mapping between SAAPdb, Gene3D and CATH is available on request and most of the
functionality is available through programmatic web service access.
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Background
The most common biologically-relevant mutations are
single base changes often referred to as single nucleotide
polymorphisms (SNPs). These account for about 90% of
sequence polymorphisms in humans [1] at an overall fre-
quency of about one per 1000 bases [2]. Traditionally,
SNPs are classified as coding or non-coding according to
their genomic location – coding SNPs are further sub-clas-
sified according to the protein product expressed. Non-
Synonymous SNPs (nsSNPs) are those that alter the
amino acid sequence of the protein product, either
through amino acid substitution (a 'single amino acid
polymorphisms', SAAP), or by the generation of trunca-
tion mutations. By contrast, synonymous SNPs (also
referred to as silent or sSNPs) are those that do not alter
the amino acid sequence of the protein product.
Not all synonymous SNPs are neutral since they may still
affect the expression of gene products or protein transla-
tion by introducing alterations into regulatory regions,
interfering with splice sites or impinging on other regula-
tory mechanisms [3,4]. Similarly, not all nsSNPs are asso-
ciated with pathological diseases, since some changes are,
by nature, milder than others, and diseases commonly
involve complex sets of alterations.
Strictly the term 'SNP' is defined as a mutation which
occurs in at least 1% of a 'normal' population. Thus SNPs
are expected to have a neutral non-deleterious or low-pen-
etrance phenotypic effect whereas the term pathogenic
deviation (PD) refers to those mutations that generally
occur at much lower frequencies in the population and
have a severe effect on phenotype.
The most commonly used database for storing informa-
tion on SNPs is dbSNP [5], which currently contains sev-
eral million validated SNPs from humans and other
species. Other sources of genomic information about
SNPs include Ensembl [6] and the HapMap Project [7].
Several efforts have been devoted to the prediction of the
pathogenicity of amino acid mutations, resulting from
single nucleotide changes. These methods make use of a
set of characteristics which may be based both on
sequence and structure, to determine whether a mutation
can affect protein function and therefore be, potentially,
associated with disease. This is an area of active research
as shown by the considerable number of publications on
the subject during the last few years [8-18].
Several efforts, SAAPdb [19] among others, have been
devoted to compiling this information and to providing a
sequence and structural analysis, where possible, aiming
to determine the origin of the pathogenicity shown. In
this type of repository, the term SNP is used to refer to
essentially phenotypically silent mutations, while PD is
used for mutations known to have a severe effect on phe-
notype, i.e. any single base change reported to correlate
with disease. Online Mendelian Inheritance in Man
(OMIM) [20] is a collection of information about inher-
ited disease and contains data on PDs. However a great
deal more information is held and maintained by individ-
ual research groups in locus-specific mutation databases
or LSMDBs [21]. Like PDs, nsSNPs are point mutations,
but by definition they occur in at least 1% of a 'normal'
population. They are expected to have a neutral non-dele-
terious or low-pentrance phenotypic effect whereas PDs
are known to be detrimental. By mapping these SAAPs (a
term we use for both PDs and mutations resulting from
nsSNPs) onto protein structures, we can begin to under-
stand how protein structure might be affected by mutant
residues, and so begin to explain the functional effect (if
any) of the mutation. SAAPdb provides potential explana-
tions for both PDs, derived from various sources, and
SNPs, derived from dbSNP [5].
The CATH [22] structural domain database is a manually
curated classification of domain structures found in the
Protein Data Bank (PDB) [23], grouped according to evo-
lutionary relationships and structural features. Hidden
Markov Models (HMMs) are derived from alignments of
these structural exemplars and used by Gene3D [24] to
identify homologues within the protein sequences of Uni-
Prot [25], RefSeq [20] and Ensembl [6].
Here we present 3DSim (3D Structural Implication of
Mutations), a system mapping single amino-acid poly-
morphisms onto structures of CATH domains. For
sequences with no known structure, the Gene3D resource
of domain structure annotations is used to map the
sequence onto the closest homologous domain of known
structure in CATH. Thus 3DSim is of particular interest
when no structural information is available for a protein
in which mutations are known to occur as it uses sequence
homology to map to the closest representative structure.
This provides a comprehensive overview of the distribu-
tion of mutations in structural space, as well as a visuali-
zation tool for pinpointing the locations of mutations on
individual structures rendered in Jmol http://
www.jmol.org/, as well as links to detailed information
on each sequence, structure and mutation. The 3DSim
application, which was designed with the aim of being
very intuitive, easy to use and user-friendly, is publicly
available at http://3DSim.bioinfo.cnio.es/. Several
worked examples are available, along with a 6-minute
video tutorial. In addition, for those advanced users need-
ing intensive programmatic access to the information
stored, the underlying database containing the mappings
between SAAPdb, Gene3D and CATH is available on
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request, and most of the functionality is available as web
services implemented in SOAP.
Results and discussion
The mapping between SAAPdb and Gene3D
SAAPdb contains polymorphism data for 11956
sequences without a structure. Almost all of these could be
mapped to Gene3D: 11904 identical sequences were
found in the Gene3D database. Of the remaining 52, 17
had sequences with the same length and associated uni-
prot accession, leaving only 35 for which a reliable match
could not be obtained directly.
The mapping between Gene3D and CATH
Where no structural data are available, the best represent-
ative CATH domain is selected on the basis of homology.
For each of the 2179 superfamilies in CATH, a database of
all CATH domains was built. For each of the 11904
Gene3D domain sequences mapped to CATH structural
superfamilies for which there is information about muta-
tions in SAAPdb (see previous section), a BLAST [26]
search was run against the corresponding superfamily
database. The closest relative found (i.e. the one with the
lowest e-value and highest sequence identity) was used to
cluster the sequences. Sequences with a sequence identity
less than 20% were placed in separate clusters. This proc-
ess yielded 2091 different groups. The groups (including
the sequence of the representative structure) were then
aligned using MUSCLE [27] and the resulting alignments
used to transfer the mutations from Gene3D sequences to
CATH domain representative structures. At the end of the
pipeline we were able to display information on 6514
point mutations, 4865 of them known to be associated
with disease, mapping to 396 CATH superfamilies. The
complete pipeline is described in Figure 1 and details are
provided in the Methods section.
Description of web application
The initial input for the system is a CATH superfamily
identifier for which the user wants to retrieve information
on mapped mutations. Alternatively, the database can be
searched using Uniprot accession codes or CATH domain
identifiers. The user can either manually introduce the
desired superfamily identifier in the provided form, or
browse the superfamilies in CATH in order to access the
information. After this initial step, information about the
The mapping pipelineFigure 1
The mapping pipeline. Illustration of the mapping process between SAAPdb and CATH via Gene3D
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selected CATH superfamily is displayed along with the
CATH domains for which there is information about
mutations in SAAPdb.
In addition, for users that are interested in a general over-
view of the distribution of mutations within structural
superfamilies in CATH, one can obtain a list of the super-
families with known mutations and analyze domains in
that superfamily.
Once the user has selected a CATH domain, 3DSim dis-
plays both an interactive Jmol plug-in that allows the vis-
ualization of the mutations projected onto the three-
dimensional structure of the representative CATH domain
and a table displaying all the information available for
that given domain in terms of available mutations,
sequence and structure positions of the mutations, patho-
genicity information, and similarity (BLAST sequence
identity) between the sequences in Gene3D and the repre-
sentative CATH domain sequence.
This similarity index provides the user with a hint about
the reliability of the homology based transference of
mutations between sequences in Gene3D and the struc-
tures in CATH. As a rule of thumb, the higher the similar-
ity the more reliable the transference of mutations is.
Tweaking this index is of particular interest when there are
few mutations in the close relatives for a given structural
family and looser constrains need to be taken into
account to allow more mutations in the analysis. By
default, the server rejects those mutations transferred from
sequences obtaining a BLAST sequence identity of less
than 20%, but – due to the interactive approach of the
server – the user can decide to establish more stringent
constrains depending on the study case.
In addition, the site is linked to several external annota-
tion providers (including CATH, Gene3D, SAAPdb, Mod-
base, PDBsum and UniProt) where more information
about the mutations, the proteins and the structures can
be gathered. In particular, SAAPdb provides information
about the structural implications of mutations. This infor-
mation can be related, in some cases, to the pathogenic
character of the mutations and provides an insight into
the mechanism of molecular function for several proteins.
Figure 2 shows a worked example of the different views
available through the server's graphical user interface.
Description of web services
In order to allow remote programmatic access to the infor-
mation contained in the database, we have developed a
total of nine SOAP web services, powered by the Perl
SOAP::Lite toolkit http://www.soaplite.com/. These allow
users to retrieve in simple XML format:
• all known mutations for a given CATH domain,
grouped by UniProt ID.
• the total number of mutations in a CATH domain.
• all the CATH domains which are associated with a
given UniProt ID.
• the amino-acid sequence of a given CATH domain.
• all CATH domains in a CATH superfamily, queried
by the four-part CATH code.
• the superfamily to which a given CATH domain
belongs.
• the description and representative structure associ-
ated with a given CATH superfamily.
• all the mutations in SAAPdb for a given UniProt
accession.
• the total number of mutations in SAAPdb for a given
UniProt accession.
The web interfaceFigur  2
The web interface. A collage showing a worked example 
of the different sections available through the server's graphi-
cal user interface. a) Browsable list of superfamilies b) Exam-
ple of structure displaying known pathogenic mutations c) 
Explanatory table of the mutations
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These services were designed in such a way as to facilitate
construction of computational analysis pipelines. For
example, a user starting with a UniProt protein of interest
could retrieve a list of all the domains found in that pro-
tein, then the CATH superfamilies to which each domain
belongs, then all the other domains found in each super-
family, and filly all known mutations in those related
domains, by chaining together four web service calls.
More information is provided at http://3DSim.bio
info.cnio.es/webservices.html. The page contains example
Perl code for querying the web-services, and examples of
output from each one.
Database update
The database storing the information presented by both
the webserver and the webservice intrinsically depends on
the other databases providing the source information (i.e.
CATH, Gene3D and SAAPdb), each one being updated at
its own pace. This fact, in addition to the computationally
expensive calculations needed to compute the mapping
between Gene3D and the representative structures in
CATH, makes it impossible to schedule an automatic
updating calendar. Therefore, the database will be
updated based on a release system, where new versions
will be made public as regularly as possible.
Typical usage example
As an illustrative example, here we present the case of the
ATP binding subunit of the kinases (CATH superfamily
1.10.510.10) which is accessible through the server's web
page http://3DSim.bioinfo.cnio.es. This superfamily cor-
responds to the Phosphotransferase domain I homology
group in CATH, and is subdivided into a number of differ-
ent domains. However, for this particular example, we
will focus only on the domain with the highest number of
mutations (24), 1rw8A02. Of these 24 mutations, only
three come from the sequence which maps directly to the
domain. The remaining 21 come from homologous
sequences with 40–65% sequence identity identified via
Gene3D (Table 1). Figure 3 shows the structure with the
pathogenic deviations coloured in blue. This image can be
obtained directly from the server, and is one of the main
features available for the analysis of the distribution of
mutations within structures. Additional links to other
structure-based databases such as PDBsum [28] are pro-
vided in order to enhance the information provided, for
this particular case, the position of the catalytic site,
involved in binding of ATP, is described to be near resi-
dues from 333 to 338. Visual inspection of the position of
the pathogenic deviations reveals that they tend to cluster
around this catalytic core of the structure. Indeed, the
higher the similarity in terms of BLAST identity between
the CATH domain and the Gene3D sequence, the closer
these positions are to the binding core and hence, more
reliable the observations are.
This PDB chain (1rw8A) maps to the UniProtKB/Swiss-
Prot accession P36897 and the information provided by
the UniProt record (accessible through the web server's
cross references) shows that it corresponds to the TGF-
beta receptor type-1 precursor in humans
(TGFR1_HUMAN) for which there is a level of association
with disease, in particular to Furlong syndrome also
known as Loeys-Dietz syndrome type 1A (LDS1); [29].
LDS1 is an aortic aneurysm syndrome with widespread
systemic involvement. The disorder is characterized by
arterial tortuosity and aneurysms, craniosynostosis,
hypertelorism, and bifid uvula (cleft palate). Other find-
ings include exotropy, micrognathia and retrognathia,
structural brain abnormalities, intellectual deficit, con-
genital heart disease, translucent skin, joint hyperlaxity
and aneurysm with dissection throughout the arterial tree.
The mutations listed as pathogenic deviations (R487P,
M318R and D400G) in the server for this protein, which
has a 100% identity between the Gene3D sequence and
the representative structure of the CATH domain are
reported in the literature [29] as involved in LDS1 devel-
opment.
Table 1: Mutations mapped to 1rw8A02. SwissProt accession P36897 maps directly to PDB code 1rw8 chain A and to CATH domain 
1rw8A02 which represents residues 285–500. Other SwissProt entries containing known pathogenic deviations (PDs) are mapped to 
this domain via Gene3D and the mutations are mapped to the 1rw8 structure.
SwissProt Accession Domain Range Sequence Identity Mutations
P36897 285–500 100% M318R, D400G, R487P
O00238 284–499 65% R486W
P36894 314–529 62% A338D, C376Y, M470T
P37023 282–497 60% C344Y, R374W, M376R
I398N, W399S, R411P
R411Q, R411W, R484W
P37173 330–546 40% Y336N, A355P, G357W
S449F, E526Q, R528C
R528H, R537C
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Conclusion
We have presented 3DSim (3D Structural Implication of
Mutations), a system that enables the localization and vis-
ualization of single amino acid polymorphisms projected
onto protein structures based on homologous relation-
ships captured in the CATH and Gene3D databases. This
provides a comprehensive overview of the distribution of
mutations in structural space.
Although there are other servers mapping mutations to
structure already (reviewed by Uzun et al. [30]) the server
presented here has several unique features not available in
existing servers. Firstly, the similar treatment of SNPs and
the rarer more harmful PDs allows users to inspect and
compare both kinds of mutation through the same inter-
face, including explanatory metadata where available. Sec-
ondly, the localization of these SAAPs within the CATH
hierarchy allows users to query and explore the distribu-
tion of mutations at various levels of structural classifica-
tion. Thirdly, the mapping of sequences onto
homologous CATH domains via Gene3D helps users pre-
dict the effects of polymorphisms in proteins whose struc-
ture has not been solved. Finally, the availability of the
data via web services and database dumps enables power
users to include this information efficiently in their own
analyses. These facilities allow the independent integra-
tion of our data in any other pipeline or workflow.
The server has been running internally since we started
working on the analysis of point mutations in protein
families [31,32] and is accessible at http://3DSim.bio
info.cnio.es/. Examples and documentation are also avail-
able, together with a tutorial video and samples of outputs
of the main functions. This website is available to all users
with no login requirement. It is likely that we will include
additional features related with the structural interpreta-
tion of mutations and their relationship with disease, after
receiving feedback from external users.
In summary the 3DSim server provides up-to-date, com-
plete information automatically to map mutations in the
domain sequences of proteins annotated in Gene3D onto
protein structures classified in the CATH database.
Methods
Obtaining the mutations from SAAPdb
SAAPdb [19] is a database of single amino acid polymor-
phisms (SAAPs) from several resources, such as dbSNP
[5], ADABase [33], G6PD [34] HAMSTeRs [35], IARC p53
Database [36], LDLR [37], OMIM http://
www.ncbi.nlm.nih.gov/omim/, OTC [38], SOD1db [39]
and ZAP70Base [33], mapped to protein structure, where
available in the PDB [23]. As of October 2008, SAAPdb
contains 9060 unique pathogenic deviations (PDs: SAAPs
associated to a disease) and 2532 unique single nucle-
otide polymorphisms (SNPs: SAAPs with no known path-
ogenic effect) successfully mapped to the UniProtKB [25]
sequences in Gene3D [24].
Both pathogenic deviations and single nucleotide poly-
morphisms were only taken into account if the alteration
introduced was non-silent, that is, if the mutation is both
in a coding residue and the resulting amino acid is differ-
ent from the native one. Where mutations are recorded
both as neutral and disease-associated, the mutations
were considered pathogenic.
Gene3D domain assignments
The process by which homologues of CATH domains are
identified in sequences, and presented in the Gene3D
database, has been described previously [40]. For this par-
ticular dataset, the CATH v3.2.0 Hmmer HMM library was
scanned against the UniProt (Swiss-Prot and TrEMBL)
sequence database in collaboration with the SIMAP data-
base [41]. FASTA files of each superfamily were generated
by extracting the subsequences of the domains belonging
to each superfamily.
Gathering the sequences from Gene3D
For each CATH superfamily a library of one or more
HMMs is generated using the SAM Target2K procedure
[22]. These HMMs are then searched against UniProt in
collaboration with the SIMAP resource at the Munich
Three-dimensional structure of CATH domain 1rw8A02Figure 3
Three-dimensional structure of CATH domain 
1rw8A02. 1rw8A02 is member of the Phosphotransferase 
superfamily in CATH (1.10.510.10). 24 positions are 
reported to be pathogenic mutations (PDs, blue).
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Information Centre for Protein Sequences [41]. The hits
are resolved into a single set of non-overlapping domains
for each sequence, using the in-house DomainFinder 2.0
protocol. The resulting domain subsequences were then
extracted and dumped into the relevant superfamily
FASTA file.
Gathering the sequences of the CATH domains
For each of the 2097 superfamiles in CATH [22], all CATH
domains were recovered along with the corresponding
amino acid sequences directly from CATH's Oracle data-
base. A total of 86463 CATH domains were found. After-
wards, all CATH domains in the same CATH superfamily
were grouped together in order to build a BLAST database
of the sequences of three-dimensional structures specific
to each of the CATH superfamilies.
Generation of the groups of Gene3D sequences 
represented by the same CATH domain
In order to assign the closest CATH domain to each of the
Gene3D sequences belonging to the same CATH super-
family, we queried each of the sequences in Gene3D
against a database of CATH domains in that superfamily
using BLAST. The best BLAST hit for each of the Gene3D
sequences – provided the identity between the hit and the
query was greater than 20% – was considered the closest
CATH domain and hence the CATH domain was assigned
as the structural representative of this sequence. After per-
forming this classification for the whole set of sequences,
all Gene3D sequences represented by the same CATH
domain were grouped together and all the sequences
within a group considered similar. A total of 2091 unique
groups were generated.
Alignment of the CATH domain groups using MUSCLE
During the previous step of the pipeline, the sequences
contained in each of the groups of Gene3D sequences rep-
resented by the same CATH domain were considered sim-
ilar. However, in order to collapse all the mutations from
the Gene3D sequences onto the representative CATH
domain sequence, the equivalence between pairs of resi-
dues needed to be established. To perform this task, mul-
tiple sequence alignments were constructed using the
alignment package MUSCLE.
Mapping SAAPdb mutations to CATH domain 
representative structures
The alignments generated by MUSCLE during the previ-
ous step of the pipeline were used to transfer the muta-
tions, both pathogenic (PDs) and neutral (SNPs), from
the sequences in Gene3D to the corresponding CATH
structural representatives.
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Abstract
Background: There is a considerable interest in characterizing the biological role of specific
protein residue substitutions through mutagenesis experiments. Additionally, recent efforts related
to the detection of disease-associated SNPs motivated both the manual annotation, as well as the
automatic extraction, of naturally occurring sequence variations from the literature, especially for
protein families that play a significant role in signaling processes such as kinases. Systematic
integration and comparison of kinase mutation information from multiple sources, covering
literature, manual annotation databases and large-scale experiments can result in a more
comprehensive view of functional, structural and disease associated aspects of protein sequence
variants. Previously published mutation extraction approaches did not sufficiently distinguish
between two fundamentally different variation origin categories, namely natural occurring and
induced mutations generated through in vitro experiments.
Results: We present a literature mining pipeline for the automatic extraction and disambiguation
of single-point mutation mentions from both abstracts as well as full text articles, followed by a
sequence validation check to link mutations to their corresponding kinase protein sequences. Each
mutation is scored according to whether it corresponds to an induced mutation or a natural
sequence variant. We were able to provide direct literature links for a considerable fraction of
previously annotated kinase mutations, enabling thus more efficient interpretation of their
biological characterization and experimental context. In order to test the capabilities of the
presented pipeline, the mutations in the protein kinase domain of the kinase family were analyzed.
Using our literature extraction system, we were able to recover a total of 643 mutations-protein
associations from PubMed abstracts and 6,970 from a large collection of full text articles. When
compared to state-of-the-art annotation databases and high throughput genotyping studies, the
mutation mentions extracted from the literature overlap to a good extent with the existing
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knowledgebases, whereas the remaining mentions suggest new mutation records that were not
previously annotated in the databases.
Conclusion: Using the proposed residue disambiguation and classification approach, we were able
to differentiate between natural variant and mutagenesis types of mutations with an accuracy of
93.88. The resulting system is useful for constructing a Gold Standard set of mutations extracted
from the literature by human experts with minimal manual curation effort, providing direct pointers
to relevant evidence sentences. Our system is able to recover mutations from the literature that
are not present in state-of-the-art databases. Human expert manual validation of a subset of the
literature extracted mutations conducted on 100 mutations from PubMed abstracts highlights that
almost three quarters (72%) of the extracted mutations turned out to be correct, and more than
half of these had not been previously annotated in databases.
Background
Protein kinases are the most ubiquitous family of signal-
ing molecules in human cells, accounting for approxi-
mately 2% of the proteins encoded by the human genome
[1]. They can be further divided into sub-families that
share significant similarity both at the sequence and struc-
tural level. A common feature of all kinases is their ability
to transfer the terminal phosphate of ATP to serine, thre-
onine or tyrosine residues of a target protein. Empirical
studies also suggest a common catalytic mechanism
whereby ATP and active site divalent cations are bound as
well, and phospho-transfer is carried out by a shared set of
amino acids. Despite these functional commonalities,
experiments in yeast models [1,2] suggest that the protein
kinase family as a whole is highly promiscuous, phospho-
rylating a range of different protein substrates, although
individual sub-families may display a remarkable sub-
strate specificity [3]. Kinases have a domain committed to
the general function of catalysis, while another region (or
even regions) are used in many cases to confer substrate
specificity to the enzyme, without altering the general
kinase folding, interfering with ATP binding or the general
reaction mechanism. For reviews on the evolution of
kinase structure and function see [4-7]. Several efforts
have been made to provide a comprehensive access to
information relevant to characterize human protein
kinases through specific databases such as KinBase [1],
KinMutBase [8] and MoKCa [9], or more general data-
bases like PDB [10], PFAM [11] and CATH [12], storing
information important to understand disease-association,
functional and structural properties of kinases.
The relation of kinases with a number of diseases [13] and
in particular with cancer [14-16] has prompted a number
of large scale studies, in particular, Greenman et al. carried
out the first large scale study of the variation associated
with 518 protein kinase genes in 210 samples of cancer
tissues and cell lines. Other HT studies not specifically
restricted to kinases have obviously also contributed in
understanding and providing information on mutations
in protein kinases [14,15]. The interest of kinases and
their implication in disease processes has continued with
the study of Sjöblom and colleagues [15]. For a detailed
review refer to Baudot et al. [17].
The sizeable amounts of information provided by large
scale variation studies and the growing efforts of data-
bases and resources to store and curate this information,
are still not perfectly/completely connected with the many
efforts dedicated to the detailed study of specific kinases
in various biological systems [18] published in individual
research papers. For instance, it is still a challenging task
to establish for which individual mutations detected in
HT studies there is already available information in the lit-
erature. Manual inspection and curation of specific varia-
tion studies and the exact linking to the textual
information requires considerable resources.
Despite difficulties in extracting more complex language
expressions referring to mutation mentions, regularities in
describing mutations based on existing nomenclature
conventions, promoted the implementation of auto-
mated information extraction and text mining systems for
the identification of mutations in the literature [19-30].
Table 1 provides a short summary of previously published
literature mining efforts for mutation information extrac-
tion.
Even though most of the existing manually curated muta-
tion annotation resources are based on reading full text
articles, existing automated systems mainly relied only on
(subsets of) PubMed abstracts or a small collection of full
text articles. To facilitate the interpretation of the biologi-
cal implications and phenotypic effects of a given muta-
tion, not only by clinical experts but also by database
curators or for designing biochemical experiments (drug
design and molecular functional studies) it is crucial to
know whether a given mutation has been experimentally
generated or is present in a naturally occurring sequence
variation. This aspect has generally been neglected by pre-
viously developed approaches. Finally, only few systems
were able to show results based on the combination of
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 heterogeneous data derived from multiple information
sources, derived from literature as well as based on exper-
imental data generated by genotyping studies.
Here we examined the use of text mining methods to
extract information from the literature about protein
kinases and their specific mutations, link this information
to the corresponding protein sequences from databases
(normalization) and analyze how this information is dis-
tributed in protein kinases related databases and reposi-
tories. The results of comparing information from
databases and text repositories are analyzed in terms of
the quality of the information provided and the signifi-
cance in terms of the knowledge related to PK structure
and function. We therefore applied an available mutation
extraction system, called MutationFinder [23] to the
whole collection of abstracts contained in PubMed data-
base as well as to a large set of automatically retrieved full
text articles. To determine if a putative mutation mention
really corresponds to a mutation or actually to something
else we developed a module that allows filtering of false
positive mutation mentions through a combination of
named entity recognition, dictionary look-up and rule
based methods. A supervised machine learning method
relying on the SVM algorithm was used to score and clas-
sify based on its context whether a given mutation men-
tion correspond to an experimentally generated (induced)
mutation or is a natural sequence variant. A protein men-
tion normalization system together with an mutation
sequence checking approach was used to detect associa-
tions between mutations and human kinases co-cited in
the literature. Validation and comparison to multiple
existing mutation resources, including the SwissProt data-
base [31] as well as the COSMIC [32], Greenman/Wood
dataset of somatic mutations [14,16], KinMutBase [8],
and SAAPdb databases [33]. The extraction and compara-
tive mutation analysis were followed by a structural exam-
ination of the distribution of the different type of
mutations in kinase regions of structural and functional
importance.
Results and discussion
Here we present a workflow for extracting mutations
within human protein kinases. The pipeline integrates
article retrieval, detection of mutations mentioned in the
literature, and a final validation of mutations linked to
their corresponding protein sources. We carried out a
comparative analysis of multiple annotation resources
containing different mutation types. An overview of the
resulting approach is presented in figure 1, illustrating the
main steps of the mutation extraction pipeline.
Systematic extraction and disambiguation of mutation 
mentions
For the initial extraction of single amino acid substitu-
tions we applied the MutationFinder system, a modular
software for point mutation recognition based on regular
expressions and patterns detecting mutation mentions
corresponding to residue abbreviations as well as other
language expressions used to describe mutation events
[34]. This system shows a competitive performance in
terms of recall/precision when compared to other strate-
gies [28] and has been evaluated using a manually gener-
ated Gold Standard collection of abstracts [23].
We applied the MutationFinder tool to the whole PubMed
database (November 2008), resulting in the detection of
302,956 mutation mentions from 88,405 records, corre-
sponding to a total of 61,329 unique mutation types (i.e.
wild type residue, sequence position and mutant residue
triplets). A more detailed analysis of the most frequent
mutation types (see additional file 2), illustrated the
importance of the Cystein to Tyrosine mutation in posi-
tion 282 (C282Y, corresponding to the
dbSNP:rs1800562) and the Histidine to Aspartic Acid
mutation at position 63 (H63D, dbSNP:rs1799945), both
occurring in the hereditary hemochromatosis protein
(HFE, SwissProt:Q30201), known to be associated to sev-
eral human diseases. These two mutations are mentioned
over 3,500 and 1,900 times respectively. Some of the most
frequent mutation types corresponded to cases of false
positive (ambiguous) mutations mentions that actually
consisted in names of cell lines (T47D cells) or mouse
strains (G93A mouse model).
As the MutationFinder system was developed and evalu-
ated using a collection of abstracts known to be relevant
for mutations, primarily derived from citations related to
mutant protein structures from the Protein Data Bank
(PDB), we carried out a coarse level consistency analysis
to determine how scalable this system is when applied to
the whole PubMed database, where many articles do not
necessarily resemble the data collection used for the initial
system development. Assuming that the overall mutation
types, contained in manually annotated resources like the
SwissProt database should be similar to the ones encoun-
tered throughout PubMed we compared mutations
extracted automatically from the literature to information
contained in SwissProt, namely mutations being anno-
tated as either natural variant, induced (mutagenesis) or
both single amino acid substitutions. A comparative anal-
ysis of the frequencies of annotated mutation pairs (wild
type residue and the associated mutation) showed that
there are considerable differences between the mutations
often encountered in naturally occurring variations as
opposed to experimentally induced amino acid changes.
The overall profiles resulting from the relative percentages
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of mutation types from different sources are similar (see
figure 2A), despite existing differences encountered in
terms of the most frequent mutations pairs extracted
through text mining when compared to manual annota-
tions (figure 2B).
The most remarkable differences in case of the relative fre-
quencies of mutation types extracted from PubMed com-
pared to SwissProt corresponded to mutations formed by
the residues, A, T, C and G (i.e. G-T, C-T, A-G and T-A sub-
stitutions). This is due to the intrinsic ambiguity of single
letter mutation mentions that can correspond to both
mutations at the DNA or protein level depending on the
context. In order to distinguish between these two muta-
tion levels, additional processing would be required. A
more detailed analysis of the wild type residue and the
mutant residue frequencies revealed that automatically
extracted mutation residues are in line from what would
be expected when examining the relative frequencies
within a manually curated database (figure 3A and 3B).
The most frequently mutated residues mentioned in
PubMed are Arginine, Glycine and Serine, corresponding
also to the top ranking ones annotated in SwissProt.
SwissProt shows more variability when comparing anno-
tations of wild type residues from naturally to induced
variations. In case of experimentally generated mutations,
the residues most frequently replaced are Serines, Lysines,
Arginines, Cysteines and Tyrosines, corresponding to
functionally important residues. Considering the mutant
residues, the literature mining extracted residues are con-
sistent with the mutant residues from SwissProt, which
shows great variation in case of Alanine induced and nat-
ural variant mutants. This can be explained by the wide-
spread use of experimental approaches relying on the
Alanine scanning method for identifying functionally rel-
evant sites, as substitutions to Alanine usually still allow
protein folding yet may give an altered phenotype. A more
detailed description of the mutation disambiguation and
filtering approach to remove false positive mutation men-
tions is provided in the method section.
Scoring variation origin categories: artificial and natural 
mutations
For extraction and management of biological annotations
and to carry out functional analysis of mutations it is cru-
cial to know the level of granularity and experimental con-
text used for determining the phenotypic effect of a given
amino acid substitution. The SwissProt database distin-
guishes here between induced or artificial (mutagenesis)
Table 1: Literature mining approaches for mutation extraction. The additional materials sections (Additional file 1) provides a more 
detailed description of each method.
Collection of existing mutation extraction approaches
Method Main characteristics and descriptive 
keywords of the approach
Ref
MEMA Uses regular expressions, gene and protein 
mention detection, co-mention proximity, 
OMIM validation
[19]
MuteXt Uses regular expressions, GPCR and NR 
mention detection, co-mention proximity, 
sequence check
[27]
Yip et al. Uses regular expressions, protein mention 
detection, SwissProt validation, extensive 
sequence check
[28]
CoagMDB Uses regular expressions, serine protease 
mention detection, sequence check
[41]
Mutation GraB Uses regular expressions, protein mention 
detection, graph shorted distance, sequence 
check
[20]
Mutation Miner Uses regular expressions, protein mention 
detection, sentence co-mention
[21]
MuGeX Uses regular expressions, protein mention 
detection, protein and DNA mutation 
disambiguation
[24]
VTag Machine learning (CRF) detection of acquired 
sequence variations mentions (mutations, 
translocations, deletions)
[26]
OSIRISv1.2 Detection of human gene variations 
corresponding to SNPs
[42]
MutationFinder Uses regular expressions and patterns, protein 
mutations, complex language expressions
[23]
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and natural variant mutations, corresponding the former
to less than 13 percent of the mutation annotations. Char-
acterizations at the level of molecular functional implica-
tions and sub-cellular interactions of specific residues are
commonly studied through experimentally induced
amino acid changes. On the other hand associations to
diseases such as certain cancer types and relevance for
population groups or patients of a given mutation is usu-
ally studied by examining naturally occurring sequence
variants. To address this important issue, allowing muta-
tion mention scoring for each of these two basic categories
of phenotypic descriptions we applied a supervised
machine learning strategy for mutation sentence classifi-
cation. We applied a SVM algorithm (using radial basis
function as kernel) trained on a balanced sample set of
3,482 (71%) labeled sentences for induced and natural
variant mutations and evaluated it on an independent test
set of 1,400 sentences (29%), obtaining an accuracy of
94.64 (recall: 94.57 and precision of 94.71) on this collec-
tion. The size of the feature dictionary used by the classi-
fier was of 11,803 word types (unique words, not
stemmed). A manual inspection of the generated feature
dictionary revealed that some of the relevant features cor-
responded to terms comprised in experimental tech-
niques used to generate artificial mutations, such as site-
directed mutagenesis. This basic evaluation schema is
suitable to determine the performance on a controlled set
of balanced instances, but does not take into account the
actual distribution of the classes within a large collection
of unlabelled data nor cases that even by human experts
can not be clearly classified into one of these binary cate-
gories. Therefore we carried out both, a classification con-
sistency analysis on the resulting sentence scores as well as
a detailed evaluation and comparison against manually
examined mutation sentences (see figures 4A to 4F).
To determine the overall classification and scoring con-
sistency on the level of the whole mutation sentence col-
lection extracted from PubMed described in the previous
subsections, we analyzed the distribution of a database
confirmed set of natural variant mutations against a ran-
domly chosen set of mutation mentions. The first collec-
tion of sentences corresponded to mutation mentions
cross-checked from SwissProt annotations as natural vari-
ants, resulting in a total of 10,886 sentences, none of these
were contained in the original training nor test set. The
second collection was constructed by randomly selecting
an equal number of mutation mentioning sentences from
PubMed abstracts. For each of these two sets we deter-
mined the corresponding sentence scores generated by the
classifier. Figure 4A shows the box plot of the sentence
classifier scores for the 10,886 natural variant mutation
sentences and the equally sized random collection of
mutation mentioning sentences. The scores of natural var-
iant mutation sentences (mean of 1.37) were significantly
higher when compared to the random subset (mean of
0.09), indicating that the overall scoring of natural variant
mutation mentioning sentences derived from the inde-
pendent SwissProt annotations are consistently higher
than a random subset.
For practical purposes it is often useful to determine the
actual performance of a system for a discrete set of score
intervals or cut-offs, to enable a more efficient selection of
instances for further examination or manual curation.
Therefore we selected random subsets for sentence score
intervals ranking from above 4 (positive class, natural var-
iant relevant) to minus 4 (negative class, induced muta-
tion or mutagenesis). Sentences of each of these sets
underwent a two-step blindfold manual classification
process to provide a more fine-grained analysis of the dif-
ferent aspects that might influence the actual systems per-
formance. The first step consisted in classifying whether
the sentence is mentioning a mutation or not to deter-
mine the effect of false positive mutation extraction. As a
separate class we also recorded cases of mutation men-
tioning sentences where the directionality of the automat-
ically extracted mutation event (wild type residue vs.
mutant residue) was wrongly derived. When considering
the mutation extraction performance across the score
intervals for mutations classified as induced and natural
variants, it seems that it was more difficult to correctly
identify mutation mentions in abstracts that where close
to the classification boundary or where scored as experi-
mentally generated mutations.
The second step involved manually classifying mutation
mentions into one of the following categories: (1) natural
variant, (2) induced mutation or (3) unclear cases. We
decided to add the latter category to take into account
mutation mentions that even by humans could not be
classified clearly into one of the two other types, either
because the context of mention is not informative enough
or because it is a truly ambiguous case. Figure 4E and 4F
provide a detailed overview of the results obtained from
this multi-step manual mutation classification for each of
the score intervals. The classifier results are identical to
human classification in over 95% of the cases for very
high and very low mutation sentences score intervals, but
drop to less than 77% for cases where mutations where
classified as natural variants with classifier scores close to
the classifier decision boundary (score interval of 1 to 0).
Finally we also selected randomly a larger set of mutation
mentions and carried out a bind fold manual labeling of
these cases, to analyze the overall performance of the
mutation classifier as well as to determine the distribution
of natural variant and induced mutation mentions from
PubMed abstracts. From the initially extracted set of muta-
tions, 93.9% corresponded to correct mutation mentions
without applying the mutation filter, compared to 97.0%
BMC Bioinformatics 2009, 10(Suppl 8):S1 http://www.biomedcentral.com/1471-2105/10/S8/S1
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when applying the false positive mutation detection step.
Out of the correctly extracted mutations, 49.75% were
manually classified as natural variant mutations, very
close to the 47.2% of mutations classified as induced
mutations. Surprisingly only 3.05% corresponded to
unclear mutation types. Evaluating the sentence classifier
results against the manually classified labels resulted in a
precision of 93.88%, a recall of 91.09% (balanced f-score
of 92.46) and an accuracy of 93.88, in line with the per-
formance obtained with the previously used test set. An
interesting false negative case was the sentence: The hexa-
meric structure is important for protein stability, as dem-
onstrated by studies with natural mutants (the Killer-of-
prune mutant of Drosophila NDP kinase and the S120G
mutant of the human NDP kinase A in neuroblastomas)
and with mutants obtained by site-directed mutagenesis.
In this particular case the authors refer to both natural var-
iants as well as induced mutations, being S120G actually
a natural mutation.
Linking mutation mentions to human kinase sequences
Providing associations of mutations to their correspond-
ing protein record and sequence is crucial to facilitate a
more detailed characterization of structural effects of a
given mutation and distribution within certain protein
domains. This also allows direct comparison to functional
annotations of proteins and mutations contained in man-
ually curated annotation databases as well as to large-scale
experimental results obtained by genotyping studies. Here
we focus on associating the extracted mutations specifi-
cally to human protein kinases.
To obtain links between mutation mentions and human
kinases we assumed that the corresponding protein
Flow chart of the presented literature mining approach for mutation extractionigure 1
Flow chart of the presented literature mining approach for mutation extraction. This flow chart provides an over-
view of the different processing steps to extract mutations relevant for human kinases. The main steps include the construction 
of a kinase relevant article collection, the detection of mutation mentions, the scoring of the type of mutation (induced/natural 
variant), the linking of mutations to the corresponding protein sequence and the comparison to existing databases.
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names should be co-mentioned in the articles. After
extracting all the mutation mentions from PubMed
abstracts and a large collection of full text articles, these
two data sets were processed for retrieving mentions of
human protein kinases. In order to detect kinase protein
mentions we applied a dictionary look-up approach, sim-
ilar to strategies that participated successfully at the gene
normalization task of BioCreative II [35]. To take into
account inter- and intra-species protein name ambiguity,
rather than using very strict protein-organism source co-
mention criteria based on relative textual distances, we
calculated for each article two scores reflecting (1) the
contextual similarity of the article to the SwissProt protein
record and (2) the overall association of the article to
human species terms from the total set of tagged species
terms.
This high recall protein normalization scoring strategy
was followed by a more stringent sequence validation
approach that allowed us to detect links of mutations and
proteins by checking whether the actual mutation men-
tion can be confirmed by looking them up at the protein
sequence position. We restricted our analysis specifically
to mutations occurring in the protein kinase domain, as
defined in Kinbase [1]. A total of 567 triplets (i.e. article-
mutation-protein associations) derived from abstracts
could be validated by checking whether the extracted wild
type residue was found at the mutated position in the pro-
tein sequence. In addition to this basic sequence look-up
validation method we implemented five complementary
mutation-sequence mapping strategies that take into
account both, errors resulting from the wrong detection of
the actual directionality of the extracted mutation with
respect to wild type and mutant residues as well as incon-
sistencies and alternative sequence counting between the
article and the database kinase sequence (see methods
section). By applying this additional matching strategies
we were able to recover 437 additional hits, correspond-
ing to 43.53 percent of the total set of sequences validated
protein mutation pairs. This resulted in a total of 1,004 tri-
plets from 714 abstracts. In case of full text articles, the
total number of triplets detected by the basic mapping was
3,911, being another 3,917 triplets recovered through
additional sequence mapping methods. This resulted in
7,828 triplets from 3,496 full text articles. The average
number of sequence validated mutations in the Protein
Mutation type frequencies from PubMed and SwissProtFigure 2
Mutation type frequencies from PubMed and SwissProt. A. Relative frequency of each mutation type derived from 
PubMed abstracts and from the SwissProt database. B. Most frequent mutation types from PubMed abstracts, and from Swiss-
Prot (SP), annotated as natural variant or induced (mutagenesis) substitutions. C. Values of the Spearman rank correlation 
between the text mining derived mutation types and the database derived mutation types. All p-values are below 10e-6, there-
fore statistically significant.
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Kinase Domain for abstracts was 1.41 and for full text arti-
cles 2.24, implying that often more than a single mutation
is described in a given paper.
The global context of co-mention of kinase proteins and
mutations defined by the multi-document collection
where these co-occur, can be indicative for the actual
importance of a particular mutation, being described and
studied in various different paper. To use information
provided by the corpus co-mention context, in addition to
the total number of documents where the sequence vali-
dated mutation-kinase pair co-occurred we calculated the
mutual information for each mutation pair.
Comparison of text mining mutations to databases and 
genotyping studies
Several genomic studies (including a comprehensive anal-
ysis of all human kinases) have been dedicated to the
characterization of mutations occurring in protein kinases
in a variety of cancer tissues and cell lines. In these studies,
a number of point mutations detected in somatic cell lines
have been found to be associated with specific cancer
types. The pathogenicity of these mutations depends on
multiple factors related to the complex molecular envi-
ronment in which protein kinase function takes place. Of
special interest are mutations found within the protein
kinase domain, as it is essential for the functional activity
of these proteins. We therefore focused our analysis on
automatic extraction of mutations mapped to this partic-
ular domain, common to all kinases, and carefully exam-
ined how they relate to previously characterized
mutations retrieved from multiple databases and experi-
mental high throughput genomic studies. We used the
kinase domain definition followed by Kinbase [1], ana-
lyzing both the distribution of mutations within the Pro-
tein Kinase Domain, as well as the distribution of
mutations according to the corresponding protein family
topology. A total of 643 kinase domain sequence muta-
tions were extracted from PubMed abstracts for a total of
128 different proteins. When considering the full text col-
lection, we were able to increase considerable this
number, obtaining a total of 6,970 mutation-protein pairs
from 325 proteins. Using full text articles resulted there-
fore in a considerable increase of recovered mutations
(more than 10 times more mutation-protein pairs when
compared to abstracts) as well as being useful to increase
the recall of proteins for which mutations had been
extracted (more than doubling the initial number derived
form abstracts alone). The increased recall for full text
papers clearly justifies the computational effort required
to retrieve and preprocess them.
Figure 5A shows the distribution of the mutations
extracted from the literature into the different groups in
which Kinbase [1] classifies the protein kinase domain of
the human kinases. For a more detailed description of the
different kinase groups refer to the methods section.
Although there are differences in the number of muta-
tions present – with more than a half of the mutations
either within the TK or the CMGC clades – all the main
groups are represented in the results both when PubMed
abstracts or full text articles are taken into consideration.
Figure 5B depicts the normalized distribution of muta-
tions in the different protein kinase domain groups in
which Kinbase classifies the human kinome when the
abstracts and the full text articles are taken into account
respectively. It is evident that no matter which dataset is
used, either abstracts or full-text articles, the distributions
are very similar independently of the very uneven abso-
lute numbers between both datasets, which confirms that
complementary results are provided by the two very dif-
ferent approaches.
Comparative analysis of wild type residues and mutations extracted from Swis Prot and using text miningFigure 3
Comparative analysis of wild type residues and muta-
tions extracted from SwissProt and using text min-
ing. This chart illustrates differences in terms of wild type 
and mutant residue frequencies derived from the SwissProt 
database and obtained through automatic literature process-
ing. A. Relative frequency of each wild type residue derived 
from mutations extracted from PubMed abstracts and from 
the SwissProt database. B. Relative frequency of each mutant 
residue derived from mutations extracted from PubMed 
abstracts and from the SwissProt database.
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Confirmation and comparison to experimental and curated data
In order to assess whether the mutations recovered from
the existing literature by our system were already present
in commonly used databases or are newly recovered
instances, we herein studied the overlap between the
mutations in the protein kinase domain both in the data-
bases and the results from our extraction pipeline. Table 2
represents the percentage of each database covered by the
Text Mining results.
Recovery of disease associated mutations: overlap with KinMutBase
KinMutBase [8] is a manually curated knowledge base for
human disease-related mutations in protein kinase
domains. At the time of the study, March 2009, a total of
83 single-point pathogenic mutations in the protein
kinase domain of 10 different proteins were provided in
KinMutBase. We were able to confirm 32 (38.55%) of
these mutations from abstracts and also the same number
 from full text articles. When combining the mutations
from both article collections we recover more than half of
the mutations from KinMutBase, namely a total of 43
mutations (51.81%). This suggests that the mutation
mentions from both document collections are essentially
complementary, and some of them could only be detected
in one of the document sets.
Recovery of natural variant and induced mutations: overlap with 
SwissProt database
The Swissprot Variant database [31] provides experimen-
tally-verified information about mutations present in
UniProtKB, containing a set of 710 mutations in the pro-
tein kinase domain of 194 different proteins. 251
(35.35%) of them corresponding to mutagenesis experi-
ments whereas 459 (64.65%) correspond to reported nat-
ural sequence variants. Using our text mining approach
we were able to recover 134 (18.87%), 328 (46.20%) and
365 (51.41%) of the mutation contained in the database
when the abstracts, the full texts and the combination of
both was used, respectively.
When considering the overlap of extracted mutations with
respect to each of these two mutation type classes (natural
variants and mutagenesis) we were able to obtain similar
percentages for both groups from the combined article
collection, 50.11% of the mutations annotated as natural
variant and 53.78% of the mutations annotated in Swiss-
Prot as mutagenesis.
Interestingly, we found differences in the overlap percent-
ages of recovered mutations from abstracts and from full
text articles when looking at these mutation classes indi-
vidually. When considering the mutations derived from
abstracts, 21.57% of the natural variant annotated muta-
tions could be detected, as opposed to only 13.94% of the
mutagenesis annotated mutations. The opposite trend
was observed in case of full text articles, where we
extracted 52.59% of the induced mutations and 42.70%
of the natural variant mutations. This suggests to certain
extent that experimentally induced mutations annotated
in SwissProt are usually not mentioned in abstracts, but
rather in full text articles.
Recovery of structurally important mutations: overlap with the 
SAAPdb repository
The SAAPdb [33] is a resource for the analysis and visual-
ization of the structural effects of mutations. At the time
of this study, SAAPdb contained 610 point mutations
located in the protein kinase domain of 230 proteins.
52.95% (323) of the information corresponds to muta-
tions previously reported as pathogenic deviations (PDs)
whereas the rest corresponds to neutral SNPs (287,
47.05%).
Our system recovered 65 (10.66%) and 106 (17.38%) of
the mutations previously stored in the database when the
abstracts and full text articles were taken into considera-
tion. For the joint abstracts-fulltext dataset, 125 (20.49%)
of the mutations present in SAAPdb were found.
With regard to the pathogenicity of the mutations found,
for the particular case of the combined dataset, we were
able to find 123 (38.08%) of the pathogenic deviations,
whereas only 2 neutral SNPs were recovered. This high-
lights the fact that the literature is biased towards those
mutations known to be functionally active and harmful
for the individual. It is interesting to remark that none of
the other databases analyzed contained records for the
neutral SNPs in SAAPdb either.
Recovery of somatic mutations: overlap with the Greenman and 
Wood dataset
The Greenman and Wood dataset was built from the
results shown in the original papers [14,16] by the
authors where they report 254 somatic mutations corre-
sponding to the protein kinase domain of 164 proteins in
diverse human cancers. In addition, the mutations are
sub-classified according to the pathogenic character pre-
dicted into drivers (cancer associated somatic mutations)
and passengers (neutral mutations). The contribution of
each class to the whole database is 46.85% and 53.15%
respectively.
Our system recovers only a very small fraction of these
somatic mutations since only 13 (5.12%) of the instances
in the dataset were able to be recovered in the best case
scenario, where the combined article set (abstracts+full-
text) was used. This means that only a small proportion of
the mutation dataset detected by experimental High
Throughput approaches could be linked directly to other
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literature evidences. Our system recovered 9 (7.56%)
driver mutations versus 4 (2.96%) passenger mutations. A
very similar trend was observed for the case of the COS-
MIC database, which shares around 95% of the informa-
tion contained in the Greenman/Wood dataset for the
particular case of the protein kinase domain.
Result summary and structural mutation distribution
Finally, we wanted to assess how many of the mutations
we were able to recover from the total set of mutations in
the 5 studied datasets (namely, SwissProt database [31] as
well as the COSMIC [32], Greenman/Wood dataset of
somatic mutations [14,16], KinMutBase [8], and SAAPdb
databases [33]) in order to get a view of the coverage of
the existing knowledge by our method. To do so we built
a non-redundant set with 1265 mutations in 317 different
Evaluation of classifying induced mutation mentions and natural variantsFig re 4
Evaluation of classifying induced mutation mentions and natural variants. A. Box plot of the sentence classifier 
scores for Natural Variant (NV) annotated mutations in SwissProt and a random subset of sentence scores from mutation 
mentioning sentences. B. Example cases of mutation mentions corresponding to natural variant and induced mutations. C. 
Example features used by the sentence classifier for the positive class (Natural Variant) and the Negative class (Figure D, 
induced mutation). E and F Manual classification result for 50 randomly selected mutation mentioning sentences for classifier 
score intervals. (1) Score above 4, (2) score range of 4-3, (3) score range 3-2, (4) score range 2-1, (5) score range 1-0, (6) 
score range 0 to minus 1, (7) score range from minus 1 to minus 2, (8) score range from minus 2 to minus 3, (9) score range 
below minus 3. Positive scores correspond to mutations classified as natural variant, negative scores correspond to mutations 
classified as induced/mutagenesis.
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Distribution of literature extracted mutations in the groups defined by KinbaseFigure 5
Distribution of literature extracted mutations in the groups defined by Kinbase. A. Number of mutations from the 
literature lodging in the different protein kinase domain groups in which Kinbase classifies the human kinome when the 
abstracts and the full text articles are taken into account respectively. B. Normalized distribution of mutations in the different 
protein kinase domain groups in which Kinbase classifies the human kinome when the abstracts and the full text articles are 
taken into account respectively
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kinases. The different databases are unevenly represented,
and the weight of each database is reported in the last row
of Table 2, where the overlap between the different data-
bases is assessed, under the epigraph 'All Databases'.
Out of the 1265 mutations in the combined database, 148
(11.70%) were found by the Text Mining approach when
the Pubmed abstracts were scanned. By contrast 354
(27.98%) mutations were recovered when the full-text
articles were taken into consideration, and 399 (31.54%)
when the combined abstracts+fulltext dataset was used.
The increased recall of this combined method clearly jus-
tifies the computational effort required.
Although there are mutations scattered everywhere in the
kinase domain structure, a considerable mutation density
is encountered close to functionally relevant parts of the
protein, i.e. the ATP binding pocket, the DFG motif in the
activation loop. Figure 6 shows a detailed view of the
mutation density distribution within the protein kinase
domain model. ATP binding Lysine 64 shows the highest
density of mutations, with a total of 65 mutations, fol-
lowed by residues forming the activation segment (up to
39 mutation per residue) and several residues conforming
the ATP binding pocket.
Worked example: the Epidermal Growth Factor Receptor
The interest of the system presented here is not only that
the user can gather mutations from the literature that are
not reported in the databases, but also that one can get a
summary of sentences mentioning those mutations that
will help to assess the pathogenicity (and in the best pos-
sible scenario, the function) of the mutations newly dis-
covered. A working example is provided here: Mutations
in the EGFR.
The epidermal growth factor receptor, also known as
EGFR, is a protein kinase involved in the control of cell
growth and differentiation which has been reported of
interest in the development of breast cancer since binding
of EGF to its receptor leads to dimerization, internaliza-
tion of the binary complex, induction of the tyrosine
kinase activity, stimulation of cell DNA synthesis, and cell
proliferation.
There are several well-known mutations reported for this
protein in current state-of-the-art databases storing infor-
mation on mutations (SwissProt [31], COSMIC [32],
Greenman/Wood [14,16], KinMutBase [8], SAAPdb [33])
Even more, for some of them, their involvement in disease
has been investigated and annotated in the corresponding
databases. For instance, the somatic mutations G719S,
L858R and T790M have been previously reported in rela-
tionship with lung cancer [16,36].
By contrast, our system was able to recall from the litera-
ture 32 mutation mentions that have not been reported in
the dedicated databases. In order to better understand the
effect of these mutations, our approach is also capable to
provide context information that can be used for the inter-
pretation of the role played by the mutations as described
herein.
To provide an example, in the case of Y845F (transformed
to Y869F due to the presence of a signal peptide) we were
able to find the following sentences 'Furthermore, tran-
sient expression of a Y845F variant EGFR in murine
fibroblasts resulted in an ablation of EGF-induced DNA
synthesis to nonstimulated levels.' (PMID:10075741),
'Stably transfected B82L cells with a point mutation of the
EGFR at Tyr-845 (B82L-Y845F) exhibited only basal Ras
activity following exposure to Zn2+' (PMID:11983694),
'In contrast, LPA-elicited DNA synthesis and migration
were augmented in cells expressing EGFR, EGFR(K721A),
or EGFR(Y845F), but not EGFR(Y5F), although the PDGF
responses were indistinguishable' (PUBMED 15364923).
The information retrieved suggests the involvement of
Tyrosine-845 from EGFR in DNA synthesis via binding to
EGF.
In addition, the system also retrieves functionally neutral
results that are often discarded and not stored in the data-
bases although they contain very useful information for
the contextual interpretation of the involvement of point
residues in protein function 'Unexpectedly, the Y845F
mutant EGFR was found to retain its full kinase activity
and its ability to activate the adapter protein SHC and
extracellular signal-regulated kinase ERK2 in response to
EGF, demonstrating that the mitogenic pathway involving
phosphorylation of Y845 is independent of ERK2-activa-
tion' (PUBMED 9990038). The structural model of this
protein together with a summary of the residue and muta-
tion information is included in additional material file 3
Conclusion
In this paper we presented the first approach to extract
human kinase mutations from both PubMed abstracts
and a large collection of full text articles, comparing the
obtained results to mutations that have been manually
curated from the literature by annotation databases as
well as data generated by genotyping studies. Automated
mutation extraction can assist manual curation efforts by
providing direct pointers to mutation evidence sentences
for quick manual examination. The MutationFinder sys-
tem was useful to detect mutation mentions from both
abstracts and full text articles combined with some addi-
tional filtering of ambiguous mutation mentions. Some
potential future improvements of this basic mutation
extraction system could consider wrongly extracted muta-
tion mentions resulting from mentions of sequence
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ranges or the inclusion of detection of stop codons (e.g.
R97X). Several strategies have been used to filter ambigu-
ous mutation mentions and to discriminate between
mutations at the level of DNA and proteins. We carried
out a detailed consistency analysis of the mutations
detected by means of literature mining to the content of
manually curated annotations. Future steps could include
a more detailed exploration of the actual reliability scor-
ing and ranking of sequence validated mutations through
the use of: (1) mutation-protein proximity analysis in full
text articles, (2) species and organism source ambiguity
examination and (3) analysis of the probability of finding
a given mutation within the target sequence per chance,
considering the actual residue composition of proteins
and kinases. By using a standard machine learning
approach we were able to score the level of phenotypic
description based on contextual information provided for
a given mutation, classifying each mutation mention as
induced (artificial, generated by mutagenesis experi-
ments) or natural variant (polymorphisms, SNPs and
somatic mutations). This aspect is especially important as
it connects mutation relevant information generated by
different scientific domains, i.e. data generated by clinical,
epidemiological and human genetics studies with molec-
ular biology and biochemical in vitro experiments. Extrac-
tion of mutation information from multi-document
collections is useful to complement different scientific dis-
coveries and characterizations described across various
papers, increasing thus efficiency in relating entries to
each other and integrating multiple complementary evi-
dences discovered by different research groups. Problems
related to sequence shifts or cases of so-called sequence
conflicts when comparing the numbering used by article
authors to the sequences contained databases like Swiss-
Prot were addressed by using various sequence validation
strategies, from the basic residue look-up to the use of text
derived sequence patterns. These Sequence conflicts can
be the result of sequencing errors, sequence variants or
isoforms that are not well characterized or even from
alternative counting when considering N-terminal signal
peptides [28]. To resolve such sequence conflicts is even a
cumbersome task for human experts. We can recover
7,184 potential mutations on kinases in the Protein
Kinase Domain from text (643 from abstracts and 6970
from full text). Information from abstracts and full text is
essentially complementary, as sometimes the full text arti-
cle for a mutation mentioning abstract is not available or
even written in another language different from English.
Although some of the extracted mutation-kinase associa-
tions might be erroneous, they still provide a very good
basis for additional annotation efforts, in some cases val-
uable for the in depth analysis of specific proteins (as in
the example shown here).
Interestingly only a very minor fraction of the mutations
detected in hight throughput genotyping studies [14,16]
correspond to previously identified mutations mentioned
in the literature. As a considerable number of these HT
generated data correspond to mutations that do not have
any deleterious effect, it is understandable that they lack
further careful characterization published in the literature.
In general we find that 31.54% of the mutations con-
tained in manually annotated databases can be directly
recovered from papers, important for assuring the data-
base-literature coherence. The remaining mutation
records lack direct evidence about its origin in text, poten-
tially due to (1) missing accessibility of the corresponding
full text articles or additional materials (especially in case
of older publications), (2) general limitations in terms of
recall of mutation mention extraction methods or (3) lim-
itations in the protein normalization and mutation to
sequence associations. We estimate that, based on the
proportion of natural and artificial variations described in
the literature, a considerable fraction of the text mining
derived mutations not contained in any of the existing
kinase mutation resources might correspond to experi-
mentally generated induced mutations. From a manual
inspection of natural variant mutations we were able to
differentiate between four main mutation types, some of
them not considered as annotation relevant by existing
databases but nevertheless important for interpreting the
practical relevance of individual mutations, these include:
(1) mutations with no clear association to the studied dis-
ease phenotypes, (2) mutations that are protective against
some pathological condition, (3) mutations that are dele-
terious and that promote the pathological condition (e.g.
increased disease risk). On the symmetric view 5.55% of
the automatic literature annotations (23.02% from
abstracts and 5.08% from full text) correspond to data-
base confirmed entries, implying that a considerable frac-
tion of the extracted mutations through literature mining
is potential new information still to be annotated. In
order to assess to which extent this new information can
be trusted a human expert manual validation protocol
was conducted on a randomly selected sample of 100
mutations taken from mutation mentioning abstracts (see
Figure 7). We demonstrate in this work how the power of
text mining combined with bioinformatics approaches
can be used to discover and link information in key areas
of biology, being able to result in a framework for sup-
porting manual mutation literature curation and with the
potential to adapt an analogous pipeline to other protein
families going beyond the kinase/mutation analysis. Our
work resulted in a collection of kinase mutation literature
links (mutations, positions, sentences) derived form both
full text articles and abstracts. Our work shows that extrac-
tion of mutations from full text articles is feasible and that
it could be applied to the whole set of full text articles
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from PubMed records in case these access to those is pro-
vide din the future.
The experiment shows that for 23% of the mutations there
was a positive confirmed record in at least one of the ana-
lyzed knowledgebases (SwissProt [31], COSMIC [32],
Greenman/Wood [14,16], KinMutBase [8], SAAPdb [33]),
being consistent with the results previously shown for the
automatic extraction pipeline. In addition, and an impor-
tant added value provided by our system, 41% of the
results were correct assignments between the protein and
the mutation extracted by text-mining that were not
reported in the knowledgebases. Finally, 8% of the muta-
tions corresponded to orthologs having the same amino
acid that the human protein at the specified position,
which can be considered positive hits as well, as they
essentially represent information generated for human
kinases using animal models. In summary, we estimate
that almost three quarters (72%) of the extracted muta-
tions correspond to positive hits being either previously
annotated mutations, correct novel mutations or muta-
tions of close orthologs.
Interestingly, a small proportion of the records (2%) were
too ambiguous even for human experts, lacking enough
information even to perform manual validation.
Materials and methods
Sequences of protein kinase domains using KinBase
The KinBase resource (http://www.kinase.com/kinbase,
[1]) is a repository storing the currently accepted classifi-
cation of eukaryotic protein kinases, which are catego-
rized into two main groups: 'conventional' protein
kinases (ePKs) and 'atypical' protein kinases (aPKs). The
ePKs form the largest group and they have been subdi-
vided into eight groups by sequence similarity of the cata-
lytic domains, the presence of accessory domains, and by
considering different modes of regulation. The eight ePK
groups defined in KinBase are: the AGC group (including
cyclic-nucleotide and calcium-phospholipid-dependent
kinases, ribosomal S6-phosphorylating kinases, G pro-
tein-coupled kinases and close relatives of these kinases),
the CAMKs (calmodulin-regulated kinases); the CK1
group (casein kinase 1 and close relatives); the CMGC
group (including cyclin-dependent kinases, mitogen-acti-
vated protein kinases, CDK-like kinases and glycogen syn-
thase kinase); the RGC group (receptor gyanylate cyclase
kinases); the STE group (MAP Kinase cascade kinases),
Tyrosine kinase group (TKs); and the TKL group (Tyrosine
kinase like family) which are a cluster of serine-threonine
kinases resembling TKs. Another broad, miscellaneous
group called 'other' is also considered for those proteins
that do not fit in any of the predefined sets.
At the time of the analysis, KinBase contained 620 human
protein sequences of which 518 correspond to protein
kinases not considered to be pseudogenes. Although
kinases described as pseudogenes are transcribed and
might even have a residual or scaffolding function, kinase
pseudogenes were not mapped onto Uniprot (SwissProt/
Trembl) since many of them are partial transcripts or have
stop codons in their sequence. Since KinBase does not
directly map its entries onto Uniprot, this mapping was
performed using a BlastP [37] search for each kinbase
sequence against a custom database containing all entries
in Uniprot annotated as human protein kinase domain.
Once the mapping was performed, we were able to map
488 Kinbase identifiers to a valid Uniprot entry, 474 of
them (97.13%) at sequence identity levels of at least 95%.
Mutation extraction from abstracts and full text articles
The used mutation extraction pipeline has been applied to
two text data sets, one consisting in the whole collection
of PubMed abstracts, and the other in a set of 19,404 full
text articles. The full text articles were automatically
downloaded using an in house full text retrieval system
that had previously been implemented. To prioritize full
text articles for download, three different criteria were
considered. The first selection criteria was based on infor-
mation contained in the corresponding abstracts, such as
mention of mutations, mention of human kinase proteins
and a combination of keywords (including 'human kinase
mutation'). The second selection criteria was based on
extracting all the PubMed references for human kinases
contained in multiple databases (e.g. SwissProt, MINT,
IntAct). The third selection criteria was based on analyz-
ing the fraction of mutation mentioning abstracts for each
journal, prioritizing a set of journals (and thus their arti-
cles) for retrieving their full text articles. These journals
included: the American Journal of Human Genetics, Euro-
pean Journal of Human Genetics, Human Genetics,
Human Mutation and Human Molecular Genetics. Each
of the full text articles was automatically converted into
plain text using pdftotext. Both abstracts and full text arti-
cles were then preprocessed applying an in house rule-
based sentence boundary detection system that we opti-
mized for PubMed abstracts. We applied the Mutation-
Finder system two both the full text and abstract sentence
collections using a cluster of 64 Mac PPC G5 processors
running Darwin.
Mutation disambiguation and filtering
The performance of information extraction methods that
detect mutation mentions from the literature is affected
by the underlying article selection criteria used. When
applied to the whole PubMed database, a fraction of
extracted mutation mentions are ambiguous, and there-
fore can, depending on the context correspond to a range
of other bio-entities, like cell lines, protein names or
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clones. Only few previously published approaches did a
more careful examination of wrongly extracted mutation
mentions, most of these ambiguous mentions correspond
to single letter mutations. Horn et al. compiled manually
a list of exceptions to avoid mislabeling of other phrases
as mutations, examining also certain terms co-mentioned
in the context (e.g. cell line, tumour or cancer). For filter-
ing single letter mentions that might correspond to muta-
tions at the level of DNA or RNA they analyzed words
surrounding the point mutation, but did not provide fur-
ther details regarding this process [27]. Erdogmus and col-
leagues addressed DNA versus protein mutation
disambiguation through a supervised learning approach
based on the Naïve Bayes algorithm, they prepared a col-
lection of 2,771 mutation mentions at the protein level
and 768 at the DNA level and obtaining an accuracy of
84.7 [24].
We propose an approach for targeted mutation pattern
sense disambiguation and filtering of mentions that do
not correspond to protein mutations. Therefore we exam-
ined manually a large collection of mutation mentions to
determine the sense inventory with respect to the context
of occurrence, discriminating the main classes of false
positive ambiguous mutation mentions and characteriz-
ing their semantic categories. The majority of these corre-
sponded to one of the following three semantic types:
• Cell lines or cell types. There are several frequently
mentioned cell lines that resemble mutation men-
tions. Among these are the human glioblastoma cell
line T98G, the T-cell line M14T, the adrenocortical cell
line H295R or other commonly used cell lines such as
T47D or T24C.
• Taxonomic entities. Certain taxonomic names, espe-
cially bacterial strains, cloning vectors and certain ani-
mal models (e.g. mouse strains) contain words that
are similar to single letter mutations. Example cases
include the strains: E. coli K12S, A. viscosus T14V, P.
pneumoniae R36A, A. naeslundii T14V, Mycoplasma
sp. G145T or the yeast strain S288C. Also clone iden-
tifiers (e.g. W12I and W12E) or plasmids (e.g. E. coli
plasmids P15A) can result in false positive mutation
hits. A special case of ambiguous mutation mentions
is encountered in transgenic mouse models like G93A
transgenic mice. It consists in a mouse strain express-
ing a G93A mutant form of human SOD1 protein, but
usually is mentioned as the name of the strain rather
than as a reference to this particular mutation.
• Protein and gene names. Several protein names do
match the patterns used to identify mutations from
the literature, although some of these correspond to
human proteins like S100D and S100E, a considerable
fraction are viral gene names (e.g. A10L of the vaccinia
virus, A11L variola virus or the poxvirus protein
A52R).
We found some additional cases of wrongly tagged muta-
tions that could be classified as drugs or compounds (e.g.
the antibiotic A83586C, the immunogen A27L or the anti-
fungal antibiotics A9145C). To determine the semantic
class of a given mutation occurrence we explored the use
Table 2: Overlap between the different knowledgebases and the literature extracted mutations
Literature derived mutations and overlap with knowledgebases
Knowledgebase (KB) Total Mutations in KB 
[weight]
Abstract Full Text Combined (Abs+FT)
SwissProt – all 710 [56.13%] 134 (18.87%) 328 (46.20%) 365 (51.41%)
SwissProt – natural 
variant
459 [36.28%] 99 (21.57%) 196 (42.70%) 230 (50.11%)
SwissProt – 
mutagenesis
251 [19.84%] 35 (13.94%) 132 (52.59%) 135 (53.78%)
SAAPdb – all 610 [48.22%] 65 (10.66%) 106 (17.38%) 125 (20.49%)
SAAPdb – pathogenic 
deviations
323 [25.53%] 64 (19.81%) 105 (32.51%) 123 (38.08%)
SAAPdb – neutral 287 [22.69%] 1 (0.35%) 1 (0.35%) 2 (0.70%)
Greenman & Wood 254 [20.08%] 4 (1.57%) 12 (4.72%) 13 (5.12%)
Greenman & Wood – 
driver
119 [9.04%] 3 (2.52%) 9 (7.56%) 9 (7.56%)
Greenman & Wood – 
passenger
135 [10.67%] 1 (0.74%) 3 (2.22%) 4 (2.96%)
COSMIC 200 [15.81%] 4 (2.00%) 11 (5.50%) 12 (6.00%)
KinMutBase 83 [6.56%] 32 (38.55%) 32 (38.55%) 43 (51.81%)
All Databases 1265 148 (11.70%) 354 (27.98%) 399 (31.54%)
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of knowledge-based methods relying on machine-reada-
ble dictionaries (MRDs) for sense disambiguation based
on local context analysis. In order to address this disam-
biguation task we assumed (1) One sense per discourse,
namely that within a given document the target mutation
mention is consistently used as either a mutation or one
of the three other semantic types previously introduced;
and (2) One sense per collocation, implying that nearby
co-mentioned words provide strong clues to the sense of
the target mutation mention.
Three lexical resources were compiled for taxonomic enti-
ties, protein/gene names as well as cell lines. Due to lim-
ited lexical coverage of cell line information in existing
biological ontologies such as the Cell Type ontology, we
generated automatically a cell line dictionary through use
of a named entity recognition method (ABNER, [28])
applied to mutation mentioning PubMed abstracts. This
resulted in a total of 9,252 cell line names, out of which
1,124 corresponded to mentions that could potentially
match mutation patterns. We incorporated from the list of
cancer cell lines contained in the COSMIC database five
additional names resembling mutations. This cell line dic-
tionary was used to filter ambiguous mutation mentions
(over 13,500 sentences). We also generated automatically
922 pattern templates based on multi-word cell line
names, where the original word resembling a mutations is
used as a slot to be filled with ambiguous mutation men-
tions (see table 3).
For taxonomic entities we assembled a dictionary of spe-
cies names derived from the NCBI Taxonomy and used a
dictionary look-up approach with these names for filter-
ing potentially ambiguous mutations. A total of 584 taxo-
nomic names (and their variations) contained words
matching mutation regular expressions, most of them
from cloning vectors and bacterial strains. Out of these we
generated 128 disambiguation patterns for taxonomic
mentions. A similar approach was followed for disam-
biguation of mutations matching protein and gene
names, relying on a protein dictionary extracted from the
UniProt database. The total number of protein and gene
names from UniProt matching mutation mentions was
295. These were exploited for generating 29 disambigua-
tion patterns that were manually revised to remove too
general patterns, resulting finally in a set of 25 patterns.
A special case of ambiguity is encountered when distin-
guishing between mutations at the level of DNA, RNA and
protein sequences. To enable discrimination between
these different mutation types official nomenclature
guidelines state that the description should be preceded
by a letter indicating the type of reference sequence, p in
case of protein sequences (e.g. pCys76Ala or p.C76A), g
for genomic sequences, c for cDNA, m for mitochondrial
sequences and r for RNA sequences [38]. Unfortunately in
practice these standards are not sufficiently followed
resulting commonly in ambiguity at the level of the corre-
sponding reference sequence type, which requires a spe-
cific disambiguation strategy. This scenario is somehow
similar to the distinction between gene and protein men-
tions, where even for human experts it is sometimes chal-
lenging to make clear decisions.
To handle the automatic distinction between DNA and
protein mutations, we explored the use of different selec-
tion criteria that humans actually follow to achieve this
task. We applied a hand crafted rule-based technique,
with the implicit advantage that it does not require the
construction of large training collections of representative
sample cases for different types of DNA/protein ambigu-
ous mutations. As contextual representation for disam-
biguation of mutation patterns we used: (a) implicit
information from the mutation itself, i.e. mutation
sequence position, (b) features derived from the local
context, i.e. words enclosed in the corresponding sen-
tence, and (c) distant content words from the whole
abstract as contextual cues, i.e. other co-occurring muta-
tions.
A useful characteristic to distinguish mutations at the
DNA and protein level is actually provided by the muta-
tion position number. The average length of sequences in
UniProt is 360 amino acids, being the longest sequence
35,213 (the Titin protein from mouse). When looking at
the mutation positions annotated in SwisProt, 96.76% are
below 2000, 98.72% are below 3000 and 99.25% are
below 4000. Therefore a basic aspect that we explored
here was to filter mutations by position numbers allowing
three positional cut-offs (2000, 3000 and 4000). Example
cases of DNA mutations that can be successfully detected
with this simple criterion are T1191C (PMID 15993850),
G2950692A (PMID 15862761) and G20210A (PMID
18501222).
The local context of a given mutation mention, repre-
sented by the sentence in which it occurs can provide
hints towards the mutation type. We generated two lists of
terms that are associated either to mutations at the level of
proteins or DNA based on manual inspection and exten-
sion of the features used by a sentence classifier trained on
a small sample set of 687 DNA and protein mutation
mentions. We used terms from these two lists mentioned
within the mutation sentences to calculated the overlap
coefficient of Lesk for scoring them as DNA or protein
associated [39].
Certain distant content words co-occurring with a muta-
tion in the whole abstract can be used as contextual cues
for disambiguation. Here we explored the use of other co-
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mentioned mutations to determine the cooperative effect
for mutation disambiguation, under the assumption that
if multiple mutation patterns co-occur, and all of them
resemble DNA mutations, it is consequently more proba-
ble for each of them to corresponds to a DNA rather than
a protein level mutation. From manual examination of
the resulting hits, we determined that at least 4 distinct
mutations had to be co-mentioned in a given abstract, and
that at least two different mutation combinations were
needed (to avoid filtering of systematic Cys to Ala-scan-
ning mutations). An example case illustrating this idea is
the PubMed record 9240741, where all the following
mutations are co-occurring: T1448C, T1366G, G1604A,
A1226G. Finally we also took into account the numerical
relation underlying the codon triplets and their encoding
for amino acids as filtering criterion for cases where for a
given ambiguous mutation, another co-mentioned muta-
tion fulfill the positional information condition: position
of DNA ambiguous mutation is equal to 3 times the posi-
tion of a co mentioned mutation, as illustrated for C684G
and N228K in: The novel mutations include T302C
(L101P), C684G (N228K), and G1063C (A354P) (PMID
9889017).
Mutation phenotype level classification: natural and 
induced
The classification of mutation mentions into natural vari-
ant or induced mutations was carried out using a sentence
classifier approach using words co-mentioned with the
mutation within the sentence. We used a SVM implemen-
tation (SVMLight, [40]) with radial basis kernel function
(default parameters) which explored several feature
weightings, finally using term frequency in order to avoid
inconsistencies resulting from the class balance when
weighting the used features. The initial feature dictionary
was filtered using an in house stop word list (See addi-
tional file 4). We carried out also additional word filtering
to remove numerical expressions and words with a length
below 3 characters. The training set of sentences was
Localization of the mutations extracted from the Pubmed abstracts within the structure of the Protein Kinase domainFigure 6
Localization of the mutations extracted from the 
Pubmed abstracts within the structure of the Protein 
Kinase domain. The ATP binding pocket is represented 
with sticks. The DFG motif (activation segment, essential for 
kinase function) allocates a big number of mutations. The 
light brown Asparagine (central part of the figure) in the 
inter-lobe region, more than 10 mutations. The highest den-
sity residue is Lysine 64 (red), allocating 65 mutations. This 
residue has been reported as essential for protein function 
and ATP binding. We observe that most of the mutations 
allocate in or near the ATP binding pocket or the activation 
segment and that mutations outside the binding pocket cor-
respond generally to low mutation density residues (colored 
in grey and green in the kinase domain model).
Success estimate of the extraction pipeline by human expert manual validationFigure 7
Success estimate of the extraction pipeline by human 
expert manual validation. These percentages were calcu-
lated upon a manual sampling and validation protocol con-
ducted on 100 abstracts. Correct – Database confirmed: 
These are the mutations that have been found already in at 
least one of the analyzed databases (Uniprot, SAAPdb, COS-
MIC, KinMutBase or Greenman). Correct-Manual validation: 
This subset corresponds to the mutation-protein pairs that 
have been found correct after manual validation on 100 
abstracts. Correct – Orthologue: This subset corresponds to 
the cases where mapping is confirmed by manual validation 
and the mutation is mapped to a non-human orthologue. 
Incorrect Mutation to Protein Assignment: Corresponds to 
the cases where both proteins share the same amino acid at 
the mutated position and the algorithm choses the incorrect 
pair. Incorrect Mutation assignment: Cases where the muta-
tion is not properly identified. An interesting particular case 
are the confusion with cell lines (accounting 66% of this cate-
gory) Too ambiguous even for human experts: Odd little 
informative cases where even human experts reading the 
abstracts are not able to identify to which protein the muta-
tion corresponds to.
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derived from mutations of proteins extracted from papers
and then cross checked using the SwissProt database
whether they corresponded to natural variant or mutagen-
esis annotations.
Protein and species mention detection
For the detection of protein and organism names we used
a dictionary look-up and maximum sub-string matching
algorithm implemented in C and Perl. The initial gene
and protein dictionary of human kinases was extracted
from SwissProt and automatically extended using heuris-
tics and rules taking into account common typographical
variations encountered in gene and protein names and
symbols. These covered aspects related to the use of
hyphens (generating variants with hyphens, with white
space and without white space), capitalization (generat-
ing variants in upper case letters and capitalized versions)
and word ordering. This resulted in a human kinase pro-
tein dictionary of 2,582,220 protein name-database iden-
tifier associations. This dictionary was further manually
processed based on the information content of each
tagged protein mention to remove some highly ambigu-
ous protein name variations.
Mutation sequence validation
To associate co-mentioned proteins and mutations from a
given article, previous efforts [19,27] often considered
local text associations in terms of distances between a
mutation and the nearest mentioned protein (proximity
scores). These document-centric associations have clear
limitations in terms of the performance, and therefore
recent efforts tried to improve the underlying perform-
ance through looking up the mutation at its correspond-
ing position within the protein sequence. In an effort to
increase the recall of the method we implemented a cas-
cade of several strategies for mutation sequence validation
that included the following strategies: (1) Sliding window
algorithm that searches for a pattern of mutations along
the sequence instead of exact position – using the num-
bering given in the mutation – co-occurrences in the
sequence. The algorithm iteratively scans each position in
the sequence and searches for co-occurrences of the other
mutations mentioned in the same abstract in positions
relative to the starting one giving priority to the distance,
in terms of sequence, between al the mutations in the
same abstract instead of the exact positions provided. The
main capability of this approach is that is able to deal with
the different means in which the starting position of a pro-
tein can be defined, the most graphic case being the pres-
ence – or not – of a signal peptide but other examples can
be provided (sequencing errors or discrepancies, inclu-
sion of promoter regions, and so on. Since the finding the
profile by chance is quite easy for trivial results (the easiest
of them all being patterns consisting of just one mutation)
a limitation in the complexity of the pattern was estab-
lished, being taken into consideration only those patterns
having at least 3 mutations at different sequence posi-
tions. (2) Basic mutation to sequence position mapping:
looking up the wild type residue of an extracted mutation
mention in the corresponding protein sequence position.
(3) Alternative mutation directionality look-up: to
account for errors in the automatic extraction of the muta-
tion directionality (i.e. wild type residue with respect to
mutant residue), we examined whether the mutant resi-
due could be matched to the corresponding sequence
position. (4) Pro-peptides and mature protein mutation
mapping: to handle alternative residue counting when
signal peptide cleavage is considered we analyzed posi-
tional wild type residue mapping for cases of proteins
with N-terminal signal peptide sequences. (5) Methionine
start site counting: we carried out mutation mapping tak-
ing into account as well as neglecting the N-terminal
methionine.
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Cancer genome projects are now being expanded in an attempt to 
provide complete landscapes of the mutations that exist in tumours. 
Although the importance of cataloguing genome variations is well 
recognized, there are obvious difficulties in bridging the gaps 
between high-throughput resequencing information and the molec-
ular mechanisms of cancer evolution. Here, we describe the cur-
rent status of the high-throughput genomic technologies, and the 
current limitations of the associated computational analysis and 
experimental validation of cancer genetic variants. We emphasize 
how the current cancer-evolution models will be influenced by the 
high-throughput approaches, in particular through efforts devoted 
to monitoring tumour progression, and how, in turn, the integration 
of data and models will be translated into mechanistic knowledge 
and clinical applications.
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Introduction
cancers result from the accumulation of genetic changes (Vogelstein 
& Kinzler, 2004), and the identification of gene variants involved in 
tumour development and progression has been a central goal of can-
cer research for years (Sidebar a). projects such as the Human cancer 
genome project, the cancer genome atlas and the international 
cancer genome consortium aim to decipher the spectrum of genetic 
variants in different cancer types. the goals of these high-throughput 
resequencing (Htr) studies are fourfold: to identify genetic changes 
associated with tumour phenotypes; to discover molecular biomark-
ers that might be used for early detection, more accurate diagnosis or 
prognosis; to determine the molecular events of tumorigenesis; and, 
ultimately, to use this knowledge to develop strategies for targeted 
therapy (chin & gray, 2008; Wood et al, 2007).
However, there is an intense debate about the extent to which 
large-scale variation data will help us to understand the molec ular 
mechanisms of tumour evolution. it is fair to say that, so far, the first 
genome-wide cancer Htr projects have had limited impact on 
molecular cancer research. these studies are rarely quoted as a start-
ing point for further experiments (supplementary table S1), although 
it is clear that more time is needed to translate gene discovery into 
mechanistic understanding. technical, cultural and scientific issues 
can be responsible for the gap between genomic data and outcomes 
in terms of the molecular understanding of tumorigenesis. in the first 
place, the current methods for the organization of genomic data are 
evolving along with sequencing developments and constitute a real 
handicap for the use of the information. Second, high-throughput 
technologies unavoidably generate noise; the computational and 
statistical methods used to filter out genomic data—on which the 
reliability of the observations provided to the community ultimately 
depend—are not exempt from complications. third, the core of the 
scientific challenge lies in the difficulty of linking genomic data to 
the molecular processes that underlie cancer evolution, as discussed 
in the final section of this review. it is therefore not surprising that 
cancer genome initiatives have generated substantial criticism, as 
many biologists are used to (and favour) more targeted approaches 
(chng et al, 2007; loeb & Bielas, 2007; Strauss, 2007).
The mutational landscape of tumours
Many types of genetic variant contribute to cancer: small structural 
changes (such as point mutations or small insertions), major struc-
tural rearrangements (such as translocations), numerical changes and 
epigenetic changes (supplementary table S2). alterations in the con-
trol of aneuploidy could also have a role (Duesberg, 2007). Mutations 
can occur spontaneously in cancer cells—through cytosine deamin-
ation, for example—after exposure to carcinogens or as the result of 
a mutator phenotype caused by mutations in poly merases and/or in 
mismatch-repair genes, which can lead to chromo somal instability 
(loeb et al, 2008). in principle, all genes that harbour modifications 
are candidate cancer genes. 
genetic variants can be transmitted through the germline or can 
arise through somatic mutation. germline variants are present in all the 
cells of an individual and contribute to inherited cancer suscepti bility. 
one particular case of germline variants are the single-nucleotide 
poly morphisms (Snps), the most common genetic variants, which 
are, by definition, present in at least 1% of the population (collins 
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et al, 1998; the international HapMap consortium, 2003). germline 
variants are typically identified through resequencing, and their 
involvement in cancer is shown using linkage or association studies 
(supplementary table S2). Somatic mutations arise in the genomes of 
dividing cells and, in fact, all adult organisms are probably mosaics 
of somatically mutated cells. Somatic changes are typically identified 
through the resequencing of candidate genes, by analysing chromo-
somal rearrange ments, or by quantifying losses or gains in gene-copy 
numbers using a range of techniques—such as microsatellite analysis 
or the quantitative polymerase chain reaction (qpcr; supplementary 
table S2). Evidence for epigenetic silencing and downregulation of 
expression provides further support for the identification of tumour-
suppressor genes, whereas increased expression can provide evi-
dence for oncogene identification. the experimental validation of 
the biochemical and/or biological effects of a given alteration is often 
considered as proof of mechanistic involvement. in this context, rna 
interference provides an additional method to study the involvement of 
gene variants in tumorigenesis. it has, for example, been recently used 
to validate mouse tumour-suppressor candidates (zender et al, 2008).
the detection of point mutations has generally been carried out 
with small-scale sequencing from one to a few genes; >25,000 
mutations identified in the well-known tumour-suppressor TP53 
(Soussi et al, 2000) have been collected using this approach.
in the past decade, technical advances have provided the oppor-
tunity to use high-throughput methods for the identification of can-
didate cancer genes. Functional genomics approaches—such as 
microarray or methylation studies—have also been used, as well as 
association analyses and, more recently, tumour Htr screenings to 
determine the genes responsible for the initiation and progression of 
cancer (supplementary table S2).
Large-scale resequencing studies
Htr studies can detect point mutations and short insertions or dele-
tions (Bardelli et al, 2003); the introduction of ‘next-generation 
sequencing’ technologies (Mardis, 2008) has not only produced 
massive amounts of data, but also allows the quantitative identif-
ication of individual gene variants and the detection of abnor-
mal transcripts (campbell et al, 2008). So far, Htr studies have 
followed two approaches, focusing either on genes or on tumour 
types (table 1). in the first approach, a subset of genes—such as 
those that encode protein kinases (greenman et al, 2007)—is 
sequenced in a relatively large number of samples. this approach 
allows the identification of genes that are mutated at low frequen-
cies, but also requires an a priori selection of genes. the second 
approach analyses the coding sequences of whole genomes in a 
smaller number of tumour samples, and has been applied to colon 
and breast tumours (Sjöblom et al, 2006; Wood et al, 2007), pan-
creas adeno carcinomas ( Jones et al, 2008) and glioblastoma (parsons 
et al, 2008). this approach allows for the identification of the most- 
frequently mutated genes (table 1). one such Htr study screened 
518 protein kinases in 26 primary lung neoplasms and seven cell 
lines, and identified 188 mutations in 141 genes (Davies et al, 2005).
Sidebar A | In need of answers
(i) How can we define a cancer gene and how many cancer genes exist?
(ii) How can the functional effects of mutations in cancer cells be predicted? 
(iii) How can cancer genes and their associated functional roles be precisely 
assessed by detailed biological research? 
(iv) How can the gene variants that are causally involved in tumour 
development or progression be identified among all the gene variants in a 
tumour? 
(v) How can the gap between the genetic variants observed in cancers and 
the current models of cancer evolution be bridged? 
(vi) How can the experimental analysis of gene variants involved in cancer 
be accelerated?
Table 1 | Catalogue of main recent high-throughput cancer genomic studies and initiatives
First author Publication 
date
Genes Tumours Screen sizes PMID
Bardelli 2003 Tyrosine kinase Colon 138 genes, 35 samples, a subset in 147 additional samples 12738854
Wang 2004 Tyrosine phosphatase Colon 87 genes, 18 samples, a subset in 157 additional samples 15155950
Stephens 2005 Kinase Breast 518 genes, 25 samples, a subset in 56 additional samples 15908952
Davies 2005 Kinase Lung 518 genes, 33 samples, a subset in 56 additional samples 16140923
Sjöblom 2006 All Breast and colon 13,023 genes, 22 samples, a subset in 48 additional samples 16959974
Greenman 2007 Kinase 210 human cancers 518 genes in 210 samples 17344846
Wood 2007 All Breast and colon 18,191 genes, 22 samples, a subset in 48 additional samples 17932254
Loriaux 2008 Tyrosine kinase Acute myeloid leukaemia 85 genes, 188 samples 18252861
Tomasson 2008 Tyrosine kinase Acute myeloid leukaemia 26 genes, 94 samples, a subset in 94 additional samples 18270328
Brown 2008 Tyrosine kinase Chronic lymphocytic 
leukaemia
70 genes, 95 samples 18754031
Jones 2008 All Pancreas 20,661 genes, 24 samples 18772397
Parsons 2008 All Glioblastoma 20,661 genes, 22 samples, a subset in 83 additional samples 18772396
CGARN 2008 601 genes Glioblastoma 601 genes, 91 samples 18772890
Ding 2008 623 genes Lung 623 genes, 188 samples 18948947
CGARN, Cancer Genome Atlas Research Network; PMID, PubMed identifier.
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regardless of the strategy used, these studies produce an over-
whelming amount of information. the results are usually provided 
as raw tables in the supplementary material of a given publication 
and the main outcomes are briefly summarized in the published 
text. a number of databases aim to compile this type of inform ation, 
such as catalogue of Somatic Mutations in cancer (coSMic), which 
lists >60,000 mutations (Forbes et al, 2008), and the cancer gene 
census (cgc), which—as of october 2008—included data for 380 
cancer genes (Futreal et al, 2004); other repositories also include 
cancer-related information (table 2; supplementary table S3). 
However, although these genomic data are of great bio logical 
value, they are, in general, not sufficiently linked to additional 
inform ation on gene annotation and regulation, or on molecular 
interactions and pathways, or to the clinical data about tumour and 
tissue types. in analysing this panorama, one realizes that the avail-
able infrastructure for organizing cancer genome inform ation is still 
in its infancy and certainly lags behind the capacity of the current 
massive experimental approaches.
Drivers and passengers
like all high-throughput approaches, Htr generates noise that is 
difficult to distinguish from real biological signals. this noise can be 
technical, coming directly from sequencing technologies or from 
limitations in tumour-cell collection; all methods are sensitive to the 
presence of the normal allele, either in tumour cells or in contam-
inating normal cells. gene variants that correspond to Snps are 
ideally pinpointed by sequencing both tumour and normal tissues 
from the same patient, or by checking polymorphism databases. 
However, the most important source of problems is the presence 
of numerous mutations that are clearly detectable but do not have 
a direct role in cancer. in fact, only a handful of gene mutations 
that have been identified in Htr studies are likely to be biologically 
meaningful. to distinguish these mutations from the background 
mutation noise is a difficult task.
Mutations can be classified as ‘drivers’ or ‘passengers’ depend-
ing on their involvement in cancer development and progression. 
this metaphor was probably used for the first time in 1964, during a 
keynote lecture by Sir christopher andrewes, in which he referred to 
the role of viruses in either causing cancer (drivers) or being merely 
passengers in infected cells (andrewes, 1964). today, the term driver 
is used to denote mutations and/or genes that are positively selected 
and contribute to tumour development or progression, whereas the 
term passenger is used to designate cancer-neutral variations that are 
retained during the evolution of the cancerous cells.
Single mutations can be responsible for the development and 
progression of a cancer (Fig 1a). Historically, analyses have focused 
on mutations that can affect protein function. these mutations are 
thought to be mainly non-synonymous (missense, nonsense or 
frameshift), in contrast to synonymous (silent) mutations. in this 
regard, the first oncogene identified—H-ras—was found to have a 
non-synonymous substitution in codon 12 that introduces an alanine 
in the position of a glycine, thereby blocking its gtpase function 
and producing a protein able to transform cells (reddy et al, 1982). 
However, this corresponds to a ‘protein-centric’ view of biology; one 
should remember that non-synonymous mutations might not always 
alter protein function (owing to amino-acid plasticity) and, impor-
tantly, that there is strong evidence showing that ‘silent’ mutations 
can be biologically relevant—for example, through the modulation 
of splicing (cartegni et al, 2002)—although it is difficult to assess 
their effects and even more difficult to predict them. additionally, 
we have to keep in mind that 98% of the genome is intergenic. in 
this respect, it is currently impossible to interpret the consequences 
of mutations in non-coding Dna regions, with the exception of 
some favourable cases in splice sites or promoters.
the current way of thinking assumes that only a small frac-
tion of the non-synonymous mutations actually cause tumours. 
Historically, the identification of mutations has been followed 
by functional analyses to evaluate their pathogenic potential. For 
example, a screening of the gene encoding the tyrosine kinase 
Flt3 (Fl cytokine receptor) identified nine non-synonymous 
mutations (Fröhling et al, 2007), four of which allow the growth of 
cultured cells independently of the presence or absence of growth 
factors. in general, only a small range of biological assays is used to 
assess pathogenicity, exploring a limited spectrum of the potential 
biological effects of candidate mutations and often being unable 
to detect small functional changes (chin & gray, 2008). When a 
direct effect on cell proliferation or the generation of apoptosis is 
not detected, other experiments are seldom used unless the func-
tional annotations point directly to a crucial biological role—as is 
the case for proteases and kinases. it is a formidable challenge to 
scale up these experiments to validate the results of genome-wide 
Htrs, and, therefore, in silico methods are a suitable alternative. 
typical computational methods are based on the assumption that 
somatic mutations considered as ‘drivers’ would have to affect 
protein function markedly (torkamani & Schork, 2007). Sequence 
and protein domain conservation, as well as protein structure, 
are used to determine the crucial positions in a given protein and 
to predict the causative effects of mutations (Fig 1a). the same 
parameters are also applied to predict the possible pathogenicity 
of Snps (supplementary information online).
Bioinformatic predictions based on sequence analysis—made by 
the SiFt (ng & Henikoff, 2003) and pMut (Ferrer-costa et al, 2005) 
Table 2 | Main cancer-specific and non-specific repositories that contain information about cancer-associated mutations
Acronym Full name* Category URL Reference
COSMIC Catalogue of Somatic Mutations in Cancers Mutations http://www.sanger.ac.uk/genetics/CGP/cosmic Forbes et al, 2008
CGC Cancer Gene Census Cancer genes http://www.sanger.ac.uk/genetics/CGP Futreal et al, 2004
OMIM Online Mendelian Inheritance in Man Disease-related genes http://www.ncbi.nlm.nih.gov/omim Hamosh et al, 2005
Ensembl – Polymorphisms http://www.ensembl.org Flicek et al, 2008
dbSNP Single Nucleotide Polymorphism Database Polymorphisms http://www.ncbi.nlm.nih.gov/SNP Sherry et al, 2001
*For information on additional repositories, please consult supplementary Table 3.
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programs—and experimental results have been compared for nine 
FLT3 mutations (Fröhling et al, 2007). the consensus bioinformatic 
predictions failed to identify two mutations that were exper imentally 
shown to affect function, whereas one predicted driver mutation 
was not found to have a functional effect. By contrast, all four of the 
mutations predicted to be passengers in silico were confirmed by the 
functional analysis. the availability of more case studies will allow a 
better assessment of the predictive capacity of computational tools.
it is important to remember that there is a great difference 
between demonstrating that a mutation alters the function of a pro-
tein and claiming that it has a pathogenic involvement in cancer. 
the effects of candidate mutations in the development of cancer 
are probably highly context dependent and the assessment of their 
biological significance in the context of human cancer needs to be 
largely extrapolated.
at a second level of analysis, the overall frequency of mutations in a 
given gene can help to detect a positive selection that would support its 
involvement as a driver for oncogenesis (Fig 1B). the usual assumption 
is that positive selection is exerted mainly on non-synonymous mut-
ations. the genetic code provides a random ratio of approx imately two 
non-synonymous mutations for each synonymous one (2:1); higher 
ratios are interpreted as evidence of positive selection and competitive 
advantage. in reality, more complex models—borrowed from the field 
of molecular evolution—are applied, which can also take into account 
the types of mutation (transition and transversion) or the neighbouring 
sequence (for example, whether a c-to-t transition occurs in a cpg 
island; a more detailed explanation of the models used can be found 
in the supplementary information online). another set of methods calc-
ulates differences between the observed and the expected frequencies 
of non-synonymous mutations. if a gene contains—in all sequenced 
tumours—more mutations than would have been expected to occur 
by chance, these have been positively selected during the process 
of tumorigenesis and, therefore, confer an advantage in this process 
(supplementary information online).
an obvious limitation of these approaches to the identification 
of cancer genes is the need to sequence many samples. Without 
enough observations, the less-frequently mutated genes would not 
meet the statistical thresholds. in fact, they would be indistinguish-
able from unselected passengers, although they can be revealed by 
functional assays (Fröhling et al, 2007). Furthermore, these statistical 
techniques do not provide information about the specific alleles—
point mutations—involved in cancer evolution. a perhaps less obv-
ious—albeit not less important—limitation of current studies is that 
they usually consider mutations individually, without modelling epi-
static interactions. in a few cases, the importance of the combination 
of otherwise neutral (passenger) mutations has been shown (chen 
et al, 2008). Epistatic effects (Moore, 2005), which are not commonly 
considered in cancer genome studies, might be even more important 
when taking genetic background into consideration, either alone or 
together with somatic mutations.
SIFT  (Ng & Henikoff, 2003)
Pfam LogR.E  (Clifford et al, 2003)
CanPredict  (Kaminker et al, 2007a)
SNP3D  (Yue et al, 2006) 
Kinase-dedicated Method (Torkamani & Schork, 2007)
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Fig 1 | Driver or passenger? Multilevel strategies used to classify mutations and genes as either ‘drivers’ or ‘passengers’ at the level of (A) mutations, (B) genes  
or (C) processes. NS, non-synonymous; S, synonymous.
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among known mutations, a large proportion occurs in a few 
genes, such as TP53 or K-RAS (Forbes et al, 2008; Soussi et al, 
2000). Hence, cancer genomes are composed of a handful of freq-
uently mutated genes and a much larger number of infrequently 
mutated genes. the number of genes that are mutated in cancers, 
although large, possibly reflects alterations in a relatively small 
number of signalling pathways (Wood et al, 2007; Fig 1c). indeed, 
many recent Htr studies provide an interpretation of their results 
in terms of alterations in ‘core pathways’ ( Jones et al, 2008; parsons 
et al, 2008). this point is crucial—particularly from a therapeutic 
point of view—because designing strategies to target proteins indi-
vidually is different from targeting a well-defined pathway (check 
Hayden, 2008). additionally, cancer genes might share other struc-
tural or functional properties (Furney et al, 2006), such as good 
evolutionary conservation or a role in essential cellular processes 
such as the cell cycle or Dna repair. the analyses based on pre-
vious knowledge of known pathways and functions can be useful 
for the interpretation of genome-wide results. However, to obtain 
new insights into the oncogenic process, it is important to avoid the 
constant re-identification of the same genes for which significant 
functional information is already available.
Cancer-evolution models and cancer genomics
Molecular biologists have been working for the past 20 years 
to determine the molecular mechanisms of cancer evolution. 
Modelling cancer evolution is more than an academic exercise as it 
has profound implications on the detection of early recurrence and 
in the choice of adjuvant therapy, among other aspects (Fig 2). to 
be useful in this context, large-scale genomic studies would have to 
complement these efforts, and help to improve our understanding of 
tumour development and progression.
Historically, cancer research has been dominated by the ‘clonal 
evolution’ model of tumour development and progression (Fig 3, 
blue arrows). this model postulates that tumour cells acquire spe-
cific genetic changes, leading to clonal expansion. these changes 
are selected in competition with other tumour cells through a 
Darwinian process, and those that confer a selective advantage 
become fixed, thereby allowing a phylogenetic tracing of the his-
tory of the evolving cell populations. in this model, it is generally 
considered that benign lesions are precursors of malignant tumours, 
genomically stable tumours precede genomically unstable ones 
and metastases are the ultimate step in tumour evolution. More 
recently, it has become evident that some experimental results do 
not fit this model. For example, some metastases of breast cancers 
bear little genetic resemblance to the primary tumour (Schmidt-
Kittler et al, 2003). Moreover, a recent study showed that a small 
proportion of normal mouse mammary epithelial cells injected 
intravenously can survive at distant sites and eventually develop 
into tumours (podsypanina et al, 2008). these observations have 
led to the proposal of the ‘parallel evolution’ model (gray, 2003; 
yokota & Kohno, 2004), in which cells that generate metastases are 
separated relatively early from the primary tumour and evolve inde-
pendently (Fig 3, red arrows). this model is reinforced by data from 
gene-expression profiles that are predictive of metastases in certain 
primary breast tumours (Bernards & Weinberg, 2002). 
the differences between both models have important conse-
quences for the interpretation and clinical use of the knowledge 
about cancer-associated mutations. in the framework of the ‘clonal 
evolution’ model, the significance of a mutation detected in a meta-
stasis—in the absence of information about its presence in the pri-
mary tumour or in pre-neoplastic lesions—is unclear. in the context 
of the ‘parallel evolution’ model, targeting this mutation for therapy 
would have no effect on the growth of the primary tumour, which 
could evolve to metastasis through other mutations. given the com-
plexity of cancer and the diversity of its phenotypic presentation, it 
is unlikely that a single paradigm will universally account for cancer 
development and progression; the different models might be com-
plementary rather than exclusive, at least when considering cancer 
globally rather than at the individual level. it seems possible that 
these two models might explain different, albeit concurrent, bio-
logical processes (Fig 3, green arrows). this integration is also rein-
forced by evidence that metastases can act as repositories from which 
additional systemic tumour-cell seedings can take place (nguyen 
& Massagué, 2007).
Htr studies are usually performed using Dna from cell lines, 
xenografts or large and advanced tumours. this bias in sample 
selection, owing to the fact that earlier stage tumours are under-
represented, is to some extent also present in low-scale studies. 
During the advanced stages of tumorigenesis, all the mutations nec-
essary for cancer development and progression are already present; 
as is commonly assumed, “such tumours contain all the mutations 
found in the early stage tumours, but the converse is not true” (Wood 
et al, 2007). the information derived from Htr studies is therefore 
intrinsically far from providing information on other stages of cancer 
evolution, and hence does not contribute to our understanding of the 
development and evolution of cancer. Furthermore, the identific ation 
of causative cancer genes and mutations—based on the methods 
adapted from evolutionary biology described above—tends to be too 
general to give specific information at the level of resolution required 
by the current cancer-evolution models. Hence, we continually have 
to revisit our understanding of the contribution of genetic variants 
based only on the study of snapshots in tumour evolution, which do 
not provide sufficient insight to elucidate the true relevance of these 
genes in the tumorigenic process. 
Molecular mechanisms
Clinical applications
Cancer evolution models
Molecular approaches 
Experimental and
computational methods
Target validation
Molecular markers
Drug development
HT approaches
Fig 2 | Modelling cancer evolution. Using the available technologies, the modelling of cancer evolution should provide insights into its development and progression.
EMBo reports Vol 10 | no 4 | 2009 ©2009 EuropEan MolEcular Biology organization364 
reviews cancer genomes to cancer models A. Baudot et al
aA B
b
c
d
e
a
b1
b1
b2
b2
c
d
e
Fig 3 | Models of cancer evolution. (A) The ‘clonal selection model’ (blue arrows) is the prevailing view to explain the successive steps of mutation and selection 
from normal tissue to primary tumour and metastasis. However, metastasis-generating cells can emerge relatively early in the tumorigenic process and ‘seed’ 
distant tissues, thereby evolving in parallel with the primary tumour and delineating the ‘parallel evolution’ model (red arrows). Finally, these two models can 
occur simultaneously and metastatic deposits can act as sites from which additional metastases can be generated, therefore leading to an integrated model 
of cancer evolution (green arrows). (B) Microphotographs provide a histological snapshot of normal skin tissue (a), primary tumour (superficial b
1
 and 
deep b
2
, macroscopic appearance inset in b), subcutaneous metastasis (c), metastasis in the lymph node (d) and metastasis in the lung (e), and are shown in 
correspondence with the cancer-evolution models. This melanoma—which originates from the transformation of pigmented skin cells—provides a visual 
example of the modelling paradigms, illustrating the gap between ideal models and actual observations. 
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in order to attain more insight into the contribution of the different 
models to cancer development, and to validate more precisely the 
significance of the genetic and genomic changes found in advanced 
tumours, one would need to obtain information about specific genes 
and mutations at different stages of tumour evolution. Knowing 
the time of appearance of a given mutation would allow for a bet-
ter estimate of its contribution to the fitness of cancer cells, which 
is essential to distinguish between the various evolution models. 
this involves several difficulties and only a few metastasis-specific 
alterations have been identified (nguyen & Massagué, 2007). First, 
it is conceivable that individual genetic alterations, or a given genetic 
programme, could render a stage-specific advantage to tumours and 
be either neutral or deleterious at later stages, as is the case for the 
epithelial–mesenchymal transition programme, which is activated in 
the invasive front of tumours but might be repressed in meta stases 
(thiery & Sleeman, 2006). additionally, changes in the tumour 
microenvironment—either locally or at metastatic sites—might 
impose different selection pressures on genetic changes and thereby 
modulate the influence of the individual mutations. Furthermore, the 
effects of genetic alterations might be incremental rather than qualit-
ative, thereby allowing for epistatic interactions, which are often not 
considered when modelling molecular pathogenesis. improvements 
in technology and more focused research on early-stage tumours are 
needed to fill these gaps. For such applications, the lack of sensitivity 
for detecting a given mutation in a low proportion of alleles is a major 
technical concern when standard sequencing technology is used. 
However, this limitation might be overcome with ultra-sequencing 
technologies (gupta, 2008). these technologies—which are already 
able to detect rare subclones with a sensitivity as low as 1 in 5,000 
copies—would be relevant to track the subpopulations of cells that 
are responsible for initiating the genetic lesions, for drug resistance or 
for metastasis (campbell et al, 2008).
integrative approaches would be a solution to overcome the 
limitations specific to both genomic and functional methods. 
the findings obtained using diverse high-throughput genomic 
techniques—such as gene mutation, copy-number variation, 
expression analyses and epigenetic changes—have recently 
been combined for glioblastoma and pancreatic ductal adeno-
carcinoma (cancer genome atlas research network, 2008; Jones 
et al, 2008; parsons et al, 2008). the gathering of independent evi-
dence supported the causative implication of genes in tumours, for 
example, by showing that a subset of the genes recurrently found 
in copy-number-alteration regions has an expression pattern that 
correlates with copy number (cancer genome atlas research 
network, 2008). in practice, the interpretation of heterogeneous 
high-throughput information is still a formidable challenge, and 
multidimensional analyses of data coming from high-throughput 
studies still face the problems of data standardization, database 
annotations and normalization of phenotypic descriptions.
the combination of all these efforts should have an impact on the 
development of improved strategies for early detection, improved 
tumour subclassification, a more rational selection of therapy and 
more accurate prognostication, all of which represent important 
aspects of patient management.
Conclusion
cancer genome studies—including the inevitably associated com-
putational analyses—have the potential to predict which genes 
and mutations contribute to tumour development (known as driver 
genes or mutations) on a large scale. However, despite the enor-
mous capacity of the experimental resequencing methodologies 
and the expected improvements therein, limitations still exist. 
indeed, the reliable detection of less-frequent mutations is still 
arduous, and it is difficult to obtain a sufficiently systematic mut-
ation analysis that will allow conclusions to be drawn about the 
prevalence and distribution of mutations according to tumour 
stage. Furthermore, mutation analysis can by itself provide only 
statistical information on potential associations with cancer and 
not direct causative information, and it is a major challenge in 
molecular terms to go from genomic information to data inter-
pretation. For example, the classification of mutations as drivers 
or passengers depends on the analysis of the possible functional 
consequences of these mutations, which is a technology that 
is not free from limitations and, in addition, does not provide a 
complete picture of the actual implication of the mutations in 
the development of cancer. in other words, the future challenge 
will be to support—or to refute—the current cancer models with 
high-throughput experimental methods within a reasonable time 
scale at an affordable cost. this would involve both the descriptive 
large-scale genomic analysis of pre-neoplastic lesions and early 
cancers, and the functional analysis of genetic variants: a com-
bined effort that is crucial to translate genomic knowledge into 
molecular pathophysiology and patient management.
We must note that many of the difficulties in the application of 
high-throughput variation approaches are similar to those found 
in the study of other complex diseases. cancer is particularly chal-
lenging—and therefore attractive—as this is the field in which the 
largest amount of molecular information is available, the diversity 
of phenotypes and pathologies is more notable, and the complex 
evolution of disease at the cellular and/or tissue level has been most 
directly addressed. these are all good reasons to believe that the 
symbiosis of high-throughput technologies, molecular and cellular 
mechanistic models, and new experimental systems and models 
will be effective first in cancer research.
Supplementary information is available at EMBO reports online 
(http://www.emboreports.org)
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INTRODUCTION
Point mutations are important events in the evolution of pro-
teins and therefore organisms. There are multiple factors that
influence whether a given mutation is accepted and this is often
based on how specific protein characteristics are affected. For
example, a mutation might alter functional residues at catalytic
sites, residues that determine the specific binding of effectors, or
general biophysical properties such as protein folding and stabil-
ity, or protection against misfolding. Equally, a mutation can
have little or no effect on the function or stability of a protein.
The most common biologically relevant mutations are single
nucleotide polymorphisms (SNPs), which account for about 90%
of sequence polymorphisms in humans1 at an overall frequency
of about one per 1000 bases in DNA2 (i.e., in translated regions)
or non-coding according to their genomic location. Coding SNPs
are further subclassified according to whether they alter the com-
position of the translated protein (Nonsynonymous SNPs,
nsSNPs), either through amino acid substitution or by the gener-
ation of truncation mutations. By contrast, synonymous SNPs
(also referred to as silent or sSNPs) are those that do not affect
the amino acid sequence of the protein product. Not all synony-
mous SNPs are completely neutral since they may still affect the
expression of gene products or protein translation by introducing
alterations into the regulatory region, interfering with splice sites
or impinging on any other regulatory mechanism.3,4 Equally, it
is also the case that not all nsSNPs are associated with pathologi-
cal diseases, since some changes are by nature milder than others,
and diseases commonly involve complex sets of alterations.
The role of point mutations is especially pertinent in the devel-
opment of cancer where large numbers of somatic mutations
accumulate in the cell during tumorigenesis. These somatic
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ABSTRACT
Protein kinases are a superfamily involved in many
crucial cellular processes, including signal transmis-
sion and regulation of cell cycle. As a consequence
of this role, kinases have been reported to be associ-
ated with many types of cancer and are considered
as potential therapeutic targets. We analyzed the dis-
tribution of pathogenic somatic point mutations
(drivers) in the protein kinase superfamily with
respect to their location in the protein, such as in
structural, evolutionary, and functionally relevant
regions. We find these driver mutations are more
clearly associated with key protein features than
other somatic mutations (passengers) that have not
been directly linked to tumor progression. This ob-
servation fits well with the expected implication of
the alterations in protein kinase function in cancer
pathogenicity. To explain the relevance of the
detected association of cancer driver mutations at
the molecular level in the human kinome, we com-
pare these with genetically inherited mutations
(SNPs). We find that the subset of nonsynonymous
SNPs that are associated to disease, but sufficiently
mild to the point of being widespread in the popula-
tion, tend to avoid those key protein regions, where
they could be more detrimental for protein function.
This tendency contrasts with the one detected for
cancer associated-driver-mutations, which seems to
be more directly implicated in the alteration of pro-
tein function. The detailed analysis of protein kinase
groups and a number of relevant examples, confirm
the relation between cancer associated-driver-muta-
tions and key regions for protein kinase structure
and function.
Proteins 2009; 00:000–000.
VC 2009 Wiley-Liss, Inc.
Key words: cancer; kinase; kinome; functional; so-
matic mutation; point mutation; driver mutation;
passenger mutation; polymorphism; SNP; single nu-
cleotide polymorphism.
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changes to a cell occur either as a result of random errors
during replication or might be directly induced by expo-
sure to carcinogens.5 Evidence suggests that only a small
number of these mutations actually contribute to tumori-
genesis, by conferring these malignant cells with a
competitive growth advantage, and often described as
‘‘driver mutations.’’ By contrast, the vast majority of
somatic mutations that accumulate in tumors during
clonal expansion do not necessarily confer growth
advantage and are generally biologically neutral (‘‘passen-
ger mutations’’).6,7
Despite the importance of mutations in the develop-
ment of malignant tissues, only around 1% of all human
genes are known to contribute to cancer in this way and
the genes that are most frequently involved are those that
encode members of the protein kinase superfamily.8
These enzymes are therefore obvious pharmaceutical tar-
gets for cancer therapies as they are involved in a wide
range of tumorigenic activities, such as immune evasion,
proliferation, anti-apoptotic activity, metastasis, and
angiogenesis.9
Protein kinases are the most ubiquitous superfamily of
signaling molecules in human cells, accounting for 2%
of the proteins encoded by the human genome.10 They
can be further divided into subfamilies that share signifi-
cant similarity both at the sequence and structural level,
which is understandable as all kinases transfer the termi-
nal phosphate of ATP to serine, threonine, or tyrosine
residues of a target protein. Furthermore, empirical stud-
ies also suggest a common catalytic mechanism whereby
ATP and an active site divalent cation are bound in iden-
tical manners, and phospho-transfer is carried out by a
shared set of amino acids. Despite this experiments in
yeast models, Refs. 11, 12 have shown the protein kinase
superfamily to be highly promiscuous as a whole, phosphor-
ylating a large number of different protein substrates,
although individual subfamilies display remarkable specific-
ity.10 This inconsistency suggests that kinases have a
domain committed to the general function of catalysis,
whereas another region (or even regions) may confer sub-
strate specificity to the enzyme, without altering the general
kinase folding, interfering with ATP binding or the general
reaction mechanism.
The aim of this study was to analyze the distribution
of different types of point mutations observed across the
catalytic domain (namely the PK domain) of the protein
kinase superfamily (including those specifically associated
with cancer) with respect to functionally and structurally
important regions. We compared the location of synony-
mous (sSNPs), nonsynonymous (nsSNPs), somatic
‘‘driver,’’ and ‘‘passenger’’ mutations, with respect to three
main categories: (a) evolutionary conservation at the pri-
mary sequence level; (b) structurally important regions;
and (c) functional regions, including substrate-binding
sites and the positions relevant to the specific recognition
of modulators and effectors. Indeed, a related set of char-
acteristics, based on both sequence and structure, is being
used by state-of-the-art predictors of pathogenicity to
determine whether a mutation can affect protein function
and therefore be, potentially, associated to disease. This is
still a hot topic as shown by the considerable number of
publications on the subject during the last few years.
Some of the more relevant ones are described in
Refs. 13–24.
RESULTS
Known germline SNPs were obtained from dbSNP for
the protein kinase superfamily, along with somatic muta-
tions6,7 that had been further classified as ‘‘driver’’ (i.e.,
disease-associated) and ‘‘passenger’’ (i.e., those point
mutations not thought to be pathogenic). We present the
results of mapping these different types of mutations onto
a representative structural model from the protein kinase
superfamily [Fig. 1] and analyzing their distribution rela-
tive to evolutionary conserved positions and known func-
tional regions (buried, functional, conserved, etc).
In the presented results, to assess the significance of
the proximity of different sets of mutations to specific
areas of the protein, we use the Xd measure.25 The rea-
son for choosing this weighted measure of distance dis-
tributions is to give priority to the differences in regions
closer to the studied regions (for example, binding sites)
over differences in the distribution of residues in posi-
tions far away from the regions of interest. Xd has been
used as a standard measure of the difference between dis-
tributions of predicted residues in the context of the
CASP challenge.26,27 Full details are given in the ‘‘Mate-
rials and Methods’’ section.
Cancer mutations in relation to sequence
conserved regions
We first examined the distances of the mutated resi-
dues from sequence conserved positions in the different
protein kinases [Fig. 2(b) and Supporting Information
Fig. S1]. Figure 2(a) shows that driver mutations are sig-
nificantly closer than passenger ones to these conserved
positions, both when defined in terms of sequence iden-
tity or similarity. This difference was also visible in terms
of Xd values25 (Xdpassenger-Xddriver [21bins] 5 21.23,
Supporting Information Table S1). As expected, the com-
parison between nonsynonymous and synonymous SNPs
revealed that nsSNPs tend to be further away from con-
served sequences, particularly for the more strict defini-
tion of conservation using sequence identity (XdsSNPs-
XdnsSNPs [21bins] 5 0.89, Supporting Information
Table S1a). In addition, the same differences were visible
when conservation was evaluated in terms of amino acid
variability using AL2CO,28 that is driver mutations are
closer to conserved positions than passenger ones
(Xdpassenger-Xddriver 5 20.88, Supporting Information
J.M.G. Izarzugaza et al.
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Fig. S2 and Supporting Information Table S1c). The
same trend was observed for the synonymous SNPs that
are closer to conserved positions (Xd 5 20.59) than
nonsynonymous ones (Xd 5 0.17), respectively.
Cancer mutations in relation to
structurally conserved regions
The distance between our different classes of mutations
and structurally conserved positions was also quantified
using the Xd values (Supporting Information Table S2)
but produced no difference between the distributions of
driver/passenger mutations (DXd 5 20.08) or of nsSNPs
and sSNPs (DXd 5 0.11) when a global score was used
to assess structural conservation. However, using a local
score—where only the vectors to residues within a radius
of 10 A˚ were taken into account—there were clear differ-
ences in the distributions. When comparing nsSNPs with
sSNPs, we found that nonsynonymous SNPs tend to be
further away from structurally conserved residues than
synonymous ones, with a difference in Xd values of 1.43.
Likewise, passenger mutations tend to be closer to struc-
turally conserved residues than driver mutations (differ-
ence of the Xd values 5 1.57)
Cancer mutations and solvent
accessibility
We also analyzed the distance of the mutated positions
to ‘‘buried’’ residues (Supporting Information Fig. S3),
defined as those with a Naccess’ relative residue solvent
accessibility score of less than 16%, and found no statisti-
cal difference between driver and passenger mutations
(Xd difference 5 20.01, Supporting Information Table
S3). There was, however, a difference between nonsynon-
ymous and synonymous SNPs (Xd Difference 5 2.26),
where synonymous SNPs tended to be closer to buried
positions than nonsynonymous SNPs (Supporting Infor-
mation Fig. S4). This is consistent with the idea that resi-
dues in the buried core of proteins tend to be conserved
and that these positions tend to change less.
Cancer mutations in relation to known
functional regions
We analyzed the distribution of the known mutations
with respect to two definitions of a functionally impor-
tant region: those directly related with ATP binding; and
those related to binding sites specific for the union of
effectors and modulators of kinase activity.
Cancer mutations versus functional binding sites
The functionally active region of protein kinases
includes the ATP binding site, the peptide-substrate-
binding sites, and the catalytic loop that is implicated in
phosphate transfer. The ATP binding pocket has three
parts as follows:
1. a region of hydrophobic residues clustered around the
adenosine of ATP;
2. an area around the Gamma-phosphate of ATP and the
divalent cation (the catalytic site) which is primarily
enclosed by charged residues;
3. a region in the large lobe composed of both hydro-
phobic and polar residues below the ATP that stabil-
izes this region, and may play a role in mediating sub-
strate interactions.
The key residues that are responsible for the positioning of
ATP and stabilizing the active conformation in the catalytic
mechanism are (according to Ref. 29, see Fig. 1—These
positions correspond to the generated structural model):
i. Lysine 74 that interacts with the alpha and beta phos-
phates of ATP and stabilizes it;
ii. a nearby Glutamic acid (E96) that forms a salt bridge
with lysine 74 and increases the stability of this
network;
iii. Aspartate 171 that serves as the catalytic base that
initiates phospho-transfer by deprotonating the
acceptor serine, threonine, or tyrosine;
iv. Asparagine 176 which interacts with a secondary
divalent cation, thereby positioning the gamma-phos-
phate of ATP; and finally,
v. Aspartate 190 that chelates the primary divalent cat-
ion, indirectly positioning ATP at the same time.
In the peptide binding site, the conservation of the sub-
strate-binding groove is particularly important (Fig. 1),
located between the catalytic loop, the P11 loop (activation
segment), helix D, helix F, helix G, and helix H (each second-
ary structure element is labeled with a letter in alphabetic
order corresponding to its position within the protein chain,
see Fig. 1). We have used the set of binding residues extracted
from the FireDB database as an operational definition of the
kinase binding site,30 which includes 32 residues directly
contacting the ATP in the binding pocket [Fig. 3(a)] and
which covers the five highly conserved residues mentioned
above (K74, E96, E171, N176, and E190).
When the distance distribution of point mutations was
examined [Fig. 3(b,c)], the driver mutations appear to be
closer than passenger mutations to the ATP binding pocket,
both as defined by FireDB30 and Knight et al.29 This tend-
ency was stronger for the residues in direct contact with the
substrate identified by FireDB [Fig. 3(a), and Supporting In-
formation Tables S4a and S4b]. As expected, nonsynony-
mous SNPs tend to be located further away from the binding
sites than synonymous SNPs, with a difference in Xd values
of 0.97 when using the FireDB definition of the binding site
and of 1.02 for the subset described by Knight et al.
Cancer mutations in relation to functional
regions involved in binding specificity
Residues differentially conserved in the various groups
of protein kinases were identified for each of the eight
Cancer-Associated Mutations in Protein Kinase Sites
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groups in which Kinbase categorizes the human
kinome10 using the appropriate bioinformatics methods
(tree-determinant residues,31,32 S3det Rausell et al., in
preparation]). We identified 35 residue positions as con-
taining sufficient information to differentiate between the
groups—i.e., residues that are conserved in specific ki-
nase groups but that are not conserved across all kinases.
The most statistically significant Tree-Determinants were
distributed among the kinase groups as follows: four in
the AGC, four in CK1, eight CMGC, and nine STE. All
tree-determinant positions were mapped onto the repre-
sentative structure (Supporting Information Fig. S5) and
visual inspection revealed that many of the Tree-Determi-
nants were located near the ATP/ pocket of the protein.
Other sets of tree-determinants were located in regions
that are known to interact with other protein partners
and that participate in intermolecular signaling events.33
We used the position of the tree-determinant residues as
a proxy for functionally important regions in protein ki-
nases, particularly those related with the specific func-
tions of each of the groups.
The distribution of point mutations with respect to
the position of tree-determinants was determined (Sup-
porting Information Fig. S6) and the corresponding Xd
values were compared (Supporting Information Table
S5). Driver mutations showed a clear tendency to be
closer to tree-determinant positions than passenger
mutations. Likewise, synonymous SNPs also tend to be
closer to the tree-determinants, even if this tendency was
not very strong, reflecting the capacity to tolerate such
substitutions in functionally important regions.
Figure 1
Our model structure of human protein kinase, based on MAP3K1,
shows the basic two-lobe kinase fold, with the N- and C-terminal (cyan
and orange, respectively) lobes joined by a hinge region (magenta). The
main recognition for the substrate protein is through interaction with
the activation segment (green), a region in the C-terminal lobe. ATP
binds at a site between the two lobes, where five highly conserved
residues*: K74, E96, D171, N176, and D190 (yellow, numbers
corresponding to positions in the generated structural model) guide the
positioning of the molecule. By contrast, the substrate-binding groove is
located between the catalytic loop, the P11 loop (activation segment),
helix D, helix F, helix G, and helix H.
Figure 2
(a) Distribution of driver mutations compared with positions predicted
to be conserved in terms of Shannon’s Entropy in the context of
identity (21bins). (b) Distribution of distances between point mutations
(driver mutations, passenger mutations, nonsynonymous SNPs, and
synonymous SNPs) and conserved residues in an ‘‘identity’’ scenario
where 21 bins are taken into account, one for each aminoacid and
another extra bin for positions with gaps.
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Analysis of cancer mutations in specific
protein kinase groups
To complete our sequence analysis of the distribution
of point mutations, we carried out a systematic compari-
son of the distribution of residues in the most important
protein kinase families, selecting those cases for which
enough sequence/structural information was available.
For this analysis, we collected all the SNPs in the proteins
belonging to each group provided by Kinbase10 in a sin-
gle representative set for each protein kinase superfamily.
This approach makes the number of SNPs (Supporting
Information Table S6) comparable to those of the cancer
related mutations specific to each group.
The comparison between nonsynonymous and all SNPs
shows that driver mutations in general tend to cluster
closer to tree-determinants than nonsynonymous SNPs.
Figure 3
(a) Distribution of nsSNPs and compared with FireDB predicted residues as part of the ATP binding pocket. The figure also illustrates the five
highly conserved residues: K74, E96, D171, N176, and D190 (yellow) that guide the positioning of the ATP molecule. (b) Distribution of distances
between point mutations (driver mutations, passenger mutations, nonsynonymous SNPs, and synonymous SNPs) with respect to the ATP binding
pocket, as described in FireDB (Van de Waals radii 10.5 A). (c) Distribution of distances between point mutations (driver mutations, passenger
mutations, nonsynonymous SNPs, and synonymous SNPs) with respect to the ATP binding pocket, as described by Knight et al.
Cancer-Associated Mutations in Protein Kinase Sites
PROTEINS 5
This is evident in Supporting Information Tables S6,
S7a, S7b, and S8, in which we have represented the dif-
ferences between Xd values corresponding to each group
of SNPs and mutations, subdivided into all, passenger
and driver mutations, with respect to several protein
features.
One interesting case study is the comparison between
driver mutations and nonsynonymous SNPs, since they
might also distort protein function and are potentially
implicated in the development of disease. In most of the
groups, driver mutations are closer to the conserved
sequence regions than nonsynonymous SNPs, irrespective
of the method used to quantify conservation (Supporting
Information Tables S6 and S8). A similar trend was
observed in terms of functional sites (FireDB and Knight
datasets), the only exceptions residing in the tyrosine ki-
nase like (TKL) and ‘‘other’’ groups when the binding
sites were taken from FireDB. In terms of accessibility to
the solvent, driver mutations were closer than nonsynon-
ymous SNPs to buried positions, with some exceptions
in groups such as AGC, Calmoldulin regulated kinases
(CAMK), and MAPK cascade kinases (STE). These ten-
dencies highlight the relationship between driver muta-
tions and the positions that are potentially important for
the correct functioning of the protein, such as conserved
positions, scaffolding positions in the hydrophobic core
of the protein, and residues that are important for the
activity of the protein (e.g., those in the ATP binding
pocket).
Differences were evident between the positions of
SNPs and cancer related mutations in terms of their
proximity to tree-determinants, both when calculated for
each group and when accumulating data across all the ki-
nase groups (Supporting Information Table S7b). The
results shown correspond to the comparison of different
types of mutations (driver, passenger, and all mutations)
with all SNPs or with all nonsynonymous SNPs. Indeed,
the results shown in Supporting Information Table S6
suggest that driver mutations generally behave differently
to nonsynonymous SNPs, and that they are closer to im-
portant specific functional sites in each protein group
(tree-determinant residues) than nsSNPs, with the excep-
tion of the AGC and TK groups. By contrast, passenger
mutations cannot generally be differentiated from nonsy-
nonymous SNPs, except in the CMGC, CK1, and TK
groups, although being passenger mutations they were
located differently when compared with all SNPs as a
whole (with the exception of the CMGC, Other, and STE
groups), further away from the specific functional regions
than SNPs. These results indicate that drastic changes
(represented by nonsynonymous SNPs) are more
directly associated with regions implicated in specific rec-
ognition than mutations like passenger mutations, which
do not seem to be particularly closely associated to
regions where they may disrupt the specific network of
interactions.
Examples of well-characterized
disease-associated mutations
affecting kinase function
Our general analysis of the distribution of mutations
in protein kinases not only provides an overview of their
relationship to function and structure, but also provide
an insight into their specific biomedical implications.
Hence, we analyzed these relationships in three well-
known scenarios.
We have reflected all the information accumulated for
the protein kinase domains in a single structure used as
a framework. The accumulation of information on muta-
tions clearly increases the significance of the results and
makes the interpretation of the general distribution of
mutations more reliable. The assumption is that the key
regions for the structure-function of the kinases are com-
mon to all of them and they can be used as a reference
for the interpretation of the mutations in any of the
kinases.
Mutations in the human insulin receptor (INSR) gene
are known to be associated with disease,34–37 and
defects in INSR are the cause of acanthosis nigricans
Type A insulin-resistant diabetes mellitus (IRAN Type A,
MIM:610549). This syndrome is characterized by severe
insulin resistance, including a failure to respond to exog-
enous insulin, which therefore increases the probability
of developing endometrial cancer and other diseases.
Several studies have reported that the altered kinase
activity of INSR may be fundamental in the accelerated
growth in young females with this syndrome.38 Indeed,
mutated INSR exhibited diminished expression in cul-
tured fibroblast, with the remaining receptors show
impaired activity.37 Patients with Type A insulin resist-
ance and decreased insulin receptor kinase activity caused
by a normal insulin-binding mutant, but with defects in
the phosporylation mechanism, have also been
described.35,36 Recent studies have further characterized
the relationship between insulin resistance and disease
(For example, see Refs. 39, 40). Moreover, studies have
also associated acanthosis nigricans with mutations in
other kinases, such as the fibroblast growth factor recep-
tors II and III (FGFR2_HUMAN and FGFR3_HUMAN,
respectively41–43).
In our analysis, we mapped a mutation in the human
insulin receptor (INSR_HUMAN) protein that intro-
duced an Alanine-Threonine shift in the ATP binding
pocket of the protein, A1161T (residue 173 in the model,
Fig. 4). This mutation was described as a driver mutation
in our analysis and it was shown to be part of the bind-
ing site in FireDB, as well as being important for the
specificity shown by certain subfamilies given its relation-
ship with subfamily specific residues (Tree-Determi-
nants). This mutation in the ATP binding pocket may
explain the difficulties to phosphorylate and the reduced
enzymatic activity that leads to the development of the
disease.
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Another interesting example is the D594G mutation in
the BRAF proto-oncogene serine/threonine protein kinase
(BRAF1_HUMAN). The RAF gene family consists of
three members (ARAF1, BRAF, and RAF1) that encode
serine/threonine kinases, which are regulated by binding
to RAS as part of the RAS-RAF-MEK-ERK-MAP kinase
pathway—this plays a critical role in cell proliferation
and is frequently activated in cancer cells. Previous stud-
ies showed that mutated-BRAF proteins have elevated ki-
nase activity44 and that the BRAF gene is somatically
mutated in non-Hodgkin lymphoma, a broad group of
cancers affecting the immune system. Hence, the RAS-
RAF kinase pathway may be regulated by somatic muta-
tions of BRAF in some NHLs.45 The SAAPdb database46
also described this mutation as a pathogenic deviation
involved in the disruption of the binding site, interacting
surface, quaternary structure, and the essential scaffolding
of hydrogen bonds. We described D594G as a driver
mutation which introduces an Asp/Gly change into the
activation loop of the kinase family (position 190 in our
model, see Fig. 4). Moreover, the results highlighted the
importance of this amino acid in ATP binding, as
described by FireDB and as a residue providing family-
specific binding. These descriptions are fully coherent
with the important role of this mutation in NH lym-
phoma development.
Finally, we considered the potential consequences of
two mutations in the human fibroblast growth factor
Type 2 receptor (FGFR2_HUMAN), T341P, and C342F
(representing positions 233 and 234 in the structural
model, respectively, see Fig. 4), to demonstrate that the
analysis may also provide insights into complex diseases
caused by more than a single mutation. Several diseases
caused by uncontrolled cell growth have been associated
with defects in FGFR2. Among them, Pfeiffer syndrome
(Acrocephalosyndactyly Type V, MIM:101600) and the
related Crouzon syndrome (Craniofacial dysostosis Type
I, MIM:123500) have been reported to be associated with
the two mutations of interest—T341P in PS and CS,
C342F in CS. We found that T341P is a driver mutation
introducing a Threonine-Proline change in a buried con-
served position, confirming a common association of
proline mutations with the disease.5 In addition, the
C342F mutation is a somatic driver mutation in a buried
residue. Both mutations were considered to be related to
binding specificity, indicative of the importance of these
two positions for protein function.
DISCUSSION
We have analyzed the distribution of point mutations
in protein kinases with the aim of characterizing the
structural and functional implications of different types
of mutations focusing exclusively on the protein kinase
catalytic domain, for which a representative number of
structures are available. The human kinome is particu-
larly amenable to this type of study, since it includes one
of the better characterized protein superfamilies at the
structural and functional level, and a large number of
cancer-associated mutations have been published for
these proteins.6,7,47 We have analyzed the main charac-
teristics of protein kinases: (a) sequence conservation as
an indicator of evolutionary important regions; (b) local-
ization in regions that are structurally conserved across
the superfamily and positions characterized by their sol-
vent accessibility; (c) organization of mutations with
respect to the functional regions defined as general pro-
tein kinase activity or binding sites, and binding sites for
specific effectors. Finally, we compared the distribution
of point mutations in the largest protein kinase groups
(i.e., AGC, CAMK, CK1, CMGC, Other, STE, TK, and
TKL).
The comparison between nonsynonymous and synony-
mous SNPs shows that there are significant differences
between the two categories in terms of sequence and
structural conservation, the distance to active/binding
site residues, and the distance to specific binding sites. As
expected synonymous replacements are tolerated in all
protein regions, whereas mutations that involve a change
of amino acid (nonsynonymous) are more tolerated in
regions distant from the important regions, which
include evolutionary conserved residues and those
involved in structural and functional features.
Driver and passenger mutations (as defined by Refs.
6, 7) also display clear differences in their distributions
in protein kinases. Driver mutations are closer to regions
important for protein function and structure, including
ATP and substrate-binding sites, conserved residues or
domains, and the apolar core of the protein, as well as
residues that confer specificity to the kinase group. This
Figure 4
Position of several disease causing mutations in the structural model.
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distribution is compatible with the proposed role of
driver mutations in the onset of tumor formation (dis-
ease association). By contrast, passenger mutations tend
to be further away from key or conserved positions, and
they do not cluster around binding sites and regions that
infer specificity. This distribution suggests that these
mutations do not have a general disruptive effect, which
is compatible with the model proposed whereby they
accumulate during the process of tumor development.
The experimental information currently available for
the various mutations is very limited, since the immense
majority is derived from genetic studies and has not been
followed by validation assays. Therefore, it is unfortu-
nately impossible to distinguish between gain and loss of
function mutants, i.e., mutations activating and deacti-
vating the kinase activity, information that could provide
very interesting insights into the molecular mechanisms
associated to the mutations.
We further compared cancer-associated mutations and
single-nucleotide polymorphisms by splitting the protein
kinases into their different groups. Interestingly, we find
significant differences in terms of conservation and acces-
sibility, whereby SNPs tend to lie further away from con-
served sequences than mutations. This finding supports
the idea that SNPs are widespread in the population and
have milder functional and structural consequences than
mutations specifically accumulated in tumors.
Indeed, driver mutations show an even stronger tend-
ency to occupy positions that are important to the pro-
tein when compared with SNPs (both all SNPs and non-
synonymous SNPs), including buried residues, active/
binding sites, conserved, and family-specific regions. This
phenomenon reinforces the idea that driver mutations
have even more critical effects on protein structure/func-
tion. In addition, this strong tendency is not observed
for passenger mutations that apparently affect protein
function less and that are possibly more easily tolerated
by cells (summarized in Supporting Information Figs. S7
and S8).
The trends observed here for cancer-associated
somatic mutations are similar to the ones describe
recently by Torkamani et al.48 for inherited poly-
morphisms confirming the relation between disease-asso-
ciated amino acid changes and key regions for protein
function/structure.
CONCLUSIONS
We have shown that the collection of cancer-associated
mutations, and in particular those more likely to be
related with the initial stages of tumorigenesis, are prone
to be related to essential facets of protein function,
including perturbation of important aspects of binding
to substrates and recognition by effectors. The so-called
driver mutations seem to accumulate less in key struc-
tural regions, which could be interpreted as having a
reduced tendency to alter the protein globally, in contrast
to passenger mutations that may produce a complete dis-
ruption of protein activity and folding when introduced
in a later phase of tumor progression.
These tendencies are different to the ones of genetically
inherited mutations (SNPs), where nonsynonymous SNPs
associated to disease but widespread in the population,
tend to avoid protein regions that could be detrimental
for protein function. This tendency contrasts with the
one for cancer-associated-driver-mutations, which seem
to be more directly implicated in the alteration of protein
function.
These results provide a better understanding of the
relationship of cancer-associated mutations with protein
function, and in particular a more clear definition of the
implication of mutations in protein kinases for cancer
progression. The modularity of the analysis carried out
here and the information collected in terms of properties
should also be useful for the development of better pre-
dictors of the consequences of point mutations and their
implications for tumor progression.
MATERIALS ANDMETHODS
Sequences of protein kinase
domains using KinBase
The KinBase resource (http://www.kinase.com/
kinbase10) is a repository storing the currently accepted
classification of eukaryotic protein kinases, which are
categorized into two main groups: ‘‘conventional’’ protein
kinases (ePKs) and ‘‘atypical’’ protein kinases (aPKs).
The ePKs form the largest group and they have been sub-
divided into eight groups by sequence similarity between
the catalytic domains, the presence of accessory domains,
and by considering different modes of regulation. The
eight ePK families defined in KinBase are as follows: the
AGC group (including cyclic-nucleotide and calcium-
phospholipid-dependent kinases, ribosomal S6-phospho-
rylating kinases, G protein-coupled kinases, and close rel-
atives of these kinases), the CAMKs (calmodulin-regu-
lated kinases); the CK1 group (casein kinase 1 and close
relatives); the CMGC group (including cyclin-dependent
kinases, mitogen-activated protein kinases, CDK-like ki-
nases, and glycogen synthase kinase); the RGC group (re-
ceptor gyanylate cyclase kinases); the STE group (MAP
Kinase cascade kinases), Tyrosine kinase group (TKs);
and the TKL group (Tyrosine kinase like family), which
are a cluster of serine-threonine kinases resembling TKs.
Another broad, miscellaneous group called ‘‘other’’ is
also considered for those proteins that do not fit in any
of the predefined sets.
At the time of the analysis, KinBase contained 620
human protein sequences of which 516 correspond to
protein kinases not considered to be pseudogenes.
Although kinases described as pseudogenes are tran-
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scribed and might even have a residual or scaffolding
function,10 kinase pseudogenes were not mapped onto
Uniprot (SwissProt/Trembl) since many of them are par-
tial transcripts or have stop codons in their sequence.
Since KinBase does not directly map its entries onto Uni-
prot, this mapping was performed using a BlastP49
search for each kinbase sequence against a custom data-
base containing all entries in Uniprot annotated as
human protein kinase domain. Once the mapping was
performed, we were able to map 488 Kinbase identifiers
to a valid Uniprot entry, 474 of them (97.13%) at
sequence identity levels of at least 95%.
Generation of a consensus model
summarizing structural domains
of protein kinases
A consensus model of the basic structure of the kinase
domain was created. This consensus model represents the
average structure of a large number of kinases in the
human kinome and therefore, it is useful to summarize
the global characteristics of these structures. To build the
model, we first selected MAP3K1 as a standard represen-
tative sequence of the family from a manually curated
multiple sequence alignment of the human kinome con-
structed using the MUSCLE alignment package.50 The
selected sequence was submitted to Modeller,51 assem-
bling the models created using all the closely related PDB
template structures returned from a BLAST search.49 The
predicted model is represented in Figure 1 where all im-
portant functional areas are represented.
Selection and classification of SNPs
Nowadays, the most commonly cited database for stor-
ing information on SNPs is dbSNP,52 which currently
contains several millions of validated SNPs from humans
and other species. The information stored in dbSNP can
also be accessed through the Ensembl53 application pro-
gramming interface (API). Every record gathered using
this API contained at least a valid Swissprot identifier,
the amino acid change of the mutation, the synonymous/
nonsynonymous character of the polymorphism, and the
position in the sequence of the protein. To get the equiv-
alent position in each 3D structure, as recovered from
the Protein Data Bank,54 the SPICE-DAS alignment
tool55 was used to recover the sequence-structure equiva-
lences. When applied to the 488 Kinbase protein domain
identifiers, after restricting the polymorphisms to those
lodging in the protein kinase domain, 569 SNPs were
recovered, 263 (46.22%) of which were subclassified as
nonsynonymous, whereas the remaining 306 (53.78%)
were annotated as synonymous.
Selection and classification of
somatic mutations
Large-scale systematic genotyping studies have been
conducted to identify mutated genes in human cancer
genomes. These studies focused on tumor type (Colon
and Breast)7 or on the protein kinase superfamily,6 and
they led to the identification of more than 3500 somatic
mutations. Further statistical analysis, based on mutation
rates for instance, or on synonymous versus nonsynony-
mous mutation ratios, have been used to classify genes as
‘‘drivers’’ (i.e., causally involved in oncogenesis) and
‘‘passengers’’ (incidentally involved in oncogenesis and
most likely arising during tumor development). In practi-
cal terms, where no additional evidence is present for a
mutation, that driver/passenger assignment for the gene
is inherited by the mutations in that gene. Those muta-
tions along with the corresponding amino acid change,
their driver/passenger character, and their sequence/struc-
ture positions (calculated using the SPICE server), were
stored. The analysis performed focuses on the protein ki-
nase catalytic domain. The protein kinase domain subset
comprises 140 mutations, 73 (52%) driver and 67 (48%)
passenger mutations.
Assigning a conservation score to each
position in the alignment
For each position in the alignment, conservation was
measured in terms of Shannon’s entropy,56 which is a
measure of the variability in the distribution of elements
in a set, as described by the formula:

Xn
i¼1
pðxiÞ log2 pðxiÞ ð1Þ
where p(xi) is the probability of having element xi in bin
i for that distribution.
Conservation was measured for each position in the
alignment in two different scenarios. The most straight-
forward one was in a context of identity, where 21 bins
were characterized, each reflecting an amino acid (plus
an extra bin for gaps). In the second scenario, the bins
represent different physical-chemical properties of the
amino acids, which permits clustering in the context of
similarity, closely related but conceptually different to the
previous one. The seven groups were defined as follows:
aliphatic (A, C, I, L, M, V), positive (R, K), polar (N, Q,
S, T), negative (D, E), special (G,P), aromatic (H, W, Y,
F), and the additional gap category.
The positions in the alignment were labeled as con-
served if their Shannon’s entropy was less than 0.20.
Additionally, in both the identity and similarity scenarios,
positions with more than 75% gaps in the corresponding
multiple sequence alignments were directly labeled as not
conserved.
Calculation of conservation with AL2CO
AL2CO28 is a program to calculate a conservation
index for each position in a multiple sequence alignment
using several methods. Amino acid frequencies at each
Cancer-Associated Mutations in Protein Kinase Sites
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position are estimated and the conservation index is cal-
culated for these frequencies. We used the AL2CO option
to weight sequences to correct for the unequal distances
between different sequence pairs in the alignment and
the matrix score that gives the most common position
occupied by residues with similar physico-chemical prop-
erties. Finally, we labeled as conserved those residues
with a normalized conservation index threshold of 70%.
Calculation of structural conservation
All human kinases in the data set were mapped to
PDB chains. These chains were then mapped to v3.1 of
CATH to assign individual domains and the majority of
kinases mapped to CATH superfamilies 1.10.510.10 and
3.30.200.20 (phosphotransferase domain and phosphoryl-
ase kinase, respectively).
To calculate the structural conservation for each amino
acid, it was necessary to generate a multiple structure
alignment using CORA.57 All 183 human kinase struc-
tures in the CATH superfamily were first clustered (com-
plete-linkage) at 35% sequence identity to ensure that a
sufficiently diverse set of kinases was used for the calcula-
tion and then, representatives (S35Reps) were taken from
these 46 clusters. Although CORA is generally able to cal-
culate accurate multiple structure alignments of all rela-
tives from an entire superfamily, problems can occur in
especially diverse folds where there is substantial structural
variation. To assess the extent of structural diversity in the
kinase superfamily, all S35Reps were aligned on a pair-
wise basis using the SSAP structure comparison algorithm.
The S35Reps were then grouped together if they shared
Simax score < 3 A˚, producing four structurally similar
groups (SSG). CORA was then used to align all SSGs.
Each fully aligned position in the SSG alignment was
scored for structural conservation using a modification
of the method presented in Ref. 57. Vectors between C-
beta atoms were calculated for a given pair of aligned
residues in a given pair of structures to all other equiva-
lent positions (including gaps, which scored 0). The
global score for each alignment position was then calcu-
lated as a sum of all the pair-wise protein scores. The
score was then normalized across the whole alignment in
the range 0–10, with 10 representing the most highly
conserved positions. Positions with a conservation score
of at least 8 were considered to be conserved.
A modification of this score was also made to focus
on the local structural conservation of each position,
where vectors were only calculated if they were between
residues within 10 A˚ of one another.
Calculation of the accessibility
with Naccess
Naccess is a stand-alone program that calculates the sol-
vent accessible area by rolling a ‘‘probe’’ with van der
Waals radius over the surface of the molecule. We defined
‘‘buried’’ residues if their relative accessible surface area
exposed to the ‘‘probe’’ is less than or equal to 16% of the
total surface of the residue (also used in Consurf58).
Xd analysis
To assess the significance of the proximity of different
sets of mutations to specific areas of the protein (buried,
functional, conserved, etc), we use the Xd measure intro-
duced previously by Ref. 25. The most relevant character-
istic of this measure of differences between distributions
is that it weights more those positions lodging in bins in
the proximity of the studied features instead of consider-
ing equally informative the complete distribution of dis-
tances. In other words, it gives more importance to dif-
ferences in the distributions of residues close to the im-
portant regions than to differences localized in distant
regions.
Xd ¼
Xi¼n
i¼1
Pic  Pia
dixn
ð2Þ
where n is the number of distance bins in the distribu-
tions, di is the upper limit for each bin, Pic is the per-
centage of residues with distance between di and di21,
and Pia is the same percentage for all residues in the pro-
tein. Defined in this way, positive values of Xd indicate
that the population of residues shifts to smaller distances
with respect to the population of all residues. In practice,
we use a difference of Xd values of 0.75 to indicate dis-
tributions of residues that are significantly different with
regards their proximity to previously defined areas of the
protein.
Active site retrieval using FireDB
The FireDB database30 contains a comprehensive cura-
ted set of substrate-binding and catalytic residues,
extracted directly from PDB54 or from the Catalytic Site
Atlas.59 FireDB binding residues for the various kinases
were mapped into the general model using the corre-
sponding multiple structure alignment.
Prediction of tree determinant positions
S3det [Rausell et al., in preparation] is a novel imple-
mentation of the sequence space approach31 using multi-
ple correspondence analysis.60 This new system is fully
automated and has been optimized to detect groups of
proteins within a kinase group with potential functional
specificities, and to identify the residues that contain
more information about that sequence classification.
S3det is based on the simultaneous vectorial represen-
tations of sequences and residues within a multiple
sequence alignment (MSA) in related spaces. Once both
protein and residue spaces have been optimally decom-
posed in their main relevant sources of variation, S3det
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supplies, by means of an unsupervised clustering algo-
rithm, an automated identification of the putative groups
of proteins that will be regarded as different functional
families within the MSA. After these protein families
have been established, they are linked with the residue
space to automatically assign the set of residues that
uniquely characterizes each group. Those residues are
predicted to be the functional specific determinants
within the protein family. S3det can naturally exploit a
supervised family classification, analogous to the MCdet
method previously developed by our group.32
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Abstract
Background: Protein Kinases are a superfamily of proteins involved in crucial cellular processes such as cell cycle
regulation and signal transduction. Accordingly, they play an important role in cancer biology. To contribute to the
study of the relation between kinases and disease we compared pathogenic mutations to neutral mutations as an
extension to our previous analysis of cancer somatic mutations. First, we analyzed native and mutant proteins in
terms of amino acid composition. Secondly, mutations were characterized according to their potential structural
effects and finally, we assessed the location of the different classes of polymorphisms with respect to kinase-
relevant positions in terms of subfamily specificity, conservation, accessibility and functional sites.
Results: Pathogenic Protein Kinase mutations perturb essential aspects of protein function, including disruption of
substrate binding and/or effector recognition at family-specific positions. Interestingly these mutations in Protein
Kinases display a tendency to avoid structurally relevant positions, what represents a significant difference with
respect to the average distribution of pathogenic mutations in other protein families.
Conclusions: Disease-associated mutations display sound differences with respect to neutral mutations: several
amino acids are specific of each mutation type, different structural properties characterize each class and the
distribution of pathogenic mutations within the consensus structure of the Protein Kinase domain is substantially
different to that for non-pathogenic mutations. This preferential distribution confirms previous observations about
the functional and structural distribution of the controversial cancer driver and passenger somatic mutations and
their use as a proxy for the study of the involvement of somatic mutations in cancer development.
Background
Point mutations of nucleotide bases are a mechanism of
crucial importance in the evolution of proteins, and
hence in the evolution of organisms. A biologically rele-
vant class of point mutation, accounting for about 90%
of sequence polymorphisms [1] at an overall frequency
of about one per 1000 bases [2] is the single nucleotide
point mutation or PM. Traditionally, polymorphisms are
classified according to their genomic location into cod-
ing or non-coding. Coding PMs can be further classified
depending on whether the resulting protein product is
changed owing to the genomic polymorphism. Non-
synonymous PMs (nsPMs) are those that alter the
amino acid sequence of the protein product through
either amino acid substitution or the insertion of trun-
cation mutations. We refer to those which generate a
single amino acid substitution as ‘single amino acid
polymorphisms’ or SAAPs. In contrast, synonymous
PMs (also referred as silent or sPM) are those that do
not alter the amino acid sequence of the protein pro-
duct expressed. A particular case of PMs corresponds to
single nucleotide polymorphisms (SNPs): those germline
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mutations frequently found (>1%) in normal individuals
and considered neutral. A major effort to catalogue and
annotate SNPs is dbSNP [3]. Although most amino acid
changes are tolerated in the native protein structure, not
all PMs are neutral. An increasing number of mutations
are prone to be associated with aberrant phenotypes and
disease. Disease-associated mutations occur at much
lower frequencies in the population and have a severe
effect on phenotype. Here, we use the term ‘pathogenic
deviation’ (PD hereafter) to refer to any single base
change reported to be correlated with disease. Although
both PDs and nsSNPs result in a change in the
expressed protein product, the former are reported to
have a severe effect on phenotype whereas nsSNPs are
expected to have a non-deleterious phenotypic effect.
About 1% of all human genes are known to contribute
to cancer as a result of acquired mutations. The family
of genes most frequently contributing to cancer is the
Protein Kinase gene family [4] which is implicated in a
huge number of tumorigenic functions including
immune evasion, proliferation, antiapoptotic activity,
metastasis and angiogenesis, possibly due to the simpli-
city of the mechanism of attaching an ATP-derived
phosphate to a substrate protein [5]. Protein Kinases are
one of the most ubiquitous families of signaling mole-
cules in the human cell, accounting for approximately
2% of the proteins encoded by the human genome [6].
Protein Kinases show a wide-scale similarity both at
sequence and structure level, attributable to the fact that
all kinases transfer the terminal phosphate of ATP to a
serine, threonine or tyrosine residue in a target protein.
Empirical studies to date also suggest a common, with a
few exceptions, catalytic mechanism whereby ATP and
an active site divalent cation are bound in identical
manners and phospho-transfer is carried out by a shared
set of amino acids [7]. Studies [8,9] on yeast models
have shown that kinases can be very promiscuous, phos-
phorylating a huge number of different protein sub-
strates albeit showing remarkable specificity. This
inconsistency suggests that kinases have a region com-
mitted to the general function of catalysis, with another
region (or regions) customizable to confirm substrate
specificity to the enzyme without any particular need to
alter fold, compromise ligand binding or modify the
subsequent reaction mechanism. Protein Kinases are a
thoroughly studied protein family and a plethora of
mutations have been previously reported in the litera-
ture [10]. These studies often include evidence of asso-
ciation with disease. Concomitantly, several efforts
[11,12] are devoted to the prediction of the pathogeni-
city of somatic kinase mutations in cancer samples.
These mutations are classified into two main categories:
those that are involved in cancer onset and development
–driver mutations– and those that are biologically
neutral –passenger– mutations. For a detailed review,
see Baudot et al.,2009 [13]. Previous work [14] charac-
terized the preferential distribution of cancer driver
kinase somatic mutations in regions of importance for
protein function, including disruption of substrate bind-
ing and/or effector recognition at family-specific posi-
tions, often avoiding structurally relevant positions.
The objectives of the work presented here are two-
fold. Firstly, we wanted to clarify whether the trends
detected for driver somatic kinase mutations can be
extended to other disease related mutations indepen-
dently of the nature of the mutation. Secondly, we
wanted to provide additional information to the discus-
sion on the interpretation of the role of kinase driver
somatic mutations in the onset of cancer.
Consequently, we carried out a detailed multi-level
comparative analysis of the differences between patho-
genic and neutral (not pathogenic) germline mutations
within the framework of the human kinome: amino acid
composition of the polymorphisms was compared,
mutations were characterized according to their poten-
tial structural effects and finally, we assessed the loca-
tion of the different classes of polymorphisms with
respect to kinase-relevant positions in terms of subfam-
ily specificity, conservation, accessibility and functional
sites.
Results and discussion
Sequence features of deleterious kinase mutations
We mapped 130 pathogenic deviations and 200 neutral
SNPs to sequences within the Protein Kinase domain
(PDPKs and SNPPKs, respectively). The native residue in
the pathogenic (PDPK) set was enriched in glycines
(p=0.01) and leucines (p=0.04) when the sequences were
compared using a two-sided Fisher exact test whereas it
was enriched in prolines (p=3x10–5) when the mutant
amino acids were considered. As expected, in the SNPPK
dataset none of the residue types were particularly
enriched, neither in the native sequences nor in the
mutated ones. Considering the native and mutant as a
residue pair, three mutations were found more often in
the PDPK dataset: leucine-proline (p=0), lysine-glutamate
(p=0.02) and arginine-proline (p=0.02). Again, in the
SNPPK dataset, no significant enrichment was found for
the the wildtype-mutated pairs. The complete set of
results can be found in Supplementary Table S2 in
Additional file 1.
Hypothesized structural effects of deleterious kinase
mutations
SAAPdb [15] provides a characterization of the struc-
tural consequences of mutations. When these features
were compared some differences between the groups
appeared. PDPKs were often observed at the interface
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(p=0.03) including sites of inter-chain binding, as well as
ligand binding. By contrast, SNPPKs significantly
(p=0.04) more often than PDPKs tend to create empty
spaces in the protein as a consequence of the difference
in volume introduced by the side chain change, either in
the core of the protein or in partially buried regions.
Protein Kinase pathogenic mutations (PDPK) compared
to pathogenic mutations outside this domain (PDnPK,
standing for ’non protein kinase’) produced striking
results: PDnPKs were more often explained by structural
analyses: the modified residues affected stability, affected
functional residues, introduced an empty region in the
interior of the protein, and affected interaction prone
positions (as annotated in MMDBBIND). By contrast,
PDPK mutations were not significantly related with any
of those categories. A complete description of these
results can be found in Supplementary Table S3 in
Additional file 1.
Proximity of deleterious kinase mutations to kinase-
specific protein features
We present here the results of mapping the different
types of mutations, PDPKs and SNPPKs, onto a repre-
sentative structural model from the Protein Kinase
superfamily. The mutations were analyzed in terms of
their distribution relative to evolutionary conserved
positions and known functional regions. We were able
to map 47 positions containing at least one of the 62
PDPK mutations and 27 positions with at least one of
the 36 SNPPKs to the consensus model (Figure 1)
described in the Methods section and in previous stu-
dies [14]. The results of these analyses are summarized
in Table 1.
Proximity of kinase mutations to known functional regions
a) Kinase mutations and the catalytic region The
active region of Protein Kinases includes the ATP bind-
ing site, the peptide-substrate binding sites and the cata-
lytic loop implicated in the transference of the
phosphate group. We defined the kinase-binding site as
the set of residues extracted from the FireDB database
[16]. This definition includes 32 residues (Figure 1) that
directly contact the ATP in the binding pocket and that
contains the five highly conserved residues that play a
critical role in positioning ATP and stabilizing the active
conformation in the catalytic mechanism [7] (see Figure
1). The distance distribution histograms (Figure 2,
panels A and B) and the results in Table 1 (see also Fig-
ure S2 in Additional file 1, where the PDPKs, SNPPKs
and catalytic residues were represented), showed a very
strong tendency of PDPKs to locate if not in catalytic
residues, at least close to them. Indeed, 13 out of the 32
residues in the binding pocket were annotated as patho-
genic whereas only three were annotated as neutral.
Moreover, 2 out of the 5 residues described as essential
Figure 1 Consensus model structure of summarizing the
human Protein Kinase family The model structure of human
Protein Kinase, based on MAP3K1, shows the basic two-lobe kinase
fold, with the N- and C-terminal (green and orange respectively)
lobes joined by a hinge region (magenta). Substrate recognition is
through interaction with the activation segment (blue), a region in
the C-terminal lobe. The substrate-binding groove is located
between the catalytic loop, the P+1 loop (activation segment), helix
D, helix F, helix G and helix H. ATP binds at a site between the two
lobes (yellow) that includes five conserved residues: (i) Lysine 74
that interacts with the alpha and beta phosphates of ATP and
thereby stabilizing it; (ii) a nearby glutamic acid (E96) forms a salt
bridge with lysine 74 increasing the stabilization network; (iii)
Aspartate 171 is the catalytic base that initiates phosphotransfer by
deprotonating the acceptor serine, threonine or tyrosine; (iv)
Asparagine 176 interacts with a secondary divalent cation, thereby
positioning the gamma-phosphate of ATP, and finally (v) Aspartate
190 which chelates the primary divalent cation, indirectly
positioning ATP at the same time.
Table 1 Results of the Xd analysis comparing PDPKs and
SNPPKs
Feature PD (Å) SNP (Å) ΔXd
Conservation - Shannon 7.17 6.71 -0.13
Conservation - AL2CO 8.49 10.49 -0.52
Structural Conservation 7.56 7.00 2.10
Accessibility - Buried 2.94 3.63 -0.83
Catalytic - FireDB 8.69 12.66 -4.74
Catalytic - Knight 11.89 16.26 -2.33
TreeDeterminants 6.00 7.94 -1.98
Where PD (Å) and SNP (Å) stand for the average closest distances in
Angstroms from the feature residue and the PDs and SNPs respectively, and
ΔXd for the difference in Xd values. Negative values indicate that the PDs are
closer to the feature residues whereas positive values indicate that SNPs are
in the surroundings of feature residues.
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for the correct functioning of the ATP binding pocket
[7] were annotated as PDPKs.
b) Kinase mutations and regions of functional sub-
specificity In this study we used the position of the
tree-determinant residues as a proxy for functionally
important regions in Protein Kinases, particularly those
related with the specific functions of each one of the
subfamilies. Residues specific to the various subfamilies
of Protein Kinases were identified for each of the eight
subfamilies in which KinBase categorizes the human
kinome [6]. Our recent implementation of the
sequence-space approach, S3det [17] identified 32
unique positions in the model as containing information
relevant for differentiating between subfamilies; that is,
residues that tend to be conserved in the specific subfa-
milies and vary to different degrees in the others (Fig.
S3 in Additional file 1 depicts the distribution of the
mutations along with these tree-determinant residues).
Out of the 32 tree-determinants in the model, five were
annotated as pathogenic (residues 50, 173, 190, 217 and
233 in the generated structural model) whereas only two
were annotated as neutral. Pathogenic deviations, if not
exactly in positions that were disease-associated, clus-
tered around tree-determinant residues in general. This
tendency was especially relevant for tree-determinants
in the ATP binding pocket, but also appreciable in the
other function specific tree-determinants. PDPKs were
closer to tree-determinant positions than neutral
SNPPKs (Fig. 2C) This was also clear in the difference of
Xd values (-1.98) indicating the existence of significant
differences between PDPKs and SNPPKs with respect to
proximity to positions characterized as important for
the function and subspecificity of the kinases.
Proximity of kinase mutations to the protein core
With the accessibility parameters defined in Methods,
99 residues were classified as buried in the kinase struc-
tural model; 20 of these buried residues are annotated
as PDPKs and 12 were annotated as SNPPKs (three resi-
dues – 58, 197 and 218 – are described in both data-
sets) (Fig. S4 in Additional file 1). The distribution of
distances (Fig. 2D) manifests a clear tendency of PDPKs
to be closer to buried residues. As a matter of fact, the
analysis of the mean distances of mutated positions to
buried residues (2.94Å and 3.63Å respectively) revealed
a tendency for the pathogenic deviations (PDPKs) to be
closer to buried residues than the neutral polymorph-
isms. This fact was supported by a Xd difference of
-0.83.
Examples of well-characterized disease-associated
mutations affecting kinase function
The statistically significant results provided after analyz-
ing the sequence features of the single amino acid poly-
morphisms (see sequence features of deleterious kinase
mutations section) are supported by several examples in
the literature. Karkkainen et al., (2000) [18] associated
human hereditary lymphedema, a particular case of lym-
phatic obstruction, with mutations in the vascular
Figure 2 Histograms of the distribution of distances between
mutated resides and the analyzed features. (A) Catalytic residues
according to FireDB. (B) Catalytic Residues according to Knight et al
(2007). (C) Tree-Determinants (D) Buried residues.
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endothelial growth factor receptor 3 (VEGFR-3). The
endothelial cells lining blood and lymphatic vessels
depend on signal transduction mediated by specific
receptor tyrosine kinases for their differentiation into a
primary vascular plexus (vasculogenesis) and for the
sprouting and splitting of new capillaries from pre-
viously existing vessels (angiogenesis). Two mutations
were reported as the cause of the disease, due to the
loss of tyrosine kinase activity and hence impaired
downstream signaling, and a slower rate of internaliza-
tion of the receptor. The suggested model highlights a
mutation in the second arginine in the highly conserved
HRDLAARN motif in the catalytic site to proline that
facilitates the hydrogen bond between aspartate and a
hydroxyl group from ATP at the binding pocket. This
aspartate is critical for protein function as it is believed
to act as the catalytic base in the phosphotransfer reac-
tion. Moreover, their study revealed that a mutation
from leucine to proline disturbed protein function due
to both a disturbance in protein structural integrity and
an interference of ATP binding. Since the pathogenic
residue is located in the middle of a b-strand, introdu-
cing a restricted mobility residue such as proline dis-
rupts the interaction with the surrounding b-strands,
destabilizing the protein fold in the region. In addition,
the sidechain of this leucine is part of the adenine-bind-
ing pocket, therefore alterations in such a relevant posi-
tion modify the shape of the cleft and might interfere
with ATP binding. With respect to the significant
lysine-glutamate mutation, Mao et al., (2001) [19]
described the commonly cited mutation K430E
(amongst others) in Bruton’s tyrosine kinase (BTK,
Q06187), speculating with regard to how it might cause
severe XLA (X-linked agammaglobulinemia), and pro-
viding a solved crystal structure. BTK is expressed on
the surface of B cells and its kinase activity is crucial in
proliferation and differentiation to mature B lympho-
cytes. According to their mechanism, upon the trans-
phosphorylation of Y551, the highly conserved K430
facilitates a hydrogen bond with E445, causing a shift of
the aC helix. The K430E mutation disables the aC helix
repositioning, which is crucial for the catalytic activity
of BTK, hence impairing the creation of mature B cells.
Assessing the possible functional role of relevant kinase
mutations by their sequence-structure characteristics
Our general analysis of the distribution of mutations in
Protein Kinases not only provided an overview of their
relation with function and structure, but also provided
an insight into their specific biomedical implications. In
the work presented here, we summarized all the knowl-
edge accumulated for the Protein Kinase domain in a
single framework structure (Fig. 1) under the assump-
tion that regions important for the structure/function of
the kinases are common to the whole family and hence
they can be used as a reference for the interpretation of
the mutations in any of the individual kinases. The
accumulation of information clearly increases the signifi-
cance of the results provided and makes the distribution
of the polymorphisms more reliable and accurate. For
instance, mutations in the insulin receptor gene in
humans (INSR) have been reported as disease-associated
in the literature. Defects in INSR are the cause of insu-
lin-resistant diabetes mellitus with acanthosis nigricans
type A (IRAN type A, MIM:610549), a syndrome char-
acterized by the association of severe insulin resistance
manifested by marked hyperinsulinemia and a failure to
respond to exogenous insulin with the skin lesion
acanthosis nigricans and overian hyperandrogenism in
adolescent female patients. The relation of the disease
with mutations in kinases is thoroughly reported in
OMIM. Recent studies have further characterized the
relationship between insulin resistance and disease (for
example, [20]). Moreover, several studies have associated
acanthosis nigricans with mutations in other kinases,
such as the fibroblast growth factor receptors II and III
[21-23]. Here, we identified A1161T (residue 173 in the
model), a well-characterized mutation that introduces
an alanine-threonine shift in the ATP binding pocket of
INSR. This mutation has been defined in our analysis as
a pathogenic deviation (PDPK). Concomitantly, it is a
catalytic residue in FireDB and is important for family
specificity. This perturbation of the ATP binding pocket
might explain the unpaired phosphorylation and there-
fore the reduced enzymatic activity leading to the aber-
rant phenotype.
Finally, we considered not only a single mutation but
a pair of consecutive mutations: T341P and C342F
(positions 233 and 234 in the structural model respec-
tively), in the human fibroblast growth factor receptor
type 2 (FGFR2) to demonstrate that although only
T341P is reported to be a pathogenic deviation in our
dataset, the analysis can provide insights into complex
diseases caused by more than one mutation at the same
time. Several diseases caused by uncontrolled cell
growth have been associated to defects on FGFR2.
Among them, two related syndromes – Pfeiffer syn-
drome (PS) and Crouzon syndrome (CS) – have been
reported to be associated to the pair of mutations of
interest (T341P in PS and CS, C342F in CS). In our ana-
lysis, we described T341P as a mutation that introduces
a change from threonine to proline in a buried
sequence-conserved position. Other authors [15,24] have
shown that mutations to proline are very often asso-
ciated with disease. Additionally, we have characterized
mutation C342F as a replacement of a buried residue. In
addition, we identified both mutations as tree-determi-
nant residues, thus considered related to binding
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specificity and indicative of the importance of these two
positions for protein function.
Conclusions
We have analyzed point mutations in the structure of
Protein Kinases in order to characterize the structural
and functional singularities of pathogenic and neutral
mutations. Although the definition of the groups is by
no means stable and the groups are constantly being
redefined as new studies on the pathogenicity of muta-
tions arise, this might be used as a proxy to deepen the
knowledge on the underlying mechanisms of disease.
The human kinome is particularly amenable for this
type of study since much is known about the structure
and function of this protein family and very relevant
cancer-associated mutations have been published for
these proteins [11,12,14].
To address this point, pathogenic deviations mapped
to the kinase domain (PDPK) and single nucleotide poly-
morphisms mapped to the kinase domain (SNPPK) were
compared on the basis of sequence, hypothesized struc-
tural effect and proximity to known kinase-specific fea-
tures within the framework of a modeled consensus
structure, representative of the whole superfamily. At
the sequence level, several mutations were differentially
observed in the PDPK and SNPPK datasets: the leucine-
proline mutation emerged as an interesting feature of
the PDPK dataset: it was identified both when analyzing
the native and mutant residues separately, and when
analyzing the mutation pairs, and it has been identified
as being indicative of disease elsewhere, both specifically
in a kinase disease dataset [24] and in wider, non-dis-
ease-specific datasets [15,25,26]. In addition, replacing
an arginine with a proline was more often observed in
the PDPK dataset. Again, this mutation has been
described as being associated both with diseases pre-
dicted to be related to mutations in kinases [24] and
across all other diseases [15,26]. Finally, replacing the
positive charge of Lysine with the bulkier, negatively
charged glutamic acid sidechain is identified in the
PDPK dataset. Unlike the well-characterized previous
mutations, this is a novel observation. These finding
provide evidence about the existence of distinctive dif-
ferences between the two types of mutations even at
such a coarse grain level as the amino acid composition.
In the second part of the analysis we focused on the
singularities of the mutations in structurally and func-
tionally relevant regions. Thus, we characterized PDPK
mutations in terms of their structural consequences by
comparing them to SNPPK mutations. PDPK mutations
were more likely to occur at the interface with ligands
and other protein chains and SNPPK mutations were
more likely to introduce a cavity in the protein core.
This is coherent with the previous publications
concluding that disease-associated mutations in kinases
often affect the site of ATP binding [16,18,19]. In addi-
tion, PDPK mutations were compared to other PD muta-
tions (PDnPK) to comment on the mechanisms by which
mutations in kinases might lead to disease. In general, it
is easier to explain PDnPKs in structural terms. Most
noticeably, very few PDPK mutations resulted in a signif-
icant cavity, an empty space, or affected protein stability
at all. An increasing body of literature attributes the
pathogenic nature of PDs to their destabilizing effect on
native protein structure [15,27-30]. The results here,
specific to the mutations in the Protein Kinase domain,
contradict this trend, indicating that the pathogenicity
of PDPKs could not be simply attributed to a decreased
stability of the resulting proteins. This might be
explained by the fact that Protein Kinases are known to
be a highly structurally conserved superfamily, while
varying significantly with respect to sequence; as such,
the structures must be tolerant to sequence variation.
Hence, considerable flexibility must exist within the pro-
tein structure to be robust to sequence diversity. It is
noticeable the relatively small number of structures
available, we are aware that the results will benefit from
a dedicated modelling pipeline, especially for very diver-
gent kinases differing from the canonical PK domain. By
contrast, a customized model for every single protein
would not only increment the complexity of the com-
parative analysis of distances but would also add some
uncertainties derived from the use of protein models.
In order to provide more detailed insight into the dis-
tinctive implication of pathogenic mutations in the disrup-
tion of protein function, we characterized the differences
between PDPKs and SNPPKs by their association to kinase-
specific functional and structural features. There were sig-
nificant differences between the two types of mutations in
terms of conservation, accessibility, distance to active/
binding site residues and distance to family specific bind-
ing sites. It is interesting to compare these results with the
ones previously obtained for driver/passenger mutations
in Protein Kinases [14] from the works by [11,12] that
constitute a subset of the many mutations stored in COS-
MIC [31]. Drivers are those mutations predicted to be
involved in cancer onset whereas passenger mutations are
those that are supposed to be accumulated during cancer
progression being neutral respect to the origin of the can-
cer. In the previous work, the main conclusion was that
driver mutations tended to be located near to important
residues such as sequence conserved positions, family spe-
cific regions and active/catalytic sites whereas passenger
mutations were located closer to structurally conserved
regions. The difference observed here for the set of PDPKs
and SNPPKs mimicked the one previously observed for dri-
ver and passenger mutations. Both datasets proved to be
non-redundant. Only 4 residues were common to both
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driver and pathogenic datasets, all of them in the human
B-raf proto-oncogene. The small overlap encountered is
consistent with the very different nature –germline and
somatic– of the mutations in each of the disease-prone
datasets. Thus, the new results presented here can be seen
as a confirmation of the functional/structural role of the
mutations that are more likely to be pathogenic (drivers
and PDs). Given that the definition of mutations as drivers
and passengers is somehow controversial (For a review,
see [13]), it is good to see that the current results could be
interpreted as an indirect support to the categorization of
mutations into drivers (disease-associated) and passengers
(disease-neutral) and their use as a proxy for the study of
the involvement of somatic mutations in cancer biology.
In summary, we have confirmed that the pathogenicity
of mutations within the Protein Kinase superfamily is
related to essential aspects of protein function, including
perturbation of substrate binding and recognition by
effectors at family-specific positions. As a matter of fact,
pathogenic deviations (PDPK) accumulate in key func-
tional regions whereas they seem to be absent from
structurally relevant positions. These observations rein-
force the idea that the pathogenicity of disease-asso-
ciated mutations can be attributed to a disruption of
native protein function while avoiding drastic changes
prone to disrupt the protein globally. This tendency was
not observed for neutral polymorphisms, which are
apparently less disruptive of protein function and tend
to be tolerated. Consequently, they are more often
found in normal individuals. However, it is clear that
further classification of the mutations in more specific
subgroups will be necessary to provide a deeper knowl-
edge on the mechanisms leading to disease. A typical
example would be the characterization of mutations into
a gain-of-function/loss-of-function on a large-scale.
The analysis presented here provides not only a char-
acterization of the mutations, but also in some cases
additional insight into the specific biomedical implica-
tions of the mutations. This type of approach will be
particularly useful as part of the bioinformatics platform
developed for the International Cancer Genome Consor-
tium and other cancer genome projects. The results dis-
cussed in this work are biologically sound not only
because they contribute to our understanding of the
role of mutations in disease, but also because they can
bee seen as a necessary step towards the development of
predictors of pathogenicity based on the combination of
the features analyzed here. Indeed, further development
of the idea presented here might naturally derive in a
classifier that making use of machine learning techni-
ques would be able to predict the pathogenicity of any
novel kinase mutation.
Moreover, although out of the scope of this work, the
methodology used to analyze the distribution of the
mutations in relation to a set of features can be applied to
other families. However, we see (as other authors in the
field [24]) advantages to the in-depth exploration of a
family with more information about sequence, structure
and mutations and for what it is feasible to obtain phyloge-
netic information to calculate subfamily specific sequence
features. It remains interesting to analyze other protein
families at a genome wide scale to corroborate to what
extend the results shown in this work can be generalized.
Methods
Protein Kinase domain sequences
The KinBase resource [6] is a repository of the currently
accepted classification of eukaryotic Protein Kinases. At
the moment of the analysis, KinBase contained 620
human protein sequences of which 516 were Protein
Kinases not defined as pseudogenes by the database
curators. Although it has been described that some
kinase pseudogenes are transcribed and even might have
a residual or scaffolding function [32] kinase pseudo-
genes were not considered in the analysis performed
here. KinBase does not map directly onto UniProtKB
[33]. The mapping was performed using a BlastP [34]
for each sequence against a custom database containing
all entries in UniProtKB annotated as Protein Kinase
domain for human. We were able to map 488 KinBase
identifiers to a valid UniProtKB entry, 474 of them
(97.13%) at sequence identity levels of at least 95%.
Classification of the mutations
SAAPdb [15] is a database of single amino acid poly-
morphisms (SAAPs) mapped to protein structure.
SAAPdb aims to provide likely structural effects of
mutations and identify differences in potential structural
consequences between neutral and pathogenic muta-
tions. The disease dataset is derived mostly from OMIM
[35] whereas the neutral dataset comes from dbSNP.
For the Protein Kinase domain of the 488 kinases in
SAAPdb contains 130 pathogenic deviations (PDPKs)
and 200 neutral polymorphisms (SNPPKs). Of these 130
PDPKs, 62 were successfully mapped to a residue in the
solved PDB structure. Similarly, of the 200 SNPPKs
mapped to sequence, 36 were mapped to a PDB struc-
ture (See Supplementary Table S1 in Additional file 1).
In order to create control datasets 9263 non-kinase PDs
(PDnPK) were retrieved from SAAPdb, out of them 4652
mapped to a structure. All three datasets contain only
unique, non-synonymous (missense) mutations. We
excluded nonsense and synonymous mutations because
these have a known, truncating effect or no effect on
the protein structure. A unique mutation was defined by
the combination of four parameters: UniProtKB acces-
sion number and sequence position, native amino acid
and mutated amino acid.
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Comparing mutations with respect to the native and/or
mutant residues
To compare the mutations with respect to their
sequence features, the native and mutant residues were
extracted from SAAPdb, as described above. Two-sided
Fisher exact tests were carried out since they allow
robust comparison of datasets of disparate sizes and
evaluation of contingency tables with empty cells.
Structural effects of mutations
The SAAPdb hypothesized structural effects are fully
described elsewhere [15] and are summarised briefly
below. (a) Mutations affecting stability: mutations on the
surface of proteins that replace a hydrophilic residue
with a hydrophobic residue are identified as introducing
unfavourable hydrophobicity on the surface. Similarly,
mutations in the core that replace a hydrophobic residue
with a hydrophilic residue are identified as introducing
unfavourable hydrophobicity in the core. Buried muta-
tions that create a charge shift are also identified. Using a
geometric analysis of PDB structures, SAAPdb identifies
mutations that affect potential disulphide bonds. Muta-
tions that introduce large cavities in the protein core or
that break hydrogen bonds are identified as well. (b)
Mutations affecting folding: unfavourable (with respect
to torsion angles) mutations from cis-proline, from gly-
cine and to proline are identified. Mutations that will
clash with existing residues are identified. (c) Mutations
to UniprotKB annotated residues: mutations at the site of
residues annotated by UniprotKB as functionally relevant.
(d) Mutations to binding residues: PDB structures are
analysed to identify residues binding to proteins, DNA or
small molecules. These data are augmented by data from
MMDBBIND. (e) Mutations disrupting the quaternary
structure (f) Mutations to sequence conserved residues.
In addition, we provide results for the summary analyses
categories of structurally explained (where at least one
structural explanation is true, i.e., any explanation apart
from the sequence conservation) and explained (where at
least one explanation is true). In order to compare the
mutations with respect to their structural effects, a binary
explanatory vector is calculated for each mutation and a
two-sided Fisher exact test was carried out.
Generation of a consensus model summarizing Protein
Kinase structures
A consensus model (Fig.1) of the basic structure of the
kinase domain was created. This consensus model
represents the average structure of a large number of
kinases widespread along the human kinome, and there-
fore it is useful to summarize global characteristics of
the structures. To build the model we first selected
MAP3K1 as a standard representative sequence of the
family from a manually curated multiple sequence
alignment of the human kinome constructed using the
alignment package MUSCLE [36]. The selected
sequence was submitted to Modeller [37] assembling
the models created using all those closely related tem-
plate PDBs structures returned from a BLAST search.
The predicted model has previously been used as a con-
sensus of the Protein Kinase domain [14]. Finally, muta-
tions were transferred from their own PDB coordinates
to the consensus model for comparison.
Calculation of important regions
Calculation of accessibility
NACCESS (Hubbard, unpublished) is a stand-alone pro-
gram that calculates accessible areas by rolling a probe
with van der Waals radius over the surface of the mole-
cule. A residue is defined as buried if 16% or less of the
residue’s surface is exposed to the probe. This is a com-
mon threshold [38] that ensures a reasonable number of
buried residues.
Definition of catalytic sites
The FireDB database [16] contains a comprehensive
curated set of substrate binding and catalytic residues,
extracted directly from the PDB [39] or from the Cataly-
tic Site Atlas [40]. FireDB binding residues for the var-
ious kinases were mapped into the general model using
the corresponding multiple structure alignments.
Prediction of Tree Determinant positions
S3det [17] is an algorithm for the detection of groups of
proteins within a family with potential functional speci-
ficities and to identify the residues that are characteristic
of that group. S3det is based on the simultaneous quan-
titative analysis of sequences and residues within a mul-
tiple sequence alignment on related multidimensional
spaces. Those residues associated with specific sequence
subfamilies tend to be determinants of functional speci-
ficity and are located in functional regions of protein
families, including substrate binding sites, functional
sites and protein interaction sites.
Xd analysis
To assess the significance of the proximity of different
sets of mutations to areas of the protein (buried, func-
tional, conserved, etc) we used the harmonic deviation,
Xd, measure introduced previously [41].
Xd
P P
d n
ic ia
ii
i n
=
−
⋅
=
=∑
1
(1)
Where n is the number of distance bins in the distri-
butions, di is the upper limit for each bin, Pic is the per-
centage of residues with distance between di and di-1
and Pia is the same percentage for all residues in the
protein. Defined this way, positive values of Xd indicate
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that the population of residues is shifted to smaller dis-
tances with respect to the population of all residues. In
practice we used a difference of Xd values of 0.75 to
indicate distributions of residues that are significantly
different regarding their proximity to previously defined
areas of the protein. This threshold – albeit arbitrary –
is based on manual inspection of previous results and
has been proved valid in a similar context [14].
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